<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PV Glossary - Pharmacovigilance Terms & Definitions</title>
    <style>
        /* PV Glossary - Styles */

:root {
    --primary: #2563eb;
    --primary-dark: #1d4ed8;
    --primary-light: #dbeafe;
    --secondary: #059669;
    --accent: #f59e0b;
    --danger: #dc2626;
    --gray-50: #f9fafb;
    --gray-100: #f3f4f6;
    --gray-200: #e5e7eb;
    --gray-300: #d1d5db;
    --gray-400: #9ca3af;
    --gray-500: #6b7280;
    --gray-600: #4b5563;
    --gray-700: #374151;
    --gray-800: #1f2937;
    --gray-900: #111827;
    --white: #ffffff;
    --shadow-sm: 0 1px 2px rgba(0,0,0,0.05);
    --shadow: 0 1px 3px rgba(0,0,0,0.1), 0 1px 2px rgba(0,0,0,0.06);
    --shadow-md: 0 4px 6px -1px rgba(0,0,0,0.1), 0 2px 4px -1px rgba(0,0,0,0.06);
    --shadow-lg: 0 10px 15px -3px rgba(0,0,0,0.1), 0 4px 6px -2px rgba(0,0,0,0.05);
    --radius: 8px;
    --radius-lg: 12px;
    --sidebar-width: 280px;
    --header-height: 70px;
    --footer-height: 40px;
}

/* Dark Theme */
[data-theme="dark"] {
    --primary: #3b82f6;
    --primary-dark: #2563eb;
    --primary-light: #1e3a5f;
    --secondary: #10b981;
    --accent: #f59e0b;
    --danger: #ef4444;
    --gray-50: #1a1a2e;
    --gray-100: #16213e;
    --gray-200: #1f2937;
    --gray-300: #374151;
    --gray-400: #6b7280;
    --gray-500: #9ca3af;
    --gray-600: #d1d5db;
    --gray-700: #e5e7eb;
    --gray-800: #f3f4f6;
    --gray-900: #f9fafb;
    --white: #0f172a;
    --shadow-sm: 0 1px 2px rgba(0,0,0,0.3);
    --shadow: 0 1px 3px rgba(0,0,0,0.4), 0 1px 2px rgba(0,0,0,0.3);
    --shadow-md: 0 4px 6px -1px rgba(0,0,0,0.4), 0 2px 4px -1px rgba(0,0,0,0.3);
    --shadow-lg: 0 10px 15px -3px rgba(0,0,0,0.4), 0 4px 6px -2px rgba(0,0,0,0.3);
}

[data-theme="dark"] .header {
    background: linear-gradient(135deg, #1e3a5f 0%, #0f172a 100%);
}

[data-theme="dark"] .sidebar {
    background: #0f172a;
    border-right-color: #1f2937;
}

[data-theme="dark"] .category-item:hover,
[data-theme="dark"] .category-item.active {
    background: #1e3a5f;
}

[data-theme="dark"] .search-box input {
    background: rgba(255,255,255,0.08);
    color: #f3f4f6;
    border-color: rgba(255,255,255,0.15);
}

[data-theme="dark"] .search-box input::placeholder {
    color: #9ca3af;
}

[data-theme="dark"] .quiz-option {
    background: #16213e;
    border-color: #374151;
    color: #e5e7eb;
}

[data-theme="dark"] .quiz-option:hover {
    border-color: #3b82f6;
}

[data-theme="dark"] .quiz-option.correct {
    background: #064e3b;
    border-color: #10b981;
}

[data-theme="dark"] .quiz-option.incorrect {
    background: #450a0a;
    border-color: #ef4444;
}

[data-theme="dark"] .quiz-setup-option {
    background: #16213e;
    border-color: #374151;
    color: #d1d5db;
}

[data-theme="dark"] .quiz-setup-option.active {
    background: #3b82f6;
    border-color: #3b82f6;
    color: #ffffff;
}

[data-theme="dark"] .example-box {
    background: #062b19;
    border-left-color: #10b981;
    color: #d1d5db;
}

[data-theme="dark"] .mistake-box {
    background: #2d0a0a;
    border-left-color: #ef4444;
    color: #d1d5db;
}

[data-theme="dark"] .inspector-box {
    background: #2d1f04;
    border-left-color: #f59e0b;
    color: #d1d5db;
}

[data-theme="dark"] mark {
    background: #854d0e;
    color: #fef3c7;
}

[data-theme="dark"] .mobile-menu {
    background: #16213e;
    border: 1px solid #1f2937;
}

[data-theme="dark"] .mobile-menu-item {
    color: #d1d5db;
    border-bottom-color: #1f2937;
}

[data-theme="dark"] .mobile-menu-item:hover {
    background: #1e3a5f;
    color: #3b82f6;
}

[data-theme="dark"] .export-btn {
    background: #16213e;
    border-color: #374151;
    color: #d1d5db;
}

[data-theme="dark"] .footer {
    background: #0f172a;
    border-top-color: #1f2937;
}

[data-theme="dark"] .search-result-item,
[data-theme="dark"] .term-card {
    background: #16213e;
    border-color: #1f2937;
}

[data-theme="dark"] .acronym-badge {
    background: #1e3a5f;
    color: #93c5fd;
}

/* Theme toggle button */
.theme-toggle-btn {
    background: none;
    border: 1px solid rgba(255,255,255,0.3);
    border-radius: var(--radius);
    color: var(--white);
    font-size: 1.1rem;
    cursor: pointer;
    padding: 6px 10px;
    line-height: 1;
    transition: all 0.2s;
}

.theme-toggle-btn:hover {
    background: rgba(255,255,255,0.2);
    border-color: rgba(255,255,255,0.5);
}

* { box-sizing: border-box; margin: 0; padding: 0; }

/* Accessibility */
.skip-link {
    position: absolute;
    top: -100px;
    left: 16px;
    background: var(--primary);
    color: var(--white);
    padding: 12px 24px;
    border-radius: var(--radius);
    z-index: 9999;
    font-weight: 600;
    text-decoration: none;
    transition: top 0.2s;
}

.skip-link:focus {
    top: 12px;
}

.sr-only {
    position: absolute;
    width: 1px;
    height: 1px;
    padding: 0;
    margin: -1px;
    overflow: hidden;
    clip: rect(0, 0, 0, 0);
    white-space: nowrap;
    border: 0;
}

/* Focus-visible styles for keyboard navigation */
*:focus-visible {
    outline: 2px solid var(--primary);
    outline-offset: 2px;
    border-radius: 4px;
}

.category-item:focus-visible {
    outline: 2px solid var(--white);
    outline-offset: -2px;
    background: rgba(255,255,255,0.15);
}

.term-card:focus-visible {
    outline: 2px solid var(--primary);
    outline-offset: 2px;
    box-shadow: var(--shadow-md);
}

.quiz-option:focus-visible {
    outline: 2px solid var(--primary);
    outline-offset: 2px;
}

.search-result-item:focus-visible {
    outline: 2px solid var(--primary);
    outline-offset: 2px;
    box-shadow: var(--shadow-md);
}

.action-btn:focus-visible {
    outline: 2px solid var(--primary);
    outline-offset: 2px;
}

[data-theme="dark"] *:focus-visible {
    outline-color: #60a5fa;
}

[data-theme="dark"] .category-item:focus-visible {
    outline-color: #60a5fa;
    background: rgba(96, 165, 250, 0.15);
}

body {
    font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
    background: var(--gray-100);
    color: var(--gray-800);
    line-height: 1.6;
    min-height: 100vh;
    transition: background-color 0.3s, color 0.3s;
}

#app {
    display: flex;
    flex-direction: column;
    min-height: 100vh;
}

/* Header */
.header {
    background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
    color: var(--white);
    height: var(--header-height);
    position: sticky;
    top: 0;
    z-index: 100;
    box-shadow: var(--shadow-md);
}

.header-content {
    max-width: 1600px;
    margin: 0 auto;
    padding: 0 24px;
    height: 100%;
    display: flex;
    align-items: center;
    justify-content: space-between;
    gap: 24px;
}

.logo-section {
    display: flex;
    align-items: center;
    gap: 12px;
}

.logo-icon { font-size: 32px; }

.logo-text h1 {
    font-size: 1.5rem;
    font-weight: 700;
    letter-spacing: -0.5px;
}

.tagline {
    font-size: 0.8rem;
    opacity: 0.9;
}

.header-actions {
    display: flex;
    align-items: center;
    gap: 12px;
}

.search-box {
    position: relative;
    display: flex;
    align-items: center;
}

.search-box .search-icon {
    position: absolute;
    left: 12px;
    font-size: 14px;
    opacity: 0.7;
}

.search-box input {
    width: 320px;
    padding: 10px 36px 10px 40px;
    border: none;
    border-radius: var(--radius);
    font-size: 0.95rem;
    background: rgba(255,255,255,0.15);
    color: var(--white);
    transition: all 0.2s;
}

.search-box input::placeholder { color: rgba(255,255,255,0.7); }
.search-box input:focus {
    outline: none;
    background: rgba(255,255,255,0.25);
    width: 380px;
}

.clear-btn {
    position: absolute;
    right: 8px;
    background: none;
    border: none;
    color: rgba(255,255,255,0.7);
    font-size: 18px;
    cursor: pointer;
    padding: 4px 8px;
    display: none;
}

.clear-btn.visible { display: block; }
.clear-btn:hover { color: var(--white); }

.mode-btn {
    padding: 8px 16px;
    border: 1px solid rgba(255,255,255,0.3);
    border-radius: var(--radius);
    background: rgba(255,255,255,0.1);
    color: var(--white);
    font-size: 0.9rem;
    cursor: pointer;
    transition: all 0.2s;
}

.mode-btn:hover {
    background: rgba(255,255,255,0.2);
    border-color: rgba(255,255,255,0.5);
}

/* Main Content */
.main-content {
    display: flex;
    flex: 1;
    max-width: 1600px;
    margin: 0 auto;
    width: 100%;
}

/* Sidebar */
.sidebar {
    width: var(--sidebar-width);
    background: var(--white);
    border-right: 1px solid var(--gray-200);
    display: flex;
    flex-direction: column;
    position: sticky;
    top: var(--header-height);
    height: calc(100vh - var(--header-height) - var(--footer-height));
    transition: width 0.3s;
    overflow: hidden;
}

.sidebar.collapsed { width: 60px; }
.sidebar.collapsed .category-name,
.sidebar.collapsed .category-count,
.sidebar.collapsed .sidebar-header h2,
.sidebar.collapsed .progress-section { display: none; }

.sidebar-header {
    padding: 16px 20px;
    border-bottom: 1px solid var(--gray-200);
    display: flex;
    justify-content: space-between;
    align-items: center;
}

.sidebar-header h2 {
    font-size: 0.9rem;
    text-transform: uppercase;
    letter-spacing: 0.5px;
    color: var(--gray-500);
}

.toggle-btn {
    background: none;
    border: none;
    cursor: pointer;
    color: var(--gray-400);
    font-size: 12px;
    padding: 4px;
}

.category-nav {
    flex: 1;
    overflow-y: auto;
    padding: 8px 0;
}

.category-item {
    display: flex;
    align-items: center;
    padding: 12px 20px;
    cursor: pointer;
    transition: all 0.2s;
    border-left: 3px solid transparent;
    gap: 12px;
}

.category-item:hover {
    background: var(--gray-50);
}

.category-item.active {
    background: var(--primary-light);
    border-left-color: var(--primary);
}

.category-icon { font-size: 20px; }

.category-name {
    flex: 1;
    font-size: 0.9rem;
    color: var(--gray-700);
}

.category-count {
    background: var(--gray-200);
    padding: 2px 8px;
    border-radius: 12px;
    font-size: 0.75rem;
    color: var(--gray-600);
}

.sidebar-footer {
    padding: 16px 20px;
    border-top: 1px solid var(--gray-200);
}

.progress-label {
    display: flex;
    justify-content: space-between;
    font-size: 0.8rem;
    color: var(--gray-600);
    margin-bottom: 6px;
}

.progress-bar {
    height: 6px;
    background: var(--gray-200);
    border-radius: 3px;
    overflow: hidden;
}

.progress-fill {
    height: 100%;
    background: linear-gradient(90deg, var(--secondary), var(--primary));
    border-radius: 3px;
    transition: width 0.3s;
    width: 0%;
}

/* Content Area */
.content-area {
    flex: 1;
    padding: 24px;
    overflow-y: auto;
    min-height: calc(100vh - var(--header-height) - var(--footer-height));
}

.view { display: none; }
.view.active { display: block; }

/* Welcome View */
.welcome-content {
    max-width: 1000px;
    margin: 0 auto;
}

.welcome-content h2 {
    font-size: 2rem;
    color: var(--gray-800);
    margin-bottom: 8px;
}

.welcome-content > p {
    color: var(--gray-500);
    font-size: 1.1rem;
    margin-bottom: 32px;
}

.quick-stats {
    display: grid;
    grid-template-columns: repeat(4, 1fr);
    gap: 16px;
    margin-bottom: 32px;
}

.stat-card {
    background: var(--white);
    padding: 20px;
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
    text-align: center;
}

.stat-value {
    font-size: 2rem;
    font-weight: 700;
    color: var(--primary);
}

.stat-label {
    font-size: 0.85rem;
    color: var(--gray-500);
}

.feature-cards {
    display: grid;
    grid-template-columns: repeat(4, 1fr);
    gap: 16px;
    margin-bottom: 40px;
}

.feature-card {
    background: var(--white);
    padding: 24px;
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
    cursor: pointer;
    transition: all 0.2s;
    text-align: center;
}

.feature-card:hover {
    transform: translateY(-2px);
    box-shadow: var(--shadow-lg);
}

.feature-icon {
    font-size: 2.5rem;
    margin-bottom: 12px;
}

.feature-card h3 {
    font-size: 1.1rem;
    color: var(--gray-800);
    margin-bottom: 8px;
}

.feature-card p {
    font-size: 0.85rem;
    color: var(--gray-500);
}

.recent-section h3 {
    font-size: 1rem;
    color: var(--gray-600);
    margin-bottom: 16px;
}

.recent-terms {
    display: flex;
    flex-wrap: wrap;
    gap: 8px;
}

.recent-term-chip {
    background: var(--white);
    padding: 8px 16px;
    border-radius: 20px;
    font-size: 0.9rem;
    color: var(--gray-700);
    cursor: pointer;
    box-shadow: var(--shadow-sm);
    transition: all 0.2s;
}

.recent-term-chip:hover {
    background: var(--primary-light);
    color: var(--primary);
}

.empty-state {
    color: var(--gray-400);
    font-style: italic;
}

/* View Header */
.view-header {
    margin-bottom: 24px;
}

.back-btn {
    background: none;
    border: none;
    color: var(--primary);
    cursor: pointer;
    font-size: 0.95rem;
    padding: 0;
    margin-bottom: 16px;
}

.back-btn:hover { text-decoration: underline; }

.view-header h2 {
    font-size: 1.75rem;
    color: var(--gray-800);
    margin-bottom: 4px;
}

.view-header p {
    color: var(--gray-500);
}

.term-actions {
    display: flex;
    gap: 8px;
    float: right;
}

.action-btn {
    background: var(--white);
    border: 1px solid var(--gray-300);
    border-radius: var(--radius);
    padding: 8px 12px;
    cursor: pointer;
    font-size: 1rem;
    transition: all 0.2s;
}

.action-btn:hover { background: var(--gray-50); }
.action-btn.active {
    background: var(--accent);
    border-color: var(--accent);
}

/* Terms List */
.terms-list {
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
    gap: 16px;
}

.term-card {
    background: var(--white);
    padding: 20px;
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
    cursor: pointer;
    transition: all 0.2s;
    border-left: 4px solid transparent;
}

.term-card:hover {
    transform: translateY(-2px);
    box-shadow: var(--shadow-md);
    border-left-color: var(--primary);
}

.term-card.learned { border-left-color: var(--secondary); }

.term-card-header {
    display: flex;
    justify-content: space-between;
    align-items: flex-start;
    margin-bottom: 8px;
}

.term-card h3 {
    font-size: 1.1rem;
    color: var(--gray-800);
}

.term-acronym {
    background: var(--primary-light);
    color: var(--primary);
    padding: 2px 8px;
    border-radius: 4px;
    font-size: 0.75rem;
    font-weight: 600;
}

.term-card p {
    font-size: 0.9rem;
    color: var(--gray-600);
    display: -webkit-box;
    -webkit-line-clamp: 2;
    -webkit-box-orient: vertical;
    overflow: hidden;
}

.term-card-footer {
    display: flex;
    gap: 6px;
    margin-top: 12px;
    flex-wrap: wrap;
}

.term-tag {
    background: var(--gray-100);
    padding: 2px 8px;
    border-radius: 4px;
    font-size: 0.7rem;
    color: var(--gray-500);
}

/* Term Detail */
.term-detail {
    background: var(--white);
    padding: 32px;
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
    max-width: 900px;
}

.term-detail-header {
    margin-bottom: 24px;
    padding-bottom: 16px;
    border-bottom: 1px solid var(--gray-200);
}

.term-detail h1 {
    font-size: 2rem;
    color: var(--gray-800);
    margin-bottom: 4px;
}

.term-detail .acronym-badge {
    display: inline-block;
    background: var(--primary);
    color: var(--white);
    padding: 4px 12px;
    border-radius: 4px;
    font-size: 0.9rem;
    font-weight: 600;
    margin-left: 12px;
}

.term-category-badge {
    display: inline-block;
    background: var(--gray-100);
    color: var(--gray-600);
    padding: 4px 12px;
    border-radius: 4px;
    font-size: 0.85rem;
    margin-top: 8px;
}

.term-section {
    margin-bottom: 24px;
}

.term-section h2 {
    font-size: 1rem;
    color: var(--gray-500);
    text-transform: uppercase;
    letter-spacing: 0.5px;
    margin-bottom: 8px;
    display: flex;
    align-items: center;
    gap: 8px;
}

.term-section-icon { font-size: 1.1rem; }

.term-section p, .term-section div {
    font-size: 1rem;
    color: var(--gray-700);
    line-height: 1.7;
}

.example-box {
    background: var(--gray-50);
    border-left: 4px solid var(--secondary);
    padding: 16px;
    border-radius: 0 var(--radius) var(--radius) 0;
}

.mistake-box {
    background: #fef2f2;
    border-left: 4px solid var(--danger);
    padding: 16px;
    border-radius: 0 var(--radius) var(--radius) 0;
}

.inspector-box {
    background: #fffbeb;
    border-left: 4px solid var(--accent);
    padding: 16px;
    border-radius: 0 var(--radius) var(--radius) 0;
}

.related-terms {
    display: flex;
    flex-wrap: wrap;
    gap: 8px;
}

.related-term {
    background: var(--primary-light);
    color: var(--primary);
    padding: 6px 14px;
    border-radius: 20px;
    font-size: 0.9rem;
    cursor: pointer;
    transition: all 0.2s;
}

.related-term:hover {
    background: var(--primary);
    color: var(--white);
}

/* Search Results */
.search-results {
    display: flex;
    flex-direction: column;
    gap: 12px;
}

.search-result-item {
    background: var(--white);
    padding: 16px 20px;
    border-radius: var(--radius);
    box-shadow: var(--shadow-sm);
    cursor: pointer;
    transition: all 0.2s;
}

.search-result-item:hover {
    box-shadow: var(--shadow);
    transform: translateX(4px);
}

.search-result-item h3 {
    font-size: 1.1rem;
    color: var(--gray-800);
    margin-bottom: 4px;
}

.search-result-item .category {
    font-size: 0.8rem;
    color: var(--primary);
    margin-bottom: 8px;
}

.search-result-item p {
    font-size: 0.9rem;
    color: var(--gray-600);
}

mark {
    background: #fef08a;
    padding: 0 2px;
    border-radius: 2px;
}

/* Quiz View */
.quiz-content {
    max-width: 700px;
    margin: 0 auto;
}

.quiz-card {
    background: var(--white);
    padding: 40px;
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow-md);
    text-align: center;
}

.quiz-question {
    font-size: 1.3rem;
    color: var(--gray-800);
    margin-bottom: 32px;
    line-height: 1.5;
}

.quiz-options {
    display: flex;
    flex-direction: column;
    gap: 12px;
}

.quiz-option {
    padding: 16px 24px;
    border: 2px solid var(--gray-200);
    border-radius: var(--radius);
    cursor: pointer;
    font-size: 1rem;
    text-align: left;
    transition: all 0.2s;
    background: var(--white);
}

.quiz-option:hover { border-color: var(--primary); }
.quiz-option.selected { border-color: var(--primary); background: var(--primary-light); }
.quiz-option.correct { border-color: var(--secondary); background: #d1fae5; }
.quiz-option.incorrect { border-color: var(--danger); background: #fee2e2; }

.quiz-actions {
    margin-top: 32px;
    display: flex;
    justify-content: center;
    gap: 16px;
}

.quiz-btn {
    padding: 12px 32px;
    border: none;
    border-radius: var(--radius);
    font-size: 1rem;
    cursor: pointer;
    transition: all 0.2s;
}

.quiz-btn-primary {
    background: var(--primary);
    color: var(--white);
}

.quiz-btn-primary:hover { background: var(--primary-dark); }
.quiz-btn-primary:disabled { background: var(--gray-300); cursor: not-allowed; }

.quiz-btn-secondary {
    background: var(--gray-200);
    color: var(--gray-700);
}

.quiz-progress {
    display: flex;
    gap: 16px;
    font-size: 0.9rem;
    color: var(--gray-600);
}

/* Quiz Setup */
.quiz-setup {
    max-width: 600px;
    margin: 0 auto;
}

.quiz-setup-card {
    background: var(--white);
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
    overflow: hidden;
}

.quiz-setup-section {
    padding: 24px;
    border-bottom: 1px solid var(--gray-100);
}

.quiz-setup-section:last-child {
    border-bottom: none;
}

.quiz-setup-section h3 {
    font-size: 0.85rem;
    text-transform: uppercase;
    letter-spacing: 0.5px;
    color: var(--gray-500);
    margin-bottom: 12px;
}

.quiz-setup-options {
    display: flex;
    flex-wrap: wrap;
    gap: 8px;
}

.quiz-setup-option {
    padding: 10px 18px;
    border: 2px solid var(--gray-200);
    border-radius: 25px;
    background: var(--white);
    cursor: pointer;
    font-size: 0.9rem;
    color: var(--gray-700);
    transition: all 0.2s;
}

.quiz-setup-option:hover {
    border-color: var(--primary);
    background: var(--primary-light);
}

.quiz-setup-option.active {
    border-color: var(--primary);
    background: var(--primary);
    color: var(--white);
}

.quiz-setup-option.weak-terms {
    border-style: dashed;
}

.quiz-setup-option.weak-terms.active {
    border-style: solid;
    background: var(--accent);
    border-color: var(--accent);
    color: var(--white);
}

.quiz-weak-count {
    font-size: 0.8rem;
    color: var(--gray-500);
    margin-top: 8px;
}

.quiz-setup-start {
    padding: 24px;
}

.quiz-setup-start button {
    width: 100%;
    padding: 16px;
    background: var(--primary);
    color: var(--white);
    border: none;
    border-radius: var(--radius);
    font-size: 1.1rem;
    font-weight: 600;
    cursor: pointer;
    transition: all 0.2s;
}

.quiz-setup-start button:hover {
    background: var(--primary-dark);
}

/* Quiz Results Enhancement */
.quiz-results-details {
    text-align: left;
    margin-top: 24px;
}

.quiz-results-details h3 {
    font-size: 0.9rem;
    color: var(--gray-500);
    text-transform: uppercase;
    letter-spacing: 0.5px;
    margin-bottom: 12px;
}

.quiz-result-item {
    display: flex;
    align-items: center;
    gap: 12px;
    padding: 10px 12px;
    border-radius: var(--radius);
    margin-bottom: 6px;
    cursor: pointer;
    transition: background 0.15s;
}

.quiz-result-item:hover {
    background: var(--gray-50);
}

.quiz-result-item.correct {
    border-left: 3px solid var(--secondary);
}

.quiz-result-item.incorrect {
    border-left: 3px solid var(--danger);
}

.quiz-result-icon {
    width: 24px;
    height: 24px;
    border-radius: 50%;
    display: flex;
    align-items: center;
    justify-content: center;
    color: var(--white);
    font-size: 0.75rem;
    flex-shrink: 0;
}

.quiz-result-item.correct .quiz-result-icon { background: var(--secondary); }
.quiz-result-item.incorrect .quiz-result-icon { background: var(--danger); }

.quiz-result-term {
    font-weight: 600;
    color: var(--gray-800);
    font-size: 0.9rem;
}

.quiz-mode-badge {
    display: inline-block;
    padding: 2px 8px;
    border-radius: 4px;
    font-size: 0.7rem;
    font-weight: 600;
    text-transform: uppercase;
    background: var(--gray-100);
    color: var(--gray-500);
    margin-bottom: 16px;
}

/* Stats View */
.stats-content {
    display: grid;
    grid-template-columns: repeat(2, 1fr);
    gap: 24px;
    max-width: 900px;
}

.stats-card {
    background: var(--white);
    padding: 24px;
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
}

.stats-card h3 {
    font-size: 1rem;
    color: var(--gray-500);
    margin-bottom: 16px;
}

.stats-card.full-width { grid-column: span 2; }

.category-progress-item {
    display: flex;
    align-items: center;
    gap: 12px;
    margin-bottom: 12px;
}

.category-progress-item .name { flex: 1; font-size: 0.9rem; }
.category-progress-item .bar {
    width: 150px;
    height: 8px;
    background: var(--gray-200);
    border-radius: 4px;
    overflow: hidden;
}

.category-progress-item .bar-fill {
    height: 100%;
    background: var(--primary);
    border-radius: 4px;
}

.category-progress-item .percent {
    width: 40px;
    text-align: right;
    font-size: 0.85rem;
    color: var(--gray-500);
}

/* Bookmarks View */
.bookmarks-list {
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
    gap: 16px;
}

/* Footer */
.footer {
    background: var(--white);
    border-top: 1px solid var(--gray-200);
    height: var(--footer-height);
    display: flex;
    align-items: center;
}

.footer-content {
    max-width: 1600px;
    margin: 0 auto;
    padding: 0 24px;
    width: 100%;
    display: flex;
    gap: 16px;
    font-size: 0.8rem;
    color: var(--gray-500);
}

/* Mobile Menu Button - hidden on desktop */
.mobile-menu-btn {
    display: none;
    background: none;
    border: 1px solid rgba(255,255,255,0.3);
    border-radius: var(--radius);
    color: var(--white);
    font-size: 1.4rem;
    cursor: pointer;
    padding: 6px 12px;
    line-height: 1;
    transition: all 0.2s;
}

.mobile-menu-btn:hover {
    background: rgba(255,255,255,0.2);
    border-color: rgba(255,255,255,0.5);
}

/* Mobile Dropdown Menu */
.mobile-menu {
    display: none;
    position: absolute;
    top: var(--header-height);
    right: 16px;
    background: var(--white);
    border-radius: 0 0 var(--radius-lg) var(--radius-lg);
    box-shadow: var(--shadow-lg);
    overflow: hidden;
    z-index: 99;
    min-width: 200px;
}

.mobile-menu.open {
    display: flex;
    flex-direction: column;
}

.mobile-menu-item {
    background: none;
    border: none;
    padding: 14px 20px;
    font-size: 0.95rem;
    color: var(--gray-700);
    cursor: pointer;
    text-align: left;
    transition: background 0.15s;
    border-bottom: 1px solid var(--gray-100);
}

.mobile-menu-item:last-child {
    border-bottom: none;
}

.mobile-menu-item:hover {
    background: var(--primary-light);
    color: var(--primary);
}

/* Responsive */
@media (max-width: 1200px) {
    .quick-stats { grid-template-columns: repeat(2, 1fr); }
    .feature-cards { grid-template-columns: repeat(2, 1fr); }
}

@media (max-width: 768px) {
    .header { position: relative; }
    .header-content { padding: 0 16px; }
    .search-box input { width: 200px; }
    .search-box input:focus { width: 240px; }
    .mode-btn { display: none; }
    .mobile-menu-btn { display: block; }
    .sidebar { position: fixed; left: 0; z-index: 50; }
    .sidebar.collapsed { left: calc(-1 * var(--sidebar-width) + 60px); }
    .content-area { padding: 16px; }
    .quick-stats { grid-template-columns: 1fr 1fr; }
    .feature-cards { grid-template-columns: 1fr 1fr; }
    .stats-content { grid-template-columns: 1fr; }
    .stats-card.full-width { grid-column: span 1; }
}

@media (max-width: 480px) {
    .search-box input { width: 140px; }
    .search-box input:focus { width: 180px; }
    .logo-text h1 { font-size: 1.2rem; }
    .tagline { display: none; }
    .quick-stats { grid-template-columns: 1fr 1fr; }
    .feature-cards { grid-template-columns: 1fr; }
}

/* ==========================================
   SCENARIO STYLES
   ========================================== */

/* Scenario Library */
.scenario-categories {
    display: flex;
    gap: 12px;
    margin-bottom: 24px;
    flex-wrap: wrap;
}

.scenario-category-btn {
    padding: 10px 20px;
    border: 2px solid var(--gray-200);
    border-radius: 25px;
    background: var(--white);
    cursor: pointer;
    font-size: 0.9rem;
    transition: all 0.2s;
    display: flex;
    align-items: center;
    gap: 8px;
}

.scenario-category-btn:hover {
    border-color: var(--primary);
    background: var(--primary-light);
}

.scenario-category-btn.active {
    border-color: var(--primary);
    background: var(--primary);
    color: var(--white);
}

.scenario-list {
    display: grid;
    gap: 16px;
}

.scenario-card {
    background: var(--white);
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
    overflow: hidden;
    transition: all 0.2s;
    cursor: pointer;
}

.scenario-card:hover {
    transform: translateY(-2px);
    box-shadow: var(--shadow-lg);
}

.scenario-card-content {
    padding: 24px;
    display: flex;
    gap: 20px;
    align-items: flex-start;
}

.scenario-icon {
    font-size: 2.5rem;
    line-height: 1;
}

.scenario-info {
    flex: 1;
}

.scenario-info h3 {
    font-size: 1.2rem;
    color: var(--gray-800);
    margin-bottom: 4px;
    display: flex;
    align-items: center;
    gap: 10px;
}

.scenario-difficulty {
    padding: 3px 10px;
    border-radius: 12px;
    font-size: 0.7rem;
    font-weight: 600;
    text-transform: uppercase;
}

.scenario-difficulty.beginner { background: #d1fae5; color: #065f46; }
.scenario-difficulty.intermediate { background: #fef3c7; color: #92400e; }
.scenario-difficulty.advanced { background: #fee2e2; color: #991b1b; }

.scenario-info p {
    color: var(--gray-600);
    font-size: 0.9rem;
    margin-bottom: 12px;
}

.scenario-meta {
    display: flex;
    gap: 16px;
    font-size: 0.8rem;
    color: var(--gray-500);
}

.scenario-card-action {
    display: flex;
    align-items: center;
    padding-right: 8px;
}

.scenario-start-btn {
    padding: 10px 24px;
    background: var(--primary);
    color: var(--white);
    border: none;
    border-radius: var(--radius);
    font-weight: 600;
    cursor: pointer;
    transition: all 0.2s;
}

.scenario-start-btn:hover {
    background: var(--primary-dark);
}

.scenario-completed {
    display: flex;
    align-items: center;
    gap: 8px;
    color: var(--secondary);
    font-size: 0.9rem;
}

/* Scenario Briefing */
.scenario-briefing {
    max-width: 700px;
    margin: 0 auto;
}

.briefing-header {
    background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
    color: var(--white);
    padding: 32px;
    border-radius: var(--radius-lg) var(--radius-lg) 0 0;
    text-align: center;
}

.briefing-header .scenario-icon {
    font-size: 3.5rem;
    margin-bottom: 16px;
}

.briefing-header h1 {
    font-size: 1.75rem;
    margin-bottom: 8px;
}

.briefing-header .meta {
    display: flex;
    justify-content: center;
    gap: 16px;
    font-size: 0.9rem;
    opacity: 0.9;
}

.briefing-body {
    background: var(--white);
    padding: 32px;
    border-radius: 0 0 var(--radius-lg) var(--radius-lg);
    box-shadow: var(--shadow);
}

.briefing-section {
    margin-bottom: 24px;
}

.briefing-section h2 {
    font-size: 0.85rem;
    text-transform: uppercase;
    letter-spacing: 0.5px;
    color: var(--gray-500);
    margin-bottom: 8px;
}

.briefing-section p {
    color: var(--gray-700);
    line-height: 1.6;
}

.briefing-objectives {
    background: var(--gray-50);
    padding: 16px;
    border-radius: var(--radius);
}

.briefing-objectives ul {
    margin: 0;
    padding-left: 20px;
}

.briefing-objectives li {
    color: var(--gray-700);
    margin-bottom: 6px;
}

.briefing-terms {
    display: flex;
    flex-wrap: wrap;
    gap: 8px;
}

.briefing-term {
    padding: 6px 12px;
    background: var(--primary-light);
    color: var(--primary);
    border-radius: 15px;
    font-size: 0.85rem;
}

.briefing-start-btn {
    width: 100%;
    padding: 16px;
    background: var(--primary);
    color: var(--white);
    border: none;
    border-radius: var(--radius);
    font-size: 1.1rem;
    font-weight: 600;
    cursor: pointer;
    transition: all 0.2s;
    margin-top: 8px;
}

.briefing-start-btn:hover {
    background: var(--primary-dark);
}

/* Scenario Active */
.scenario-header {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 20px;
    padding-bottom: 16px;
    border-bottom: 1px solid var(--gray-200);
}

.scenario-header-left {
    display: flex;
    align-items: center;
    gap: 12px;
}

.scenario-exit-btn {
    background: none;
    border: none;
    color: var(--gray-500);
    cursor: pointer;
    font-size: 1.2rem;
    padding: 4px;
}

.scenario-exit-btn:hover {
    color: var(--gray-700);
}

.scenario-title-small {
    font-size: 1rem;
    color: var(--gray-700);
}

.scenario-header-right {
    display: flex;
    align-items: center;
    gap: 20px;
}

.scenario-progress-bar {
    display: flex;
    gap: 6px;
}

.scenario-progress-dot {
    width: 32px;
    height: 6px;
    border-radius: 3px;
    background: var(--gray-200);
}

.scenario-progress-dot.completed { background: var(--secondary); }
.scenario-progress-dot.current { background: var(--primary); }

.scenario-score {
    font-size: 0.9rem;
    color: var(--primary);
    font-weight: 600;
}

.scenario-content {
    max-width: 800px;
    margin: 0 auto;
}

.scenario-step-card {
    background: var(--white);
    border-radius: var(--radius-lg);
    box-shadow: var(--shadow);
    overflow: hidden;
}

.scenario-step-header {
    background: var(--gray-50);
    padding: 16px 24px;
    border-bottom: 1px solid var(--gray-200);
}

.scenario-step-header h2 {
    font-size: 1.1rem;
    color: var(--gray-800);
    margin: 0;
}

.scenario-step-body {
    padding: 24px;
}

/* Content Types */
.scenario-content-box {
    background: var(--gray-100);
    border-radius: var(--radius);
    padding: 20px;
    margin-bottom: 24px;
}

.scenario-content-box.voicemail {
    background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
    border-left: 4px solid #0ea5e9;
}

.scenario-content-box.email {
    background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
    border-left: 4px solid #eab308;
}

.scenario-content-box.case {
    background: linear-gradient(135deg, #f0fdf4 0%, #dcfce7 100%);
    border-left: 4px solid #22c55e;
}

.scenario-content-box.interview {
    background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
    border-left: 4px solid #a855f7;
}

.scenario-content-meta {
    font-size: 0.8rem;
    color: var(--gray-500);
    margin-bottom: 12px;
    display: flex;
    align-items: center;
    gap: 8px;
}

.scenario-content-text {
    color: var(--gray-700);
    line-height: 1.7;
    font-size: 0.95rem;
}

.scenario-content-text.quote {
    font-style: italic;
}

.scenario-highlight {
    background: #fef08a;
    padding: 2px 6px;
    border-radius: 3px;
}

/* Question & Options */
.scenario-question {
    margin-bottom: 20px;
}

.scenario-question h3 {
    font-size: 1.05rem;
    color: var(--gray-800);
    display: flex;
    align-items: flex-start;
    gap: 8px;
}

.scenario-options {
    display: flex;
    flex-direction: column;
    gap: 12px;
    margin-bottom: 20px;
}

.scenario-option {
    display: flex;
    align-items: flex-start;
    gap: 12px;
    padding: 16px;
    border: 2px solid var(--gray-200);
    border-radius: var(--radius);
    cursor: pointer;
    transition: all 0.2s;
}

.scenario-option:hover:not(.disabled) {
    border-color: var(--primary);
    background: var(--primary-light);
}

.scenario-option.selected {
    border-color: var(--primary);
    background: var(--primary-light);
}

.scenario-option.correct {
    border-color: var(--secondary);
    background: #d1fae5;
}

.scenario-option.incorrect {
    border-color: var(--danger);
    background: #fee2e2;
}

.scenario-option.disabled {
    cursor: default;
    opacity: 0.7;
}

.scenario-option input {
    margin-top: 3px;
}

.scenario-option-text {
    flex: 1;
    color: var(--gray-700);
}

.scenario-option-icon {
    font-size: 1.2rem;
}

/* Hint */
.scenario-hint-btn {
    background: none;
    border: none;
    color: var(--primary);
    cursor: pointer;
    font-size: 0.9rem;
    padding: 0;
    margin-bottom: 16px;
}

.scenario-hint-btn:hover {
    text-decoration: underline;
}

.scenario-hint-box {
    background: #fef3c7;
    border: 1px solid #fcd34d;
    border-radius: var(--radius);
    padding: 12px 16px;
    margin-bottom: 16px;
    font-size: 0.9rem;
    color: #92400e;
}

/* Feedback */
.scenario-feedback {
    border-radius: var(--radius);
    padding: 20px;
    margin-bottom: 20px;
}

.scenario-feedback.correct {
    background: #d1fae5;
    border: 1px solid #6ee7b7;
}

.scenario-feedback.incorrect {
    background: #fee2e2;
    border: 1px solid #fca5a5;
}

.scenario-feedback h4 {
    font-size: 1.1rem;
    margin-bottom: 12px;
    display: flex;
    align-items: center;
    gap: 8px;
}

.scenario-feedback.correct h4 { color: #065f46; }
.scenario-feedback.incorrect h4 { color: #991b1b; }

.scenario-feedback p {
    color: var(--gray-700);
    margin-bottom: 12px;
    line-height: 1.6;
}

.scenario-feedback-points {
    margin: 16px 0;
}

.scenario-feedback-point {
    display: flex;
    align-items: flex-start;
    gap: 10px;
    padding: 8px 0;
    font-size: 0.9rem;
}

.scenario-feedback-point-icon {
    width: 20px;
    height: 20px;
    border-radius: 50%;
    display: flex;
    align-items: center;
    justify-content: center;
    font-size: 0.75rem;
    flex-shrink: 0;
}

.scenario-feedback-point-icon.met { background: var(--secondary); color: white; }
.scenario-feedback-point-icon.notmet { background: var(--danger); color: white; }
.scenario-feedback-point-icon.info { background: var(--primary); color: white; }
.scenario-feedback-point-icon.warning { background: var(--accent); color: white; }

.scenario-inspector-tip {
    background: rgba(255,255,255,0.5);
    border-radius: var(--radius);
    padding: 12px;
    margin-top: 12px;
    font-size: 0.9rem;
}

.scenario-inspector-tip strong {
    color: var(--gray-800);
}

.scenario-related-terms {
    margin-top: 16px;
    padding-top: 16px;
    border-top: 1px solid var(--gray-200);
}

.scenario-related-terms p {
    font-size: 0.8rem;
    color: var(--gray-500);
    margin-bottom: 8px;
}

.scenario-related-terms .terms {
    display: flex;
    flex-wrap: wrap;
    gap: 8px;
}

.scenario-related-terms .term {
    padding: 4px 12px;
    background: var(--gray-100);
    color: var(--gray-600);
    border-radius: 15px;
    font-size: 0.8rem;
    cursor: pointer;
    transition: all 0.2s;
}

.scenario-related-terms .term:hover {
    background: var(--primary-light);
    color: var(--primary);
}

/* Actions */
.scenario-actions {
    display: flex;
    gap: 12px;
}

.scenario-submit-btn,
.scenario-next-btn {
    flex: 1;
    padding: 14px 24px;
    border: none;
    border-radius: var(--radius);
    font-size: 1rem;
    font-weight: 600;
    cursor: pointer;
    transition: all 0.2s;
}

.scenario-submit-btn {
    background: var(--primary);
    color: white;
}

.scenario-submit-btn:hover:not(:disabled) {
    background: var(--primary-dark);
}

.scenario-submit-btn:disabled {
    background: var(--gray-300);
    cursor: not-allowed;
}

.scenario-next-btn {
    background: var(--secondary);
    color: white;
}

.scenario-next-btn:hover {
    background: #047857;
}

/* Scenario Debrief */
.scenario-debrief {
    max-width: 700px;
    margin: 0 auto;
}

.debrief-header {
    text-align: center;
    padding: 40px;
    border-radius: var(--radius-lg) var(--radius-lg) 0 0;
}

.debrief-header.passed {
    background: linear-gradient(135deg, var(--secondary) 0%, #047857 100%);
    color: white;
}

.debrief-header.failed {
    background: linear-gradient(135deg, var(--accent) 0%, #d97706 100%);
    color: white;
}

.debrief-header .icon {
    font-size: 4rem;
    margin-bottom: 16px;
}

.debrief-header h1 {
    font-size: 1.75rem;
    margin-bottom: 8px;
}

.debrief-header p {
    font-size: 1.1rem;
    opacity: 0.9;
}

.debrief-body {
    background: var(--white);
    padding: 32px;
    border-radius: 0 0 var(--radius-lg) var(--radius-lg);
    box-shadow: var(--shadow);
}

.debrief-section {
    margin-bottom: 28px;
}

.debrief-section h2 {
    font-size: 1rem;
    color: var(--gray-700);
    margin-bottom: 12px;
    display: flex;
    align-items: center;
    gap: 8px;
}

.debrief-answers {
    display: flex;
    flex-direction: column;
    gap: 8px;
}

.debrief-answer {
    display: flex;
    align-items: center;
    gap: 12px;
    padding: 12px;
    border-radius: var(--radius);
}

.debrief-answer.correct { background: #d1fae5; }
.debrief-answer.incorrect { background: #fee2e2; }

.debrief-answer-icon {
    width: 24px;
    height: 24px;
    border-radius: 50%;
    display: flex;
    align-items: center;
    justify-content: center;
    color: white;
    font-size: 0.8rem;
}

.debrief-answer.correct .debrief-answer-icon { background: var(--secondary); }
.debrief-answer.incorrect .debrief-answer-icon { background: var(--danger); }

.debrief-takeaways {
    background: var(--gray-50);
    padding: 16px;
    border-radius: var(--radius);
}

.debrief-takeaways ul {
    margin: 0;
    padding-left: 20px;
}

.debrief-takeaways li {
    color: var(--gray-700);
    margin-bottom: 8px;
    line-height: 1.5;
}

.debrief-terms {
    display: flex;
    flex-wrap: wrap;
    gap: 8px;
}

.debrief-term {
    padding: 6px 14px;
    background: var(--primary-light);
    color: var(--primary);
    border-radius: 20px;
    font-size: 0.9rem;
    cursor: pointer;
    transition: all 0.2s;
}

.debrief-term:hover {
    background: var(--primary);
    color: white;
}

.debrief-actions {
    display: flex;
    gap: 12px;
    margin-top: 24px;
}

.debrief-btn {
    flex: 1;
    padding: 14px;
    border: none;
    border-radius: var(--radius);
    font-size: 1rem;
    font-weight: 600;
    cursor: pointer;
    transition: all 0.2s;
}

.debrief-btn-secondary {
    background: var(--gray-200);
    color: var(--gray-700);
}

.debrief-btn-secondary:hover {
    background: var(--gray-300);
}

.debrief-btn-primary {
    background: var(--primary);
    color: white;
}

.debrief-btn-primary:hover {
    background: var(--primary-dark);
}

/* ==========================================
   EXPORT & PRINT STYLES
   ========================================== */

/* Bookmarks header row */
.bookmarks-header-row {
    display: flex;
    justify-content: space-between;
    align-items: center;
    flex-wrap: wrap;
    gap: 12px;
}

.bookmarks-export-actions {
    display: flex;
    gap: 8px;
}

.export-btn {
    padding: 8px 16px;
    border: 1px solid var(--gray-300);
    border-radius: var(--radius);
    background: var(--white);
    color: var(--gray-700);
    font-size: 0.85rem;
    cursor: pointer;
    transition: all 0.2s;
}

.export-btn:hover {
    background: var(--primary-light);
    border-color: var(--primary);
    color: var(--primary);
}

/* Print Stylesheet */
@media print {
    /* Force light theme for print */
    :root, [data-theme="dark"] {
        --gray-50: #f9fafb;
        --gray-100: #f3f4f6;
        --gray-200: #e5e7eb;
        --gray-800: #1f2937;
        --white: #ffffff;
    }

    /* Hide non-content elements */
    .header,
    .sidebar,
    .footer,
    .mobile-menu,
    .mobile-menu-btn,
    .theme-toggle-btn,
    .skip-link,
    .sr-only,
    .back-btn,
    .term-actions,
    .bookmarks-export-actions,
    .mode-btn,
    .search-box,
    .feature-cards,
    .quick-stats,
    .recent-section,
    .quiz-actions,
    .related-term {
        display: none !important;
    }

    /* Reset layout */
    body {
        background: white;
        color: black;
        font-size: 11pt;
        line-height: 1.5;
    }

    #app {
        display: block;
    }

    .main-content {
        display: block;
        max-width: 100%;
    }

    .content-area {
        padding: 0;
        min-height: auto;
    }

    /* Show only the active view */
    .view { display: none !important; }
    .view.active { display: block !important; }

    /* Term detail print styles */
    .term-detail {
        box-shadow: none;
        padding: 0;
        max-width: 100%;
    }

    .term-detail-header {
        border-bottom: 2px solid #333;
        padding-bottom: 12px;
        margin-bottom: 16px;
    }

    .term-detail h1 {
        font-size: 18pt;
        color: black;
    }

    .term-section {
        page-break-inside: avoid;
        margin-bottom: 16px;
    }

    .term-section h2 {
        font-size: 11pt;
        color: #333;
        border-bottom: 1px solid #ccc;
        padding-bottom: 4px;
    }

    .example-box,
    .mistake-box,
    .inspector-box {
        border-left-width: 3px;
        padding: 10px;
        background: #f5f5f5 !important;
        -webkit-print-color-adjust: exact;
        print-color-adjust: exact;
    }

    .acronym-badge {
        background: #333 !important;
        color: white !important;
        -webkit-print-color-adjust: exact;
        print-color-adjust: exact;
    }

    /* Study sheet print styles */
    .print-study-sheet {
        font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
    }

    .print-study-sheet .print-term {
        page-break-inside: avoid;
        margin-bottom: 20px;
        padding-bottom: 16px;
        border-bottom: 1px solid #ddd;
    }

    .print-study-sheet .print-term:last-child {
        border-bottom: none;
    }

    .print-study-sheet .print-term h2 {
        font-size: 13pt;
        margin-bottom: 4px;
    }

    .print-study-sheet .print-term-category {
        font-size: 9pt;
        color: #666;
        margin-bottom: 8px;
    }

    .print-study-sheet .print-term-section {
        margin-bottom: 8px;
    }

    .print-study-sheet .print-term-section strong {
        font-size: 9pt;
        text-transform: uppercase;
        color: #555;
    }

    .print-study-sheet .print-term-section p {
        font-size: 10pt;
        margin-top: 2px;
    }
}

    </style>
</head>
<body>
    <div id="app">
        <!-- Skip to content link for keyboard users -->
        <a href="#mainContent" class="skip-link">Skip to main content</a>
        
        <!-- Header -->
        <header class="header" role="banner">
            <div class="header-content">
                <div class="logo-section">
                    <div class="logo-icon">üìö</div>
                    <div class="logo-text">
                        <h1>PV Glossary</h1>
                        <span class="tagline">Pharmacovigilance Terms & Definitions</span>
                    </div>
                </div>
                <div class="header-actions">
                    <div class="search-box">
                        <span class="search-icon">üîç</span>
                        <input type="text" id="searchInput" placeholder="Search terms, definitions, acronyms..." aria-label="Search glossary terms" role="searchbox" autocomplete="off">
                        <button id="clearSearch" class="clear-btn" title="Clear search" aria-label="Clear search">√ó</button>
                    </div>
                    <button id="scenarioModeBtn" class="mode-btn" title="Scenarios">üé¨ Scenarios</button>
                    <button id="quizModeBtn" class="mode-btn" title="Quiz Mode">üéØ Quiz</button>
                    <button id="bookmarksBtn" class="mode-btn" title="Bookmarks">‚≠ê Saved</button>
                    <button id="statsBtn" class="mode-btn" title="Statistics">üìä</button>
                    <button id="themeToggleBtn" class="theme-toggle-btn" title="Toggle dark mode" aria-label="Toggle dark mode">üåô</button>
                    <button id="mobileMenuBtn" class="mobile-menu-btn" title="Menu" aria-label="Open menu">‚ò∞</button>
                </div>
                <!-- Mobile Dropdown Menu -->
                <div id="mobileMenu" class="mobile-menu">
                    <button class="mobile-menu-item" onclick="PVGlossary.mobileMenuAction('scenarios')">üé¨ Scenarios</button>
                    <button class="mobile-menu-item" onclick="PVGlossary.mobileMenuAction('quiz')">üéØ Quiz Mode</button>
                    <button class="mobile-menu-item" onclick="PVGlossary.mobileMenuAction('bookmarks')">‚≠ê Saved Terms</button>
                    <button class="mobile-menu-item" onclick="PVGlossary.mobileMenuAction('stats')">üìä Statistics</button>
                    <button class="mobile-menu-item" onclick="PVGlossary.mobileMenuAction('random')">üé≤ Random Term</button>
                    <button class="mobile-menu-item" onclick="PVGlossary.mobileMenuAction('theme')" id="mobileThemeBtn">üåô Dark Mode</button>
                </div>
            </div>
        </header>

        <!-- Main Content -->
        <main class="main-content" role="main">
            <!-- Sidebar - Categories -->
            <aside class="sidebar" id="sidebar" role="navigation" aria-label="Term categories">
                <div class="sidebar-header">
                    <h2>Categories</h2>
                    <button id="toggleSidebar" class="toggle-btn" aria-label="Toggle sidebar">‚óÄ</button>
                </div>
                <nav class="category-nav" id="categoryNav" aria-label="Category list">
                    <!-- Categories populated by JS -->
                </nav>
                <div class="sidebar-footer">
                    <div class="progress-section">
                        <div class="progress-label">
                            <span>Learning Progress</span>
                            <span id="progressPercent">0%</span>
                        </div>
                        <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" aria-label="Learning progress" id="progressBar">
                            <div class="progress-fill" id="progressFill"></div>
                        </div>
                    </div>
                </div>
            </aside>

            <!-- Content Area -->
            <div class="content-area" id="mainContent">
                <!-- Screen reader announcements -->
                <div id="srAnnounce" class="sr-only" aria-live="polite" aria-atomic="true"></div>
                
                <!-- Welcome View -->
                <section id="welcomeView" class="view active">
                    <div class="welcome-content">
                        <h2>Welcome to PV Glossary</h2>
                        <p>Your comprehensive reference for Pharmacovigilance terminology</p>
                        
                        <div class="quick-stats" id="quickStats">
                            <!-- Stats populated by JS -->
                        </div>

                        <div class="feature-cards">
                            <div class="feature-card" onclick="document.getElementById('searchInput').focus()">
                                <div class="feature-icon">üîç</div>
                                <h3>Search</h3>
                                <p>Find terms by name, acronym, or definition</p>
                            </div>
                            <div class="feature-card" onclick="PVGlossary.showScenarioLibrary()">
                                <div class="feature-icon">üé¨</div>
                                <h3>Scenarios</h3>
                                <p>Practice with real-world PV situations</p>
                            </div>
                            <div class="feature-card" onclick="PVGlossary.startQuiz()">
                                <div class="feature-icon">üéØ</div>
                                <h3>Quiz Mode</h3>
                                <p>Test your knowledge with flashcards</p>
                            </div>
                            <div class="feature-card" onclick="PVGlossary.showRandomTerm()">
                                <div class="feature-icon">üé≤</div>
                                <h3>Random Term</h3>
                                <p>Discover a random term to learn</p>
                            </div>
                        </div>

                        <div class="recent-section" id="recentSection">
                            <h3>Recently Viewed</h3>
                            <div class="recent-terms" id="recentTerms">
                                <p class="empty-state">No recently viewed terms</p>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Category View -->
                <section id="categoryView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.showWelcome()">‚Üê Back</button>
                        <h2 id="categoryTitle">Category Name</h2>
                        <p id="categoryDescription">Category description</p>
                    </div>
                    <div class="terms-list" id="termsList">
                        <!-- Terms populated by JS -->
                    </div>
                </section>

                <!-- Term Detail View -->
                <section id="termView" class="view">
                    <div class="view-header">
                        <button class="back-btn" id="termBackBtn">‚Üê Back</button>
                        <div class="term-actions" role="toolbar" aria-label="Term actions">
                            <button id="bookmarkBtn" class="action-btn" title="Bookmark" aria-label="Bookmark this term">‚òÜ</button>
                            <button id="learnedBtn" class="action-btn" title="Mark as Learned" aria-label="Mark as learned">‚úì</button>
                            <button id="shareBtn" class="action-btn" title="Copy Link" aria-label="Copy term to clipboard">üîó</button>
                            <button id="printTermBtn" class="action-btn" title="Print Term" aria-label="Print this term">üñ®Ô∏è</button>
                        </div>
                    </div>
                    <article class="term-detail" id="termDetail">
                        <!-- Term content populated by JS -->
                    </article>
                </section>

                <!-- Search Results View -->
                <section id="searchView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.clearSearch()">‚Üê Clear Search</button>
                        <h2>Search Results</h2>
                        <p id="searchResultsCount" aria-live="polite">0 results</p>
                    </div>
                    <div class="search-results" id="searchResults">
                        <!-- Results populated by JS -->
                    </div>
                </section>

                <!-- Quiz Setup View -->
                <section id="quizSetupView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.showWelcome()">‚Üê Back</button>
                        <h2>üéØ Quiz Mode</h2>
                        <p>Test your pharmacovigilance knowledge</p>
                    </div>
                    <div class="quiz-setup" id="quizSetup">
                        <!-- Setup populated by JS -->
                    </div>
                </section>

                <!-- Quiz Active View -->
                <section id="quizView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.exitQuiz()">‚Üê Exit Quiz</button>
                        <h2>Quiz Mode</h2>
                        <div class="quiz-progress">
                            <span id="quizProgress">1 / 10</span>
                            <span id="quizScore">Score: 0</span>
                        </div>
                    </div>
                    <div class="quiz-content" id="quizContent">
                        <!-- Quiz populated by JS -->
                    </div>
                </section>

                <!-- Bookmarks View -->
                <section id="bookmarksView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.showWelcome()">‚Üê Back</button>
                        <h2>Bookmarked Terms</h2>
                        <div class="bookmarks-header-row">
                            <p id="bookmarksCount">0 saved terms</p>
                            <div class="bookmarks-export-actions" id="bookmarksExportActions">
                                <button class="export-btn" onclick="PVGlossary.exportBookmarks('print')" title="Print study sheet">üñ®Ô∏è Print</button>
                                <button class="export-btn" onclick="PVGlossary.exportBookmarks('html')" title="Download as HTML">üìÑ Download</button>
                            </div>
                        </div>
                    </div>
                    <div class="bookmarks-list" id="bookmarksList">
                        <!-- Bookmarks populated by JS -->
                    </div>
                </section>

                <!-- Stats View -->
                <section id="statsView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.showWelcome()">‚Üê Back</button>
                        <h2>Your Statistics</h2>
                    </div>
                    <div class="stats-content" id="statsContent">
                        <!-- Stats populated by JS -->
                    </div>
                </section>

                <!-- Scenario Library View -->
                <section id="scenarioLibraryView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.showWelcome()">‚Üê Back</button>
                        <h2>üé¨ Scenario Library</h2>
                        <p>Learn by doing - practice real-world PV situations</p>
                    </div>
                    <div class="scenario-categories" id="scenarioCategories">
                        <!-- Categories populated by JS -->
                    </div>
                    <div class="scenario-list" id="scenarioList">
                        <!-- Scenarios populated by JS -->
                    </div>
                </section>

                <!-- Scenario Briefing View -->
                <section id="scenarioBriefingView" class="view">
                    <div class="view-header">
                        <button class="back-btn" onclick="PVGlossary.showScenarioLibrary()">‚Üê Back to Library</button>
                    </div>
                    <div class="scenario-briefing" id="scenarioBriefing">
                        <!-- Briefing populated by JS -->
                    </div>
                </section>

                <!-- Scenario Active View -->
                <section id="scenarioActiveView" class="view">
                    <div class="scenario-header" id="scenarioHeader">
                        <!-- Header populated by JS -->
                    </div>
                    <div class="scenario-content" id="scenarioContent">
                        <!-- Content populated by JS -->
                    </div>
                </section>

                <!-- Scenario Debrief View -->
                <section id="scenarioDebriefView" class="view">
                    <div class="scenario-debrief" id="scenarioDebrief">
                        <!-- Debrief populated by JS -->
                    </div>
                </section>
            </div>
        </main>

        <!-- Footer -->
        <footer class="footer" role="contentinfo">
            <div class="footer-content">
                <span>PV Glossary v<span id="versionNum">1.0.0</span></span>
                <span>|</span>
                <span id="totalTermsFooter">0</span> Terms
                <span>|</span>
                <span>Built: <span id="buildDate">-</span></span>
                <span>|</span>
                <span>¬© Gaurav</span>
            </div>
        </footer>
    </div>

    <script>
        const GLOSSARY_DATA = {
  "categories": [
    {
      "id": "case-intake",
      "name": "Case Intake & Triage",
      "description": "Terms related to receiving, validating, and prioritizing adverse event reports",
      "icon": "üì•",
      "termCount": 20
    },
    {
      "id": "case-processing",
      "name": "Case Processing & Data Entry",
      "description": "Terms related to coding, documenting, and processing adverse event data",
      "icon": "‚öôÔ∏è",
      "termCount": 20
    },
    {
      "id": "seriousness-causality",
      "name": "Seriousness & Causality Assessment",
      "description": "Terms related to evaluating severity, seriousness, and causal relationship of adverse events",
      "icon": "‚öñÔ∏è",
      "termCount": 20
    },
    {
      "id": "quality-review",
      "name": "Quality Review",
      "description": "Terms related to quality control, compliance, and data integrity in pharmacovigilance",
      "icon": "‚úÖ",
      "termCount": 20
    },
    {
      "id": "medical-review",
      "name": "Medical Review",
      "description": "Terms related to clinical assessment, medical evaluation, and safety oversight",
      "icon": "üë®‚Äç‚öïÔ∏è",
      "termCount": 20
    },
    {
      "id": "regulatory-reporting",
      "name": "Regulatory Reporting",
      "description": "Terms related to expedited and periodic safety reporting to regulatory authorities",
      "icon": "üì§",
      "termCount": 20
    },
    {
      "id": "signal-management",
      "name": "Signal Management",
      "description": "Terms related to detecting, validating, and evaluating safety signals",
      "icon": "üìä",
      "termCount": 20
    },
    {
      "id": "aggregate-reporting",
      "name": "Aggregate Reporting",
      "description": "Terms related to periodic safety reports and cumulative safety analysis",
      "icon": "üìã",
      "termCount": 20
    },
    {
      "id": "risk-management",
      "name": "Risk Management",
      "description": "Terms related to Risk Management Plans and risk minimization activities",
      "icon": "üõ°Ô∏è",
      "termCount": 20
    },
    {
      "id": "audits-inspections",
      "name": "Audits & Inspections",
      "description": "Terms related to regulatory inspections and internal audits of pharmacovigilance systems",
      "icon": "üîç",
      "termCount": 20
    }
  ],
  "terms": {
    "valid-case": {
      "id": "valid-case",
      "term": "Valid Case",
      "acronym": null,
      "definition": "An adverse event report that contains the four minimum required elements: an identifiable patient, an identifiable reporter, a suspect product, and an adverse event or outcome.",
      "regulatorySource": "ICH E2D, FDA 21 CFR 314.80",
      "example": "A physician (reporter) calls to report that a 45-year-old male patient (identifiable patient) developed severe headache (adverse event) after taking Drug X (suspect product). This meets all four criteria and is a valid case.",
      "commonMistakes": "Accepting cases where the reporter is completely anonymous with no way to follow up, or where the adverse event is actually a lack of efficacy without any actual adverse reaction.",
      "inspectorQuestion": "How do you determine if a case is valid? Show me your SOP and demonstrate with a recent example how you applied the minimum criteria.",
      "relatedTerms": [
        "minimum-information",
        "identifiable-patient",
        "identifiable-reporter",
        "icsr"
      ],
      "tags": [
        "fundamental",
        "intake",
        "validity"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "minimum-information": {
      "id": "minimum-information",
      "term": "Minimum Information",
      "acronym": "MI",
      "definition": "The four essential data elements required to consider an adverse event report valid and processable: identifiable reporter, identifiable patient, suspect product, and adverse event/reaction.",
      "regulatorySource": "ICH E2D Section 3.1",
      "example": "A report states 'someone took a pill and felt sick' - this lacks minimum information because neither the patient nor reporter is identifiable. Compare to 'Dr. Smith reports that his patient John had nausea after taking Aspirin' - this has all four elements.",
      "commonMistakes": "Confusing minimum information with minimum required data fields in the E2B form. Minimum information relates to validity, not data completeness.",
      "inspectorQuestion": "Walk me through how you handle a report that has three of four minimum elements. What attempts do you make to obtain the missing element?",
      "relatedTerms": [
        "valid-case",
        "identifiable-patient",
        "data-lock"
      ],
      "tags": [
        "fundamental",
        "validity",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "identifiable-patient": {
      "id": "identifiable-patient",
      "term": "Identifiable Patient",
      "acronym": null,
      "definition": "A patient in an adverse event report who can be identified by at least one qualifier such as initials, date of birth, age, age group, gender, or patient identification number.",
      "regulatorySource": "ICH E2D Section 3.1.1",
      "example": "A patient can be identified as '65-year-old female' even without a name. However, 'a patient' without any qualifying information is not identifiable.",
      "commonMistakes": "Rejecting cases where only age group (e.g., 'elderly') is provided. Age group alone can qualify as identifiable patient.",
      "inspectorQuestion": "If a reporter provides only 'adult male' as patient information, do you consider this identifiable? What is your rationale?",
      "relatedTerms": [
        "valid-case",
        "minimum-information",
        "identifiable-reporter"
      ],
      "tags": [
        "validity",
        "patient",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "identifiable-reporter": {
      "id": "identifiable-reporter",
      "term": "Identifiable Reporter",
      "acronym": null,
      "definition": "The person reporting the adverse event who can be identified by name, initials, address, qualification, or contact information sufficient for follow-up if needed.",
      "regulatorySource": "ICH E2D Section 3.1.2",
      "example": "A nurse who provides her name and hospital phone number is identifiable. An anonymous caller who refuses to provide any identifying information is not identifiable.",
      "commonMistakes": "Assuming consumer reports are invalid because the reporter isn't a healthcare professional. Consumers are valid reporters if identifiable.",
      "inspectorQuestion": "How do you handle situations where a healthcare professional requests anonymity but provides valid case information?",
      "relatedTerms": [
        "valid-case",
        "reporter-type",
        "hcp"
      ],
      "tags": [
        "validity",
        "reporter",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "reporter-type": {
      "id": "reporter-type",
      "term": "Reporter Type",
      "acronym": null,
      "definition": "Classification of the person reporting an adverse event: healthcare professional (HCP), consumer/patient, lawyer, regulatory authority, or other. This affects follow-up strategy and some regulatory reporting.",
      "regulatorySource": "ICH E2B(R3) Data Elements",
      "example": "A physician report may carry more clinical weight, but a patient's first-hand account of symptoms can provide unique detail. Both are valid but may be weighted differently in causality assessment.",
      "commonMistakes": "Automatically assuming healthcare professional reports are more reliable than consumer reports. Consumers often provide critical real-world usage information.",
      "inspectorQuestion": "How does reporter type influence your case processing and follow-up activities?",
      "relatedTerms": [
        "identifiable-reporter",
        "hcp",
        "consumer-report"
      ],
      "tags": [
        "reporter",
        "classification",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "hcp": {
      "id": "hcp",
      "term": "Healthcare Professional",
      "acronym": "HCP",
      "definition": "A medically qualified person such as a physician, pharmacist, nurse, or dentist who reports or is involved in an adverse event case. HCP reports may be weighted differently in safety assessments.",
      "regulatorySource": "ICH E2D, EU GVP Module VI",
      "example": "An oncologist reporting a patient's unexpected reaction has medical training to describe symptoms accurately, note relevant medical history, and assess potential causality.",
      "commonMistakes": "Including medical students or administrative hospital staff as HCPs. The definition typically requires licensed practitioners.",
      "inspectorQuestion": "What qualifications do you require to classify a reporter as a healthcare professional in your database?",
      "relatedTerms": [
        "reporter-type",
        "identifiable-reporter",
        "medically-confirmed"
      ],
      "tags": [
        "reporter",
        "classification",
        "medical"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "spontaneous-report": {
      "id": "spontaneous-report",
      "term": "Spontaneous Report",
      "acronym": null,
      "definition": "An unsolicited adverse event report that comes from sources outside organized data collection systems, typically from healthcare professionals or patients who voluntarily report their experience.",
      "regulatorySource": "ICH E2D Section 2.1",
      "example": "A pharmacist notices a pattern of patients complaining about dizziness after starting a new medication and calls the manufacturer to report this observation. This is spontaneous because it wasn't requested.",
      "commonMistakes": "Classifying reports from patient support programs as spontaneous. If the company actively collects information, reports may be solicited.",
      "inspectorQuestion": "How do you distinguish between spontaneous and solicited reports in your patient support programs?",
      "relatedTerms": [
        "solicited-report",
        "stimulated-reporting",
        "post-marketing"
      ],
      "tags": [
        "report-type",
        "spontaneous",
        "post-marketing"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "solicited-report": {
      "id": "solicited-report",
      "term": "Solicited Report",
      "acronym": null,
      "definition": "An adverse event report obtained through organized data collection systems such as clinical trials, registries, patient support programs, or active surveillance programs.",
      "regulatorySource": "ICH E2D Section 2.2",
      "example": "During a Phase III clinical trial, a patient reports headache during a scheduled follow-up call. This is solicited because it was collected as part of an organized protocol.",
      "commonMistakes": "Treating all patient support program reports as spontaneous. If the program involves active follow-up or questionnaires, reports are typically solicited.",
      "inspectorQuestion": "Describe your process for determining whether a report from a patient support program should be classified as solicited or spontaneous.",
      "relatedTerms": [
        "spontaneous-report",
        "clinical-trial",
        "registry"
      ],
      "tags": [
        "report-type",
        "solicited",
        "clinical-trial"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "day-zero": {
      "id": "day-zero",
      "term": "Day Zero",
      "acronym": "D0",
      "definition": "The date when a company first becomes aware of information that constitutes a valid, reportable adverse event case. This date starts the regulatory reporting clock.",
      "regulatorySource": "ICH E2D Section 4.3, EU GVP Module VI",
      "example": "A sales rep receives verbal information about a serious adverse event on Monday. On Tuesday, they report it to drug safety. Day 0 is Monday - when the company (via its employee) first learned of it.",
      "commonMistakes": "Setting Day 0 as when the drug safety department receives the case, rather than when any company employee first learns of it.",
      "inspectorQuestion": "If a sales representative learns of a serious adverse event on Friday but doesn't report it until Monday, what is Day 0? How do you train field staff on this?",
      "relatedTerms": [
        "clock-start",
        "awareness-date",
        "expedited-reporting"
      ],
      "tags": [
        "timeline",
        "reporting",
        "regulatory"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "clock-start": {
      "id": "clock-start",
      "term": "Clock Start",
      "acronym": null,
      "definition": "The initiation of the regulatory reporting timeline, triggered when minimum criteria for a reportable case are met. The clock determines the deadline for submitting expedited or periodic reports.",
      "regulatorySource": "ICH E2D, 21 CFR 314.80",
      "example": "A company receives partial information on Day 0. On Day 3, they receive the final piece confirming a valid, serious case. The clock starts on Day 3, and a 15-day expedited report would be due by Day 18.",
      "commonMistakes": "Starting the clock before having all four minimum elements. The clock only starts when you have a valid, reportable case.",
      "inspectorQuestion": "Show me an example where the clock start date differs from the initial receipt date and explain your rationale.",
      "relatedTerms": [
        "day-zero",
        "expedited-reporting",
        "reporting-timeline"
      ],
      "tags": [
        "timeline",
        "reporting",
        "regulatory"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "initial-report": {
      "id": "initial-report",
      "term": "Initial Report",
      "acronym": null,
      "definition": "The first submission of an Individual Case Safety Report (ICSR) to a regulatory authority, containing all available information at the time of submission.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "Upon receiving a serious, unexpected adverse event, the company submits an initial 15-day report with available information. Later follow-up information is submitted as a follow-up report.",
      "commonMistakes": "Waiting for complete information before submitting the initial report. Initial reports should be submitted within timelines even if incomplete.",
      "inspectorQuestion": "How do you decide what information is sufficient for an initial report versus waiting for follow-up data?",
      "relatedTerms": [
        "follow-up-report",
        "icsr",
        "expedited-reporting"
      ],
      "tags": [
        "reporting",
        "icsr",
        "timeline"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "follow-up-report": {
      "id": "follow-up-report",
      "term": "Follow-up Report",
      "acronym": "FU",
      "definition": "A subsequent submission that provides new, additional, or corrected information to a previously submitted ICSR.",
      "regulatorySource": "ICH E2B(R3), ICH E2D",
      "example": "After submitting an initial report, the company obtains autopsy results that change the outcome from 'hospitalization' to 'death.' A follow-up report is submitted with this significant new information.",
      "commonMistakes": "Submitting follow-up reports for trivial changes. Follow-ups should contain meaningful new information affecting safety assessment.",
      "inspectorQuestion": "What criteria do you use to determine if new information warrants a follow-up report submission?",
      "relatedTerms": [
        "initial-report",
        "icsr",
        "significant-follow-up"
      ],
      "tags": [
        "reporting",
        "icsr",
        "follow-up"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "duplicate-detection": {
      "id": "duplicate-detection",
      "term": "Duplicate Detection",
      "acronym": null,
      "definition": "The process of identifying whether a newly received adverse event report describes the same occurrence as a previously recorded case, to avoid counting the same event multiple times.",
      "regulatorySource": "EU GVP Module VI.C.6.2",
      "example": "A physician reports an event to both the manufacturer and the FDA. The manufacturer later receives the FDA forwarded report. Duplicate detection identifies these as the same case to prevent double-counting.",
      "commonMistakes": "Relying solely on patient name matching. Many duplicates have different reporter sources or slight variations in details.",
      "inspectorQuestion": "What algorithm or criteria do you use for duplicate detection? How do you handle cases where you're uncertain if two reports are duplicates?",
      "relatedTerms": [
        "case-series",
        "master-case",
        "icsr"
      ],
      "tags": [
        "quality",
        "data-management",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "triage": {
      "id": "triage",
      "term": "Triage",
      "acronym": null,
      "definition": "The initial assessment process to prioritize incoming adverse event reports based on seriousness, expectedness, and regulatory reporting requirements.",
      "regulatorySource": "Company SOPs, EU GVP Module VI",
      "example": "Upon receipt, a case describing hospitalization for anaphylaxis is triaged as high priority (serious, potentially unexpected), while a case of mild headache is routine priority.",
      "commonMistakes": "Triaging based solely on seriousness without considering expectedness. An unexpected non-serious event may require faster assessment than an expected serious event.",
      "inspectorQuestion": "Walk me through your triage criteria. How do you ensure expedited cases are identified within appropriate timeframes?",
      "relatedTerms": [
        "serious-ae",
        "expedited-reporting",
        "case-processing"
      ],
      "tags": [
        "workflow",
        "priority",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "source-document": {
      "id": "source-document",
      "term": "Source Document",
      "acronym": null,
      "definition": "Original records or certified copies containing raw data and observations about an adverse event, such as medical records, lab reports, emails, or call recordings.",
      "regulatorySource": "ICH E6 (GCP), 21 CFR Part 11",
      "example": "A hospital discharge summary documenting a patient's adverse reaction is a source document. The ICSR derived from it should accurately reflect the source information.",
      "commonMistakes": "Discarding original emails or call notes after entering data into the safety database. Source documents must be retained.",
      "inspectorQuestion": "Show me the source documents for this case. How do you ensure traceability between the database entry and original sources?",
      "relatedTerms": [
        "data-traceability",
        "case-narrative",
        "audit-trail"
      ],
      "tags": [
        "documentation",
        "quality",
        "compliance"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "literature-report": {
      "id": "literature-report",
      "term": "Literature Report",
      "acronym": null,
      "definition": "An adverse event case identified through published medical or scientific literature that mentions the company's product in association with an adverse event.",
      "regulatorySource": "ICH E2D Section 2.4, EU GVP Module VI",
      "example": "A case report published in a medical journal describes anaphylaxis in a patient taking Drug X. The MAH must capture this as an ICSR if it involves their product.",
      "commonMistakes": "Only monitoring major journals. Regulatory expectations include systematic monitoring of global literature including regional publications.",
      "inspectorQuestion": "Describe your literature monitoring process. How frequently do you search, and what databases do you use?",
      "relatedTerms": [
        "literature-screening",
        "spontaneous-report",
        "icsr"
      ],
      "tags": [
        "literature",
        "monitoring",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "consumer-report": {
      "id": "consumer-report",
      "term": "Consumer Report",
      "acronym": null,
      "definition": "An adverse event report received from a patient, family member, or other non-healthcare professional individual who has direct experience with the product.",
      "regulatorySource": "ICH E2D, FDA MedWatch",
      "example": "A patient's daughter calls to report that her father developed confusion after starting a new medication. Though not medically trained, she provides valuable first-hand observations.",
      "commonMistakes": "Undervaluing consumer reports because they lack medical terminology. Consumers often provide unique insights about real-world product use.",
      "inspectorQuestion": "How do you follow up on consumer reports when medical confirmation is needed but the consumer cannot provide HCP contact information?",
      "relatedTerms": [
        "reporter-type",
        "hcp",
        "patient-report"
      ],
      "tags": [
        "reporter",
        "consumer",
        "intake"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "awareness-date": {
      "id": "awareness-date",
      "term": "Awareness Date",
      "acronym": null,
      "definition": "The date when a company first becomes aware of a reportable adverse event through any of its employees, contractors, or partners acting on its behalf.",
      "regulatorySource": "ICH E2D Section 4.3",
      "example": "A contract research organization monitoring social media identifies a safety report on behalf of the sponsor company. The awareness date is when the CRO identified it, not when the sponsor received their report.",
      "commonMistakes": "Not including partner or contractor awareness dates. Any entity acting on behalf of the company contributes to awareness.",
      "inspectorQuestion": "How do you ensure contractors and partners notify you of adverse events promptly? What contractual provisions do you have?",
      "relatedTerms": [
        "day-zero",
        "clock-start",
        "business-partner"
      ],
      "tags": [
        "timeline",
        "awareness",
        "compliance"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "medical-information-request": {
      "id": "medical-information-request",
      "term": "Medical Information Request",
      "acronym": "MIR",
      "definition": "An inquiry to the company's medical information department that may contain embedded adverse event information requiring capture and processing.",
      "regulatorySource": "Company SOPs, ICH E2D",
      "example": "A physician calls medical information asking about liver toxicity risk, mentioning that their patient just developed elevated liver enzymes. This requires adverse event capture.",
      "commonMistakes": "Medical information staff not recognizing embedded adverse events in general product questions. Training on AE identification is essential.",
      "inspectorQuestion": "How are medical information staff trained to identify reportable adverse events? Show me your screening procedures.",
      "relatedTerms": [
        "spontaneous-report",
        "triage",
        "case-intake"
      ],
      "tags": [
        "intake",
        "medical-information",
        "training"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "worldwide-safety-database": {
      "id": "worldwide-safety-database",
      "term": "Worldwide Safety Database",
      "acronym": "WWSD",
      "definition": "A centralized system where all adverse event reports are collected, stored, and managed globally for a pharmaceutical company's products.",
      "regulatorySource": "ICH E2B(R3), EU GVP Module VI",
      "example": "Reports from the US, Europe, Japan, and other regions are all entered into a single global database, allowing comprehensive signal detection and regulatory reporting.",
      "commonMistakes": "Maintaining separate regional databases without proper integration, leading to incomplete global safety profiles.",
      "inspectorQuestion": "How do you ensure data integrity and consistency across your global database? Describe your data reconciliation processes.",
      "relatedTerms": [
        "icsr",
        "safety-database",
        "signal-detection"
      ],
      "tags": [
        "database",
        "global",
        "data-management"
      ],
      "categoryId": "case-intake",
      "categoryName": "Case Intake & Triage"
    },
    "icsr": {
      "id": "icsr",
      "term": "Individual Case Safety Report",
      "acronym": "ICSR",
      "definition": "A structured report documenting a single patient's adverse event experience with a medicinal product, formatted according to ICH E2B standards for regulatory submission.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "When a patient experiences Stevens-Johnson syndrome after taking an antibiotic, all relevant information (patient demographics, event details, drug information, outcome) is compiled into an ICSR for submission.",
      "commonMistakes": "Including multiple unrelated patients in a single ICSR. Each ICSR should represent one patient's experience.",
      "inspectorQuestion": "Show me how you ensure ICSR completeness before submission. What quality checks are in place?",
      "relatedTerms": [
        "e2b",
        "valid-case",
        "expedited-reporting"
      ],
      "tags": [
        "report",
        "regulatory",
        "fundamental"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "e2b": {
      "id": "e2b",
      "term": "E2B Format",
      "acronym": "E2B",
      "definition": "The ICH standardized electronic format for transmitting Individual Case Safety Reports between pharmaceutical companies, regulatory authorities, and other stakeholders.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "A company submits an expedited report to the FDA in E2B(R3) format, which allows automated import into the FDA's Adverse Event Reporting System (FAERS).",
      "commonMistakes": "Not validating E2B files before submission, leading to rejection. Files must pass validation rules for acceptance.",
      "inspectorQuestion": "What is your E2B validation process? How do you handle rejected submissions?",
      "relatedTerms": [
        "icsr",
        "ack",
        "gateway-submission"
      ],
      "tags": [
        "electronic",
        "format",
        "regulatory"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "meddra": {
      "id": "meddra",
      "term": "Medical Dictionary for Regulatory Activities",
      "acronym": "MedDRA",
      "definition": "A standardized international medical terminology used to classify and code adverse events, medical history, and indications in regulatory submissions and safety databases.",
      "regulatorySource": "ICH, MedDRA MSSO",
      "example": "A patient reports 'my heart was racing and skipping beats.' The safety processor codes this using MedDRA Preferred Terms 'Tachycardia' and 'Palpitations' for standardized analysis.",
      "commonMistakes": "Coding to the lowest level term (LLT) that matches verbatim text without considering if a more appropriate Preferred Term exists.",
      "inspectorQuestion": "How do you ensure consistency in MedDRA coding across processors? What training and quality processes are in place?",
      "relatedTerms": [
        "preferred-term",
        "llt",
        "soc"
      ],
      "tags": [
        "coding",
        "terminology",
        "meddra"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "preferred-term": {
      "id": "preferred-term",
      "term": "Preferred Term",
      "acronym": "PT",
      "definition": "A MedDRA term representing a single medical concept used for analysis, reporting, and signal detection. It is the primary level for regulatory safety analysis.",
      "regulatorySource": "MedDRA Hierarchy",
      "example": "Both 'heart attack' and 'myocardial infarction' reported verbatim would be coded to the same Preferred Term 'Myocardial infarction' for consistent analysis.",
      "commonMistakes": "Using Lower Level Terms for analysis instead of Preferred Terms, which fragments data and impairs signal detection.",
      "inspectorQuestion": "How do you aggregate and analyze safety data at the Preferred Term level? Show me your signal detection queries.",
      "relatedTerms": [
        "meddra",
        "llt",
        "soc",
        "hlgt"
      ],
      "tags": [
        "coding",
        "meddra",
        "analysis"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "llt": {
      "id": "llt",
      "term": "Lowest Level Term",
      "acronym": "LLT",
      "definition": "The most granular level in the MedDRA hierarchy, representing verbatim terms, synonyms, and lexical variants that link to a single Preferred Term.",
      "regulatorySource": "MedDRA Hierarchy",
      "example": "The verbatim 'feeling faint' might map to LLT 'Feeling faint' which links to PT 'Presyncope.' The verbatim is preserved while standardized coding is achieved.",
      "commonMistakes": "Always selecting the first LLT match without reviewing the linked PT for clinical appropriateness.",
      "inspectorQuestion": "When coding a complex verbatim, how does your team decide which LLT/PT combination best represents the reporter's intent?",
      "relatedTerms": [
        "preferred-term",
        "meddra",
        "verbatim-term"
      ],
      "tags": [
        "coding",
        "meddra",
        "terminology"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "soc": {
      "id": "soc",
      "term": "System Organ Class",
      "acronym": "SOC",
      "definition": "The highest level in the MedDRA hierarchy, grouping Preferred Terms by body system, etiology, or purpose (e.g., Cardiac disorders, Infections and infestations).",
      "regulatorySource": "MedDRA Hierarchy",
      "example": "The PT 'Myocardial infarction' belongs to SOC 'Cardiac disorders,' while PT 'Pneumonia' belongs to SOC 'Infections and infestations.'",
      "commonMistakes": "Forgetting that some PTs can have multiple SOC assignments (multiaxiality). Primary SOC assignment is used for display purposes.",
      "inspectorQuestion": "How do you handle MedDRA terms that have multiple SOC assignments in your aggregate analyses?",
      "relatedTerms": [
        "meddra",
        "preferred-term",
        "hlgt"
      ],
      "tags": [
        "coding",
        "meddra",
        "hierarchy"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "verbatim-term": {
      "id": "verbatim-term",
      "term": "Verbatim Term",
      "acronym": null,
      "definition": "The exact words used by the reporter to describe an adverse event, medical history, or other clinical information, preserved exactly as reported.",
      "regulatorySource": "ICH E2B(R3), GVP Module VI",
      "example": "A patient reports 'my stomach was doing flip-flops.' This verbatim is preserved in the database and coded to an appropriate MedDRA term like 'Gastrointestinal discomfort.'",
      "commonMistakes": "Modifying or 'correcting' verbatim terms before coding. The original reporter language must be preserved.",
      "inspectorQuestion": "Show me how verbatim terms are captured and preserved in your database. Can you demonstrate the traceability to source documents?",
      "relatedTerms": [
        "llt",
        "meddra",
        "source-document"
      ],
      "tags": [
        "coding",
        "data-entry",
        "terminology"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "case-narrative": {
      "id": "case-narrative",
      "term": "Case Narrative",
      "acronym": null,
      "definition": "A concise, clinically coherent written summary of an adverse event case that synthesizes all relevant information into a readable format for medical review.",
      "regulatorySource": "ICH E2B(R3), EU GVP Module VI",
      "example": "A narrative might read: 'A 67-year-old male with history of hypertension developed acute liver failure 3 weeks after starting Drug X 100mg daily. The patient was hospitalized, Drug X was discontinued, and liver function normalized within 2 weeks.'",
      "commonMistakes": "Writing narratives that are simply a list of data fields rather than a coherent clinical story. Narratives should flow logically.",
      "inspectorQuestion": "Show me your narrative template. How do you ensure narratives accurately reflect the source documents and support medical assessment?",
      "relatedTerms": [
        "medical-review",
        "source-document",
        "icsr"
      ],
      "tags": [
        "documentation",
        "writing",
        "medical"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "rechallenge": {
      "id": "rechallenge",
      "term": "Rechallenge",
      "acronym": null,
      "definition": "The readministration of a suspected drug to a patient after an adverse event, with observation of whether the reaction recurs. Positive rechallenge strongly supports causality.",
      "regulatorySource": "ICH E2A, Naranjo Algorithm",
      "example": "A patient developed rash after taking Drug X, which resolved upon discontinuation. When Drug X was inadvertently restarted, the rash recurred. This positive rechallenge supports a causal relationship.",
      "commonMistakes": "Confusing rechallenge with dechallenge. Rechallenge is restarting; dechallenge is stopping.",
      "inspectorQuestion": "How do you capture and code rechallenge information? How does it influence your causality assessment?",
      "relatedTerms": [
        "dechallenge",
        "causality-assessment",
        "positive-rechallenge"
      ],
      "tags": [
        "causality",
        "clinical",
        "assessment"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "dechallenge": {
      "id": "dechallenge",
      "term": "Dechallenge",
      "acronym": null,
      "definition": "The discontinuation or dose reduction of a suspected drug following an adverse event, with observation of whether the reaction improves or resolves.",
      "regulatorySource": "ICH E2A, Naranjo Algorithm",
      "example": "A patient's drug-induced hepatitis (elevated liver enzymes) resolved after stopping the suspect medication. This positive dechallenge supports the causal relationship between drug and event.",
      "commonMistakes": "Recording dechallenge as 'positive' simply because the drug was stopped, without documenting whether the event actually improved.",
      "inspectorQuestion": "How do you document and differentiate between positive, negative, and unknown dechallenge outcomes?",
      "relatedTerms": [
        "rechallenge",
        "causality-assessment",
        "drug-withdrawal"
      ],
      "tags": [
        "causality",
        "clinical",
        "assessment"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "time-to-onset": {
      "id": "time-to-onset",
      "term": "Time to Onset",
      "acronym": "TTO",
      "definition": "The duration between the start of drug exposure and the first occurrence of an adverse event, a critical factor in assessing plausibility of causal relationship.",
      "regulatorySource": "ICH E2B(R3), Causality Assessment",
      "example": "A patient started Drug X on January 1 and developed rash on January 8. Time to onset is 7 days. For a drug-induced rash, this timing is biologically plausible.",
      "commonMistakes": "Calculating time to onset from the first dose date when the patient actually started treatment earlier and the date was simply when they enrolled in a study.",
      "inspectorQuestion": "How do you calculate and validate time to onset when start dates are incomplete or approximate?",
      "relatedTerms": [
        "causality-assessment",
        "drug-exposure",
        "latency"
      ],
      "tags": [
        "timing",
        "causality",
        "calculation"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "concomitant-medication": {
      "id": "concomitant-medication",
      "term": "Concomitant Medication",
      "acronym": "ConMed",
      "definition": "Any medication taken by the patient alongside the suspected drug during the adverse event period, which may contribute to, confound, or interact with the event.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "A patient on Drug X (suspect) develops bleeding. They were also taking aspirin and warfarin. These concomitant medications must be documented as they could independently cause or contribute to bleeding.",
      "commonMistakes": "Only capturing prescription medications and missing over-the-counter drugs, supplements, or herbal products.",
      "inspectorQuestion": "How do you ensure complete capture of concomitant medications, including OTC products and supplements?",
      "relatedTerms": [
        "drug-interaction",
        "suspect-drug",
        "medical-history"
      ],
      "tags": [
        "medication",
        "data-entry",
        "clinical"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "suspect-drug": {
      "id": "suspect-drug",
      "term": "Suspect Drug",
      "acronym": null,
      "definition": "A medicinal product that is suspected of causing or contributing to the reported adverse event, as determined by the reporter or safety assessor.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "A patient on three medications develops liver injury. After assessment, one drug is classified as 'suspect' based on its known hepatotoxicity profile, while others are classified as concomitant.",
      "commonMistakes": "Classifying all medications as suspect when clinical judgment and temporal relationship suggest only one is likely causal.",
      "inspectorQuestion": "What criteria do you use to determine suspect vs concomitant drug classification?",
      "relatedTerms": [
        "concomitant-medication",
        "interacting-drug",
        "drug-role"
      ],
      "tags": [
        "medication",
        "classification",
        "causality"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "batch-number": {
      "id": "batch-number",
      "term": "Batch Number",
      "acronym": null,
      "definition": "A unique identifier assigned to a specific production batch of a drug product, essential for quality investigations and potential recalls.",
      "regulatorySource": "21 CFR 211, EU GMP Annex 11",
      "example": "A cluster of adverse events is reported. By capturing batch numbers, the company identifies all cases involve the same batch, triggering a quality investigation that reveals a manufacturing deviation.",
      "commonMistakes": "Not attempting to collect batch numbers for serious or unexpected events where quality issues could be involved.",
      "inspectorQuestion": "How do you attempt to collect batch information? What is your follow-up procedure when batch is missing from serious reports?",
      "relatedTerms": [
        "product-quality-complaint",
        "follow-up-report",
        "recall"
      ],
      "tags": [
        "product",
        "quality",
        "identification"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "outcome": {
      "id": "outcome",
      "term": "Outcome",
      "acronym": null,
      "definition": "The patient's status at the time of the last observation: recovered/resolved, recovering/resolving, not recovered/not resolved, recovered with sequelae, fatal, or unknown.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "A patient who had drug-induced hepatitis with elevated liver enzymes that returned to normal after discontinuation would have outcome 'Recovered/Resolved.'",
      "commonMistakes": "Recording outcome at event onset rather than at the time of last available information. Outcome should reflect the current known status.",
      "inspectorQuestion": "How do you update case outcomes when follow-up information is received? Show me your data lock and amendment procedures.",
      "relatedTerms": [
        "recovered",
        "fatal",
        "sequelae"
      ],
      "tags": [
        "patient",
        "status",
        "data-entry"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "autopsy": {
      "id": "autopsy",
      "term": "Autopsy",
      "acronym": null,
      "definition": "A post-mortem examination that may provide definitive information about cause of death in fatal adverse event cases.",
      "regulatorySource": "ICH E2D, GVP Module VI",
      "example": "A patient death initially attributed to the study drug is later found via autopsy to result from a massive pulmonary embolism unrelated to the drug. This changes the causality assessment.",
      "commonMistakes": "Not actively pursuing autopsy results for fatal cases where they could clarify causality.",
      "inspectorQuestion": "What is your procedure for requesting and following up on autopsy results in fatal cases?",
      "relatedTerms": [
        "fatal",
        "cause-of-death",
        "follow-up-report"
      ],
      "tags": [
        "fatal",
        "investigation",
        "clinical"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "data-lock": {
      "id": "data-lock",
      "term": "Data Lock",
      "acronym": null,
      "definition": "The point at which case data is frozen for regulatory submission or periodic report preparation, after which changes require formal amendments.",
      "regulatorySource": "Company SOPs, EU GVP",
      "example": "For a PSUR with data lock date of December 31, all cases with awareness dates up to and including December 31 are included. Cases received after data lock go into the next reporting period.",
      "commonMistakes": "Including cases received after data lock or excluding cases that should have been captured before the cutoff.",
      "inspectorQuestion": "How do you manage cases that arrive very close to data lock? What is your cut-off procedure?",
      "relatedTerms": [
        "psur",
        "periodic-report",
        "submission-deadline"
      ],
      "tags": [
        "reporting",
        "deadline",
        "data-management"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "drug-dictionary": {
      "id": "drug-dictionary",
      "term": "Drug Dictionary",
      "acronym": null,
      "definition": "A standardized reference database (such as WHODrug) used to consistently code and classify drug names, substances, and formulations across adverse event reports.",
      "regulatorySource": "WHO Drug Dictionary, ICH E2B(R3)",
      "example": "A patient reports taking 'Tylenol.' Using WHODrug dictionary, this is coded to the generic name 'Paracetamol' with ATC code N02BE01, enabling consistent analysis.",
      "commonMistakes": "Not updating to the current version of the drug dictionary, missing new medications or formulation changes.",
      "inspectorQuestion": "What drug dictionary do you use and how often do you update it? How do you handle drugs not found in the dictionary?",
      "relatedTerms": [
        "whodrug",
        "atc-code",
        "coding"
      ],
      "tags": [
        "coding",
        "terminology",
        "standardization"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "medical-history": {
      "id": "medical-history",
      "term": "Medical History",
      "acronym": null,
      "definition": "The patient's relevant pre-existing conditions, prior medications, allergies, and risk factors that may influence adverse event assessment and causality.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "A patient with pre-existing cirrhosis develops elevated liver enzymes on a new drug. The medical history is critical context for assessing whether the event is drug-related or disease progression.",
      "commonMistakes": "Recording only conditions explicitly stated as relevant, missing potentially important background (e.g., smoking, alcohol use, family history).",
      "inspectorQuestion": "How do you determine what medical history is relevant to capture? What is your approach when detailed history is unavailable?",
      "relatedTerms": [
        "risk-factor",
        "concomitant-medication",
        "baseline"
      ],
      "tags": [
        "patient",
        "clinical",
        "data-entry"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "product-quality-complaint": {
      "id": "product-quality-complaint",
      "term": "Product Quality Complaint",
      "acronym": "PQC",
      "definition": "A report concerning the quality, integrity, or physical characteristics of a drug product, which may or may not be associated with an adverse event.",
      "regulatorySource": "21 CFR 211, EU GMP",
      "example": "A patient notices unusual tablet discoloration and reports stomach upset. This is both a PQC (discoloration) and potentially an adverse event (stomach upset), requiring coordination between quality and safety teams.",
      "commonMistakes": "Treating PQCs and adverse events in complete silos without cross-referencing to identify quality-related safety issues.",
      "inspectorQuestion": "How do you coordinate between your quality and pharmacovigilance teams when a complaint has both PQC and AE components?",
      "relatedTerms": [
        "batch-number",
        "deviation",
        "recall"
      ],
      "tags": [
        "quality",
        "complaint",
        "coordination"
      ],
      "categoryId": "case-processing",
      "categoryName": "Case Processing & Data Entry"
    },
    "serious-ae": {
      "id": "serious-ae",
      "term": "Serious Adverse Event",
      "acronym": "SAE",
      "definition": "An adverse event that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, results in persistent/significant disability, is a congenital anomaly, or is an important medical event.",
      "regulatorySource": "ICH E2A, 21 CFR 312.32",
      "example": "A patient taking Drug X is hospitalized for severe allergic reaction requiring IV treatment. Even if the patient fully recovers, this is an SAE because it required inpatient hospitalization.",
      "commonMistakes": "Confusing 'serious' with 'severe.' Severe describes intensity; serious is a regulatory classification. A severe headache is not automatically serious.",
      "inspectorQuestion": "How do you distinguish between serious and severe? Give me an example of a severe but non-serious event and a mild but serious event.",
      "relatedTerms": [
        "seriousness-criteria",
        "life-threatening",
        "hospitalization",
        "important-medical-event"
      ],
      "tags": [
        "seriousness",
        "fundamental",
        "regulatory"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "seriousness-criteria": {
      "id": "seriousness-criteria",
      "term": "Seriousness Criteria",
      "acronym": null,
      "definition": "The six regulatory criteria used to determine if an adverse event qualifies as serious: death, life-threatening, hospitalization, disability, congenital anomaly, or important medical event.",
      "regulatorySource": "ICH E2A, 21 CFR 312.32",
      "example": "When assessing seriousness, ask: Did the patient die? Was their life at risk? Were they hospitalized? Do they have lasting disability? Was there a birth defect? Is it otherwise medically important?",
      "commonMistakes": "Applying only the hospitalization criterion and missing events that qualify under 'important medical event' (e.g., near-miss events requiring intervention to prevent serious harm).",
      "inspectorQuestion": "Walk me through how you apply each seriousness criterion. How do you train staff on borderline cases?",
      "relatedTerms": [
        "serious-ae",
        "life-threatening",
        "important-medical-event"
      ],
      "tags": [
        "seriousness",
        "criteria",
        "assessment"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "life-threatening": {
      "id": "life-threatening",
      "term": "Life-Threatening",
      "acronym": null,
      "definition": "An adverse event that places the patient at immediate risk of death at the time of the event. This refers to the event's immediate impact, not its potential future consequences.",
      "regulatorySource": "ICH E2A",
      "example": "Anaphylaxis requiring emergency epinephrine is life-threatening because without intervention, the patient could die. Cancer, while potentially fatal, is not typically 'life-threatening' in this immediate sense.",
      "commonMistakes": "Classifying all potentially fatal diseases as life-threatening. The criterion refers to immediate, acute risk of death during the event.",
      "inspectorQuestion": "How do you differentiate between 'life-threatening' and 'could potentially cause death in the future'? Provide examples.",
      "relatedTerms": [
        "serious-ae",
        "seriousness-criteria",
        "icu-admission"
      ],
      "tags": [
        "seriousness",
        "criteria",
        "clinical"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "hospitalization": {
      "id": "hospitalization",
      "term": "Hospitalization",
      "acronym": null,
      "definition": "Formal inpatient admission to a hospital for treatment or observation, which qualifies an adverse event as serious. Emergency room visits alone typically do not qualify unless followed by admission.",
      "regulatorySource": "ICH E2A, FDA Guidance",
      "example": "A patient admitted overnight for observation after a syncopal episode meets the hospitalization criterion for seriousness, even if discharged the next day with no sequelae.",
      "commonMistakes": "Counting ER visits without admission as hospitalization, or counting elective surgeries unrelated to an adverse event.",
      "inspectorQuestion": "How do you handle cases where a patient visits the ER but is not formally admitted? What about same-day surgery facilities?",
      "relatedTerms": [
        "serious-ae",
        "seriousness-criteria",
        "inpatient"
      ],
      "tags": [
        "seriousness",
        "criteria",
        "hospital"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "important-medical-event": {
      "id": "important-medical-event",
      "term": "Important Medical Event",
      "acronym": "IME",
      "definition": "An adverse event that may not meet other seriousness criteria but requires medical judgment because it may jeopardize the patient or require intervention to prevent a serious outcome.",
      "regulatorySource": "ICH E2A, EMA IME List",
      "example": "Drug-induced agranulocytosis caught early through routine blood monitoring. While not yet causing hospitalization, without intervention it could lead to life-threatening infection.",
      "commonMistakes": "Overusing or underusing this criterion. It requires medical judgment and shouldn't be applied arbitrarily or ignored for truly significant events.",
      "inspectorQuestion": "How do you apply medical judgment for 'important medical event'? Who makes this determination and what training do they have?",
      "relatedTerms": [
        "serious-ae",
        "seriousness-criteria",
        "medical-judgment"
      ],
      "tags": [
        "seriousness",
        "medical",
        "judgment"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "disability": {
      "id": "disability",
      "term": "Persistent or Significant Disability",
      "acronym": null,
      "definition": "A substantial disruption of the patient's ability to conduct normal life functions resulting from an adverse event, qualifying it as serious.",
      "regulatorySource": "ICH E2A",
      "example": "A patient develops permanent hearing loss after taking an ototoxic antibiotic. This persistent disability meets the seriousness criterion regardless of whether hospitalization occurred.",
      "commonMistakes": "Including temporary symptoms as disability. The criterion requires persistent or significant disruption to normal life functions.",
      "inspectorQuestion": "How do you assess whether an impairment rises to the level of 'significant disability'? What documentation do you require?",
      "relatedTerms": [
        "serious-ae",
        "sequelae",
        "permanent-injury"
      ],
      "tags": [
        "seriousness",
        "outcome",
        "disability"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "causality-assessment": {
      "id": "causality-assessment",
      "term": "Causality Assessment",
      "acronym": null,
      "definition": "The systematic evaluation of the likelihood that a suspect drug caused or contributed to an adverse event, using clinical judgment and established algorithms.",
      "regulatorySource": "ICH E2A, WHO-UMC Guidelines",
      "example": "After reviewing timing, dechallenge, rechallenge, alternative causes, and biological plausibility, the assessor concludes the drug is 'probably' related to the patient's hepatotoxicity.",
      "commonMistakes": "Relying solely on algorithms without clinical judgment, or conversely, making assessments without any structured approach.",
      "inspectorQuestion": "Describe your causality assessment methodology. How do you ensure consistency across assessors?",
      "relatedTerms": [
        "naranjo-algorithm",
        "who-umc",
        "related",
        "unrelated"
      ],
      "tags": [
        "causality",
        "assessment",
        "fundamental"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "naranjo-algorithm": {
      "id": "naranjo-algorithm",
      "term": "Naranjo Algorithm",
      "acronym": null,
      "definition": "A probability scale using 10 weighted questions to estimate the likelihood of an adverse drug reaction, producing scores categorized as definite, probable, possible, or doubtful.",
      "regulatorySource": "Naranjo et al. 1981, Clinical Pharmacology",
      "example": "A case with positive dechallenge (+2), reasonable time sequence (+2), confirmed by rechallenge (+3), and no alternative explanation (+2) scores 9, indicating 'definite' causality.",
      "commonMistakes": "Mechanically applying scores without considering the clinical context. The algorithm is a guide, not a replacement for medical judgment.",
      "inspectorQuestion": "Do you use the Naranjo algorithm? How do you handle cases where the algorithm score doesn't align with clinical judgment?",
      "relatedTerms": [
        "causality-assessment",
        "who-umc",
        "probability-scale"
      ],
      "tags": [
        "causality",
        "algorithm",
        "methodology"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "who-umc": {
      "id": "who-umc",
      "term": "WHO-UMC Causality Assessment",
      "acronym": null,
      "definition": "A system developed by the WHO Uppsala Monitoring Centre using clinical judgment to classify causality as certain, probable/likely, possible, unlikely, conditional, or unassessable.",
      "regulatorySource": "WHO-UMC Guidelines",
      "example": "Using WHO-UMC criteria: Certain = positive rechallenge; Probable = reasonable time, positive dechallenge, unlikely alternative; Possible = reasonable time but alternative explanations exist.",
      "commonMistakes": "Confusing 'conditional' (awaiting more data) with 'unassessable' (insufficient data to assess).",
      "inspectorQuestion": "What causality categories do you use? How do you reconcile differences between company and reporter assessments?",
      "relatedTerms": [
        "causality-assessment",
        "naranjo-algorithm",
        "related"
      ],
      "tags": [
        "causality",
        "who",
        "methodology"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "related": {
      "id": "related",
      "term": "Related (Causality)",
      "acronym": null,
      "definition": "A causality assessment conclusion indicating a reasonable possibility that the drug caused or contributed to the adverse event, triggering reporting obligations.",
      "regulatorySource": "21 CFR 312.32, ICH E2A",
      "example": "A patient develops a known drug-class effect with appropriate timing and positive dechallenge. The assessment concludes the event is 'related' to the suspect drug.",
      "commonMistakes": "Requiring certainty for a 'related' assessment. Regulatory definitions typically use 'reasonable possibility' as the threshold.",
      "inspectorQuestion": "What threshold do you use for a 'related' assessment? How do you document the rationale?",
      "relatedTerms": [
        "causality-assessment",
        "unrelated",
        "reasonable-possibility"
      ],
      "tags": [
        "causality",
        "classification",
        "related"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "unrelated": {
      "id": "unrelated",
      "term": "Unrelated (Causality)",
      "acronym": null,
      "definition": "A causality assessment conclusion indicating no reasonable possibility that the drug caused or contributed to the adverse event, typically due to clear alternative etiology or implausible timing.",
      "regulatorySource": "ICH E2A, Company SOPs",
      "example": "A patient in a clinical trial has a car accident causing fractures. With no plausible mechanism linking the study drug to the accident, the event is assessed as 'unrelated.'",
      "commonMistakes": "Assessing events as unrelated simply because they are listed in the label or because they seem unlikely, without proper evaluation.",
      "inspectorQuestion": "What criteria must be met to classify an event as unrelated? Show me documentation from a case assessed as unrelated.",
      "relatedTerms": [
        "causality-assessment",
        "related",
        "alternative-etiology"
      ],
      "tags": [
        "causality",
        "classification",
        "unrelated"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "expectedness": {
      "id": "expectedness",
      "term": "Expectedness",
      "acronym": null,
      "definition": "Whether an adverse event's nature and severity are consistent with the applicable reference safety information (product label, IB, or RSI).",
      "regulatorySource": "ICH E2A, ICH E2D",
      "example": "If 'nausea' is listed in the product label but 'hepatic necrosis' is not, a case of nausea is expected while hepatic necrosis is unexpected, potentially triggering expedited reporting.",
      "commonMistakes": "Confusing expectedness with seriousness or frequency. A rare but listed event is still expected; a common but unlisted event is unexpected.",
      "inspectorQuestion": "What reference document do you use for expectedness assessment? How do you handle events partially matching label language?",
      "relatedTerms": [
        "unexpected-ae",
        "listed",
        "rsi"
      ],
      "tags": [
        "expectedness",
        "label",
        "assessment"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "unexpected-ae": {
      "id": "unexpected-ae",
      "term": "Unexpected Adverse Event",
      "acronym": null,
      "definition": "An adverse event whose nature, severity, specificity, or outcome is not consistent with the applicable reference safety information for the product.",
      "regulatorySource": "21 CFR 312.32, ICH E2A",
      "example": "If the label mentions 'transaminase elevation' but a patient develops fulminant hepatic failure, the severity exceeds what is described, making this unexpected.",
      "commonMistakes": "Only comparing event terms literally. Expectedness also considers severity, specificity, and outcome beyond simple term matching.",
      "inspectorQuestion": "How do you assess expectedness for terms that are similar but not identical to label language?",
      "relatedTerms": [
        "expectedness",
        "listed",
        "unlisted",
        "susar"
      ],
      "tags": [
        "expectedness",
        "unexpected",
        "regulatory"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "listed": {
      "id": "listed",
      "term": "Listed (Expectedness)",
      "acronym": null,
      "definition": "An adverse event that is described in the Reference Safety Information, meaning it is an expected or known risk of the medicinal product.",
      "regulatorySource": "EU GVP Module VI",
      "example": "The EU SmPC Section 4.8 lists 'headache' as a common adverse reaction. When a patient reports headache, this event is classified as 'listed' for expectedness purposes.",
      "commonMistakes": "Classifying an event as listed based on class effects without verifying it appears in the specific product's RSI.",
      "inspectorQuestion": "How do you maintain current RSI for expectedness assessment? How often do you update when labels change?",
      "relatedTerms": [
        "expectedness",
        "unlisted",
        "rsi",
        "smpc"
      ],
      "tags": [
        "expectedness",
        "listed",
        "label"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "severity": {
      "id": "severity",
      "term": "Severity",
      "acronym": null,
      "definition": "The intensity or grade of an adverse event (mild, moderate, severe, life-threatening, fatal), which is distinct from regulatory seriousness.",
      "regulatorySource": "ICH E2A, CTCAE",
      "example": "A patient reports severe abdominal pain (Grade 3 intensity) that resolved with OTC medication and didn't require medical attention. This is severe but not serious.",
      "commonMistakes": "Using severity and seriousness interchangeably. A mild event can be serious (e.g., mild symptoms leading to hospitalization for observation).",
      "inspectorQuestion": "How do you document severity in your database? What grading scale do you use?",
      "relatedTerms": [
        "serious-ae",
        "ctcae",
        "intensity"
      ],
      "tags": [
        "assessment",
        "grading",
        "clinical"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "ctcae": {
      "id": "ctcae",
      "term": "Common Terminology Criteria for Adverse Events",
      "acronym": "CTCAE",
      "definition": "A standardized grading scale (1-5) developed by NCI to describe the severity of adverse events, commonly used in oncology clinical trials.",
      "regulatorySource": "NCI CTCAE v5.0",
      "example": "Neutropenia is graded: Grade 1 (ANC <LLN-1500), Grade 2 (1000-1500), Grade 3 (500-1000), Grade 4 (<500), Grade 5 (death from neutropenia complications).",
      "commonMistakes": "Applying CTCAE grades outside the clinical trial context where they were designed, or using outdated versions.",
      "inspectorQuestion": "How do you handle severity grading when CTCAE criteria don't exactly fit a reported event?",
      "relatedTerms": [
        "severity",
        "grading",
        "oncology"
      ],
      "tags": [
        "grading",
        "oncology",
        "clinical-trial"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "alternative-etiology": {
      "id": "alternative-etiology",
      "term": "Alternative Etiology",
      "acronym": null,
      "definition": "A potential cause of an adverse event other than the suspect drug, such as underlying disease, concomitant medications, or environmental factors.",
      "regulatorySource": "ICH E2A, Causality Guidelines",
      "example": "A patient on a study drug develops pneumonia. The alternative etiology of viral infection is identified by diagnostic testing, reducing the likelihood of drug causality.",
      "commonMistakes": "Dismissing drug causality simply because an alternative exists. Multiple factors can contribute to an event simultaneously.",
      "inspectorQuestion": "How do you weigh drug causality against alternative etiologies when both are plausible?",
      "relatedTerms": [
        "causality-assessment",
        "confounding",
        "differential-diagnosis"
      ],
      "tags": [
        "causality",
        "assessment",
        "clinical"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "biological-plausibility": {
      "id": "biological-plausibility",
      "term": "Biological Plausibility",
      "acronym": null,
      "definition": "The extent to which a causal relationship between drug and event is consistent with known pharmacology, mechanism of action, or scientific evidence.",
      "regulatorySource": "ICH E2A, Bradford Hill Criteria",
      "example": "A patient on an anticoagulant develops bleeding - this is biologically plausible given the drug's mechanism. The same patient developing blue skin would be biologically implausible.",
      "commonMistakes": "Requiring established mechanism for every adverse event. Novel reactions can occur even without known biological explanation.",
      "inspectorQuestion": "How does biological plausibility factor into your causality assessment when the mechanism is unknown?",
      "relatedTerms": [
        "causality-assessment",
        "mechanism-of-action",
        "pharmacology"
      ],
      "tags": [
        "causality",
        "science",
        "plausibility"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "company-causality": {
      "id": "company-causality",
      "term": "Company Causality Assessment",
      "acronym": null,
      "definition": "The Marketing Authorization Holder's or sponsor's evaluation of causality, which may differ from the reporter's assessment but must be documented and justified.",
      "regulatorySource": "ICH E2B(R3), EU GVP Module VI",
      "example": "A physician reports a case as 'definitely related' but company assessment after full review concludes 'possible' due to confounding factors. Both assessments are captured in the ICSR.",
      "commonMistakes": "Automatically adopting the reporter's assessment without independent medical review, or routinely downgrading without documented rationale.",
      "inspectorQuestion": "How do you reconcile differences between reporter and company causality? Who has authority to make the final company assessment?",
      "relatedTerms": [
        "causality-assessment",
        "reporter-causality",
        "medical-review"
      ],
      "tags": [
        "causality",
        "company",
        "assessment"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "ae-outcome": {
      "id": "ae-outcome",
      "term": "Adverse Event Outcome",
      "acronym": null,
      "definition": "The final status of an adverse event at the time of the last observation, categorized as recovered, recovering, not recovered, recovered with sequelae, fatal, or unknown.",
      "regulatorySource": "ICH E2B(R3)",
      "example": "A patient's drug-induced rash completely resolved 2 weeks after stopping the medication. The outcome is 'Recovered/Resolved' with no sequelae.",
      "commonMistakes": "Recording outcome at the time of event occurrence rather than at last follow-up. Outcomes should reflect the most recent available information.",
      "inspectorQuestion": "How do you update outcomes when follow-up information is received? What triggers a follow-up submission?",
      "relatedTerms": [
        "outcome",
        "sequelae",
        "fatal",
        "follow-up-report"
      ],
      "tags": [
        "outcome",
        "status",
        "assessment"
      ],
      "categoryId": "seriousness-causality",
      "categoryName": "Seriousness & Causality Assessment"
    },
    "quality-control": {
      "id": "quality-control",
      "term": "Quality Control",
      "acronym": "QC",
      "definition": "The systematic process of reviewing adverse event cases for completeness, accuracy, and compliance before regulatory submission or database finalization.",
      "regulatorySource": "EU GVP Module I, ICH E2D",
      "example": "Before an expedited ICSR is submitted, a QC reviewer verifies the MedDRA coding is accurate, the narrative matches source documents, and all mandatory fields are populated correctly.",
      "commonMistakes": "Treating QC as a simple checklist without clinical context. Effective QC requires understanding the case to identify logical inconsistencies.",
      "inspectorQuestion": "Describe your QC process. What percentage of cases undergo QC, and what are your rejection/return rates?",
      "relatedTerms": [
        "quality-assurance",
        "case-processing",
        "audit-trail"
      ],
      "tags": [
        "quality",
        "review",
        "compliance"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "quality-assurance": {
      "id": "quality-assurance",
      "term": "Quality Assurance",
      "acronym": "QA",
      "definition": "The broader systematic activities that ensure pharmacovigilance processes are performed according to established standards and regulations.",
      "regulatorySource": "EU GVP Module I",
      "example": "QA conducts periodic audits of the case processing workflow, reviews compliance metrics, and ensures SOPs are current and followed consistently.",
      "commonMistakes": "Confusing QA with QC. QC is case-level review; QA is system-level oversight ensuring processes are adequate.",
      "inspectorQuestion": "How does your QA function oversee pharmacovigilance activities? What KPIs do you monitor?",
      "relatedTerms": [
        "quality-control",
        "audit",
        "capa"
      ],
      "tags": [
        "quality",
        "system",
        "oversight"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "audit-trail": {
      "id": "audit-trail",
      "term": "Audit Trail",
      "acronym": null,
      "definition": "A chronological record that traces all changes made to safety database records, including who made changes, when, and what was changed.",
      "regulatorySource": "21 CFR Part 11, EU GVP Annex I",
      "example": "When a case processor changes the seriousness from 'No' to 'Yes,' the audit trail captures: user ID, timestamp, field changed, old value, new value, and reason for change.",
      "commonMistakes": "Allowing deletion of audit trail entries or having gaps in the trail. Audit trails must be complete and unalterable.",
      "inspectorQuestion": "Show me the audit trail for this case. Can you demonstrate that entries cannot be modified or deleted?",
      "relatedTerms": [
        "data-integrity",
        "electronic-records",
        "traceability"
      ],
      "tags": [
        "compliance",
        "documentation",
        "electronic"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "data-integrity": {
      "id": "data-integrity",
      "term": "Data Integrity",
      "acronym": "DI",
      "definition": "The assurance that safety data is accurate, complete, consistent, and reliable throughout its lifecycle, following ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available).",
      "regulatorySource": "FDA Data Integrity Guidance, EU GMP Annex 11",
      "example": "Data integrity ensures that when a case narrative states 'patient hospitalized on January 5,' this matches the source document, was entered contemporaneously, and remains unchanged unless formally amended.",
      "commonMistakes": "Assuming data integrity is only about electronic systems. It applies equally to paper records and hybrid systems.",
      "inspectorQuestion": "How do you ensure data integrity in your safety database? Describe your ALCOA+ compliance approach.",
      "relatedTerms": [
        "audit-trail",
        "alcoa",
        "validation"
      ],
      "tags": [
        "compliance",
        "data",
        "fundamental"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "reconciliation": {
      "id": "reconciliation",
      "term": "Reconciliation",
      "acronym": null,
      "definition": "The process of comparing safety databases between parties (e.g., MAH and CRO, or MAH and partner companies) to ensure all cases are captured consistently.",
      "regulatorySource": "EU GVP Module VI, Safety Agreements",
      "example": "Monthly reconciliation between the sponsor and CRO reveals 3 cases in the CRO database not received by the sponsor. Investigation identifies a transmission failure, and cases are transferred.",
      "commonMistakes": "Limiting reconciliation to case counts without verifying case-level data consistency (seriousness, coding, etc.).",
      "inspectorQuestion": "How frequently do you reconcile with partners? What parameters do you compare beyond case counts?",
      "relatedTerms": [
        "safety-data-exchange",
        "sdea",
        "partner-company"
      ],
      "tags": [
        "quality",
        "data-management",
        "partnership"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "capa": {
      "id": "capa",
      "term": "Corrective and Preventive Action",
      "acronym": "CAPA",
      "definition": "A systematic approach to investigating the root cause of quality issues and implementing actions to correct and prevent recurrence.",
      "regulatorySource": "ICH Q10, 21 CFR 820.100",
      "example": "Multiple late submissions are identified. CAPA investigation reveals inadequate triage training. Corrective action: re-train staff. Preventive action: implement automated alerts for approaching deadlines.",
      "commonMistakes": "Addressing only the immediate correction without investigating root cause or implementing preventive measures.",
      "inspectorQuestion": "Show me a recent CAPA from your pharmacovigilance operations. How did you verify effectiveness of the actions taken?",
      "relatedTerms": [
        "quality-assurance",
        "deviation",
        "root-cause"
      ],
      "tags": [
        "quality",
        "improvement",
        "compliance"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "deviation": {
      "id": "deviation",
      "term": "Deviation",
      "acronym": null,
      "definition": "A departure from approved procedures, regulations, or specifications that requires documentation, investigation, and potential corrective action.",
      "regulatorySource": "ICH E6 (GCP), Company SOPs",
      "example": "A case processor forgot to submit an expedited report, causing it to be 2 days late. This deviation is documented, root cause analyzed, and CAPA implemented if needed.",
      "commonMistakes": "Not documenting minor deviations or treating all deviations equally regardless of impact on patient safety or data quality.",
      "inspectorQuestion": "How do you classify and handle deviations? Show me your deviation log and trending analysis.",
      "relatedTerms": [
        "capa",
        "non-compliance",
        "investigation"
      ],
      "tags": [
        "quality",
        "compliance",
        "documentation"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "sop": {
      "id": "sop",
      "term": "Standard Operating Procedure",
      "acronym": "SOP",
      "definition": "A documented procedure that provides step-by-step instructions for performing pharmacovigilance activities consistently and in compliance with regulations.",
      "regulatorySource": "EU GVP Module I, ICH E6",
      "example": "The SOP for expedited reporting defines who triages cases, criteria for expedited submission, steps for E2B transmission, and documentation requirements.",
      "commonMistakes": "Having SOPs that are overly complex, outdated, or not aligned with actual practice. SOPs must be practical and current.",
      "inspectorQuestion": "Show me your SOP index. How do you ensure staff are trained and that SOPs reflect current practice?",
      "relatedTerms": [
        "psmf",
        "compliance",
        "training"
      ],
      "tags": [
        "documentation",
        "compliance",
        "procedure"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "metric": {
      "id": "metric",
      "term": "Performance Metric",
      "acronym": "KPI",
      "definition": "A quantifiable measure used to evaluate the effectiveness and compliance of pharmacovigilance processes, such as timeliness, accuracy, and completeness rates.",
      "regulatorySource": "EU GVP Module I",
      "example": "Key metrics include: percentage of expedited reports submitted on time (target: 100%), average processing time (target: <5 days), QC return rate (target: <5%).",
      "commonMistakes": "Tracking only submission timeliness without measuring data quality metrics like coding accuracy or narrative completeness.",
      "inspectorQuestion": "What metrics do you track for pharmacovigilance performance? Show me trending data and how you address negative trends.",
      "relatedTerms": [
        "quality-assurance",
        "compliance",
        "dashboard"
      ],
      "tags": [
        "quality",
        "measurement",
        "performance"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "validation": {
      "id": "validation",
      "term": "System Validation",
      "acronym": null,
      "definition": "The documented process of demonstrating that a computerized system (e.g., safety database) consistently performs according to specifications and regulatory requirements.",
      "regulatorySource": "21 CFR Part 11, EU GMP Annex 11",
      "example": "Before deploying a new safety database, validation testing confirms that E2B exports are correctly formatted, audit trails capture all changes, and calculations (like time to onset) are accurate.",
      "commonMistakes": "Completing initial validation but not maintaining validated state through change control and periodic review.",
      "inspectorQuestion": "Is your safety database validated? Show me your validation documentation and change control records.",
      "relatedTerms": [
        "part-11",
        "computer-system",
        "change-control"
      ],
      "tags": [
        "electronic",
        "compliance",
        "system"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "training-record": {
      "id": "training-record",
      "term": "Training Record",
      "acronym": null,
      "definition": "Documentation demonstrating that personnel have been trained on pharmacovigilance procedures, regulations, and systems before performing related tasks.",
      "regulatorySource": "EU GVP Module I, 21 CFR 211.25",
      "example": "Before a new case processor handles cases independently, their training record must show completion of: GVP training, database training, SOP training, and competency assessment.",
      "commonMistakes": "Relying on signature sheets alone without evidence of comprehension. Training should include competency verification.",
      "inspectorQuestion": "Show me the training records for the person who processed this case. How do you verify training effectiveness?",
      "relatedTerms": [
        "sop",
        "qualification",
        "competency"
      ],
      "tags": [
        "compliance",
        "personnel",
        "documentation"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "coding-consistency": {
      "id": "coding-consistency",
      "term": "Coding Consistency",
      "acronym": null,
      "definition": "The degree to which similar adverse events are coded using the same MedDRA terms across cases and processors, essential for accurate signal detection.",
      "regulatorySource": "MedDRA Best Practices",
      "example": "Both 'heart racing' and 'rapid heartbeat' should consistently be coded to the same PT 'Palpitations' or 'Tachycardia' based on clinical meaning, not just literal translation.",
      "commonMistakes": "Allowing individual processor preferences to drive coding decisions, resulting in same events coded differently across the database.",
      "inspectorQuestion": "How do you ensure MedDRA coding consistency? Do you have a coding dictionary or conventions document?",
      "relatedTerms": [
        "meddra",
        "quality-control",
        "data-integrity"
      ],
      "tags": [
        "coding",
        "quality",
        "consistency"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "peer-review": {
      "id": "peer-review",
      "term": "Peer Review",
      "acronym": null,
      "definition": "A quality process where a colleague reviews a processed case for accuracy, completeness, and compliance before finalization or submission.",
      "regulatorySource": "Company SOPs",
      "example": "After Case Processor A completes an expedited ICSR, Case Processor B performs peer review checking coding, narrative accuracy, and regulatory compliance before QC submission.",
      "commonMistakes": "Making peer review a rubber stamp exercise. Effective peer review requires thorough independent assessment.",
      "inspectorQuestion": "How do you structure peer review to ensure independence and thoroughness?",
      "relatedTerms": [
        "quality-control",
        "four-eyes-principle",
        "case-processing"
      ],
      "tags": [
        "quality",
        "review",
        "process"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "case-lock": {
      "id": "case-lock",
      "term": "Case Lock",
      "acronym": null,
      "definition": "The finalization of a case record in the safety database after all processing and quality review is complete, preventing further changes without formal amendment.",
      "regulatorySource": "Company SOPs, Data Integrity",
      "example": "Once an ICSR passes QC and is submitted to regulators, the case is locked. Any subsequent changes (e.g., follow-up information) require creating an amendment with documented rationale.",
      "commonMistakes": "Locking cases before quality review is complete, or allowing locked cases to be informally modified.",
      "inspectorQuestion": "What triggers case lock in your system? How do you handle post-lock corrections?",
      "relatedTerms": [
        "data-lock",
        "amendment",
        "audit-trail"
      ],
      "tags": [
        "data-management",
        "control",
        "process"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "amendment": {
      "id": "amendment",
      "term": "Amendment",
      "acronym": null,
      "definition": "A formal, documented change to a previously finalized case record, with clear rationale and audit trail.",
      "regulatorySource": "Data Integrity Guidelines, Company SOPs",
      "example": "After case lock, medical review identifies an incorrect seriousness assessment. An amendment is created documenting the error, correction, rationale, and reviewer approval.",
      "commonMistakes": "Making amendments without proper documentation or approval, which compromises data integrity.",
      "inspectorQuestion": "Walk me through your amendment process. Who has authority to approve amendments?",
      "relatedTerms": [
        "case-lock",
        "audit-trail",
        "data-integrity"
      ],
      "tags": [
        "data-management",
        "change",
        "control"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "compliance-rate": {
      "id": "compliance-rate",
      "term": "Compliance Rate",
      "acronym": null,
      "definition": "The percentage of regulatory submissions completed within required timeframes, a key indicator of pharmacovigilance operational performance.",
      "regulatorySource": "EU GVP Module I, FDA Compliance",
      "example": "Of 100 expedited reports due this quarter, 98 were submitted on time, yielding a 98% compliance rate. The 2 late submissions are investigated for root cause.",
      "commonMistakes": "Celebrating high compliance rates without investigating the late submissions, which may indicate systemic issues.",
      "inspectorQuestion": "What is your expedited reporting compliance rate? How do you investigate and address late submissions?",
      "relatedTerms": [
        "metric",
        "expedited-reporting",
        "timeliness"
      ],
      "tags": [
        "compliance",
        "measurement",
        "regulatory"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "source-data-verification": {
      "id": "source-data-verification",
      "term": "Source Data Verification",
      "acronym": "SDV",
      "definition": "The process of comparing data entered in the safety database against original source documents to verify accuracy and completeness.",
      "regulatorySource": "ICH E6 (GCP), Data Integrity",
      "example": "QC reviewer compares the database entry showing 'hospitalization date: Jan 15' against the source hospital discharge summary confirming this date is accurate.",
      "commonMistakes": "Verifying only a sample of fields rather than key data elements that impact safety assessment and regulatory compliance.",
      "inspectorQuestion": "What percentage of cases undergo source data verification? Which fields are verified?",
      "relatedTerms": [
        "source-document",
        "data-integrity",
        "quality-control"
      ],
      "tags": [
        "quality",
        "verification",
        "accuracy"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "escalation": {
      "id": "escalation",
      "term": "Escalation",
      "acronym": null,
      "definition": "The process of raising an issue or decision to higher authority when standard procedures are insufficient or when significant issues are identified.",
      "regulatorySource": "Company SOPs, Quality Management",
      "example": "Case processor identifies a potential cluster of unexpected serious events. This is escalated to the medical safety officer for urgent review and potential signal evaluation.",
      "commonMistakes": "Not having clear escalation pathways or criteria, leading to delayed response to critical safety issues.",
      "inspectorQuestion": "Describe your escalation procedures. Give an example of a recent escalation and how it was handled.",
      "relatedTerms": [
        "safety-issue",
        "management-review",
        "decision-authority"
      ],
      "tags": [
        "process",
        "management",
        "urgency"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "root-cause": {
      "id": "root-cause",
      "term": "Root Cause Analysis",
      "acronym": "RCA",
      "definition": "A systematic investigation method to identify the fundamental underlying reason(s) for a deviation, error, or quality issue.",
      "regulatorySource": "ICH Q10, Quality Management",
      "example": "Three late submissions occurred. Root cause analysis using '5 Whys' reveals: Why late? ‚Üí Processor was on vacation ‚Üí Why no backup? ‚Üí Training not complete ‚Üí Why? ‚Üí Resource constraints. Root cause: staffing/training.",
      "commonMistakes": "Stopping at surface-level causes rather than drilling down to true root causes that can be systematically addressed.",
      "inspectorQuestion": "Show me a root cause analysis you performed. How did you verify you reached the true root cause?",
      "relatedTerms": [
        "capa",
        "deviation",
        "investigation"
      ],
      "tags": [
        "quality",
        "investigation",
        "improvement"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "controlled-document": {
      "id": "controlled-document",
      "term": "Controlled Document",
      "acronym": null,
      "definition": "A document that is formally managed with version control, approval workflows, and distribution tracking to ensure only current approved versions are in use.",
      "regulatorySource": "ICH E6, Quality Management",
      "example": "SOPs, safety data exchange agreements, and the PSMF are controlled documents. When updated, previous versions are archived and staff are trained on the new version.",
      "commonMistakes": "Having unofficial working documents that circumvent the controlled document system, creating compliance gaps.",
      "inspectorQuestion": "How do you manage controlled documents? Show me your document control system and version history.",
      "relatedTerms": [
        "sop",
        "version-control",
        "document-management"
      ],
      "tags": [
        "documentation",
        "control",
        "compliance"
      ],
      "categoryId": "quality-review",
      "categoryName": "Quality Review"
    },
    "medical-review": {
      "id": "medical-review",
      "term": "Medical Review",
      "acronym": null,
      "definition": "The clinical assessment of adverse event cases by a qualified medical professional to evaluate seriousness, causality, expectedness, and medical significance.",
      "regulatorySource": "EU GVP Module I, ICH E2D",
      "example": "A physician reviewer examines a hepatotoxicity case, considering the patient's medical history, concomitant medications, lab values, and temporal relationship to determine company causality assessment.",
      "commonMistakes": "Having unqualified personnel make medical judgments, or treating medical review as a documentation step rather than genuine clinical evaluation.",
      "inspectorQuestion": "Who performs medical review and what are their qualifications? How do you ensure timely medical review for expedited cases?",
      "relatedTerms": [
        "causality-assessment",
        "qppv",
        "medical-officer"
      ],
      "tags": [
        "medical",
        "review",
        "clinical"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "qppv": {
      "id": "qppv",
      "term": "Qualified Person for Pharmacovigilance",
      "acronym": "QPPV",
      "definition": "The EU regulatory requirement for MAHs to have a designated qualified individual responsible for the establishment and maintenance of the pharmacovigilance system.",
      "regulatorySource": "EU Directive 2001/83/EC, EU GVP Module I",
      "example": "The QPPV signs off on PSURs, is notified of urgent safety issues, and is ultimately responsible for regulatory compliance of the pharmacovigilance system.",
      "commonMistakes": "Treating QPPV as a purely administrative role. The QPPV must have sufficient authority and resources to fulfill their responsibilities.",
      "inspectorQuestion": "Who is your QPPV? Demonstrate how they are notified of urgent safety issues and their involvement in key decisions.",
      "relatedTerms": [
        "psmf",
        "pv-system",
        "regulatory-compliance"
      ],
      "tags": [
        "regulatory",
        "eu",
        "oversight"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "pv-physician": {
      "id": "pv-physician",
      "term": "Pharmacovigilance Physician",
      "acronym": null,
      "definition": "A medically qualified professional who provides clinical expertise in evaluating adverse events, assessing causality, and making safety determinations.",
      "regulatorySource": "EU GVP Module I",
      "example": "The PV physician reviews complex cases involving unexpected serious events, assesses the medical plausibility of reported relationships, and provides input for signal evaluation.",
      "commonMistakes": "Not involving PV physicians early enough in case processing, or having insufficient physician resources for case volume.",
      "inspectorQuestion": "How many PV physicians support your operations? What criteria trigger physician review?",
      "relatedTerms": [
        "medical-review",
        "causality-assessment",
        "hcp"
      ],
      "tags": [
        "medical",
        "personnel",
        "clinical"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "medically-confirmed": {
      "id": "medically-confirmed",
      "term": "Medically Confirmed Case",
      "acronym": null,
      "definition": "An adverse event case where the diagnosis or clinical details have been verified by a healthcare professional, enhancing the reliability of the reported information.",
      "regulatorySource": "ICH E2D, FDA Guidance",
      "example": "A consumer reports a cardiac event. Follow-up with the treating cardiologist confirms the diagnosis as myocardial infarction based on ECG, enzymes, and angiography. The case is now medically confirmed.",
      "commonMistakes": "Assuming all HCP-reported cases are medically confirmed. The event itself, not just the reporter, must be professionally diagnosed.",
      "inspectorQuestion": "How do you document medical confirmation? What follow-up efforts do you make to obtain confirmation for serious reports?",
      "relatedTerms": [
        "hcp",
        "follow-up-report",
        "diagnostic-confirmation"
      ],
      "tags": [
        "confirmation",
        "medical",
        "reliability"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "benefit-risk": {
      "id": "benefit-risk",
      "term": "Benefit-Risk Assessment",
      "acronym": "B/R",
      "definition": "The ongoing evaluation comparing a medicine's therapeutic benefits against its risks to determine if the overall profile remains favorable for patients.",
      "regulatorySource": "EU GVP Module V, ICH E2C(R2)",
      "example": "A new serious adverse reaction is identified. Benefit-risk assessment considers: How often does it occur? How severe is it? Can it be prevented or managed? How does this compare to the drug's benefits?",
      "commonMistakes": "Focusing only on risks without adequately considering benefits, or making benefit-risk determinations without sufficient data.",
      "inspectorQuestion": "How do you conduct benefit-risk assessments? Walk me through a recent example where new safety data impacted the assessment.",
      "relatedTerms": [
        "signal-management",
        "labeling",
        "risk-management"
      ],
      "tags": [
        "assessment",
        "regulatory",
        "safety"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "labeling": {
      "id": "labeling",
      "term": "Product Labeling",
      "acronym": null,
      "definition": "The official prescribing information, package insert, or Summary of Product Characteristics (SmPC) that describes a medicine's approved uses, warnings, and adverse reactions.",
      "regulatorySource": "21 CFR 201, EU Directive 2001/83/EC",
      "example": "Signal evaluation determines that a new serious adverse reaction should be added to the label. A safety variation is submitted to update Section 4.8 (Adverse Reactions) of the SmPC.",
      "commonMistakes": "Not maintaining current copies of all regional labels, leading to inconsistent expectedness assessments.",
      "inspectorQuestion": "How do you maintain current product labeling across regions? How quickly do you update after label changes are approved?",
      "relatedTerms": [
        "smpc",
        "expectedness",
        "rsi"
      ],
      "tags": [
        "regulatory",
        "documentation",
        "safety"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "smpc": {
      "id": "smpc",
      "term": "Summary of Product Characteristics",
      "acronym": "SmPC",
      "definition": "The EU official document describing a medicinal product's properties and approved conditions of use, serving as the basis for healthcare professional information.",
      "regulatorySource": "EU Directive 2001/83/EC",
      "example": "The SmPC Section 4.8 lists 'Very common (‚â•1/10): headache; Common (‚â•1/100): nausea' providing expectedness reference and frequency information for adverse reactions.",
      "commonMistakes": "Using the US PI for EU expectedness assessment or vice versa. Regional documents must be used for their respective regions.",
      "inspectorQuestion": "Do you maintain current SmPCs for all your EU-marketed products? How do you track updates?",
      "relatedTerms": [
        "labeling",
        "rsi",
        "expectedness"
      ],
      "tags": [
        "eu",
        "documentation",
        "regulatory"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "rsi": {
      "id": "rsi",
      "term": "Reference Safety Information",
      "acronym": "RSI",
      "definition": "The document used to determine expectedness of adverse reactions for regulatory reporting purposes, typically the company core safety information (CCSI) for marketed products or Investigator's Brochure for clinical trials.",
      "regulatorySource": "EU GVP Module VI, ICH E2D",
      "example": "For a global marketed product, the company maintains a CCSI that serves as RSI. A reaction is 'expected' if it appears in the RSI, regardless of whether it's in individual country labels.",
      "commonMistakes": "Using different expectedness references inconsistently across regions or not updating RSI when new safety information emerges.",
      "inspectorQuestion": "What document do you use as RSI? How often is it reviewed and updated?",
      "relatedTerms": [
        "expectedness",
        "ccsi",
        "investigators-brochure"
      ],
      "tags": [
        "reference",
        "expectedness",
        "documentation"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "ccsi": {
      "id": "ccsi",
      "term": "Company Core Safety Information",
      "acronym": "CCSI",
      "definition": "The reference document maintained by the MAH containing all relevant safety information about a product, serving as the basis for national labels and expectedness determination.",
      "regulatorySource": "ICH E2C(R2), EU GVP Module V",
      "example": "When a new adverse reaction is confirmed through signal evaluation, the CCSI is updated first, then variations are submitted to align individual country labels.",
      "commonMistakes": "Allowing regional labels to diverge from CCSI without systematic tracking and justification.",
      "inspectorQuestion": "How do you maintain your CCSI? How do you ensure alignment between CCSI and regional labels?",
      "relatedTerms": [
        "rsi",
        "smpc",
        "labeling"
      ],
      "tags": [
        "documentation",
        "global",
        "safety"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "investigators-brochure": {
      "id": "investigators-brochure",
      "term": "Investigator's Brochure",
      "acronym": "IB",
      "definition": "A document containing clinical and nonclinical information about an investigational product that is relevant to the study of the product in humans.",
      "regulatorySource": "ICH E6 (GCP), 21 CFR 312.23",
      "example": "The IB Section 7 lists known adverse reactions from previous studies. During a clinical trial, this serves as the RSI for determining if an event is expected or unexpected (SUSAR determination).",
      "commonMistakes": "Not updating the IB promptly when significant new safety information emerges from ongoing trials.",
      "inspectorQuestion": "How often do you update your IB? How do you ensure investigators receive current versions?",
      "relatedTerms": [
        "rsi",
        "susar",
        "clinical-trial"
      ],
      "tags": [
        "clinical-trial",
        "documentation",
        "reference"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "safety-variation": {
      "id": "safety-variation",
      "term": "Safety Variation",
      "acronym": null,
      "definition": "A regulatory submission to update product labeling or other safety documents based on new safety information, typically requiring expedited review.",
      "regulatorySource": "EU Variation Regulation, FDA SUPAC",
      "example": "Signal evaluation confirms a new serious adverse reaction. A Type II variation (EU) is submitted to add this to SmPC Section 4.8, with urgent safety restriction if needed.",
      "commonMistakes": "Delaying safety variations when urgent updates are needed, or not coordinating timing across regions.",
      "inspectorQuestion": "Describe your process for submitting safety-related label changes. What triggers an urgent safety restriction?",
      "relatedTerms": [
        "labeling",
        "signal-management",
        "regulatory-submission"
      ],
      "tags": [
        "regulatory",
        "labeling",
        "change"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "drug-safety-committee": {
      "id": "drug-safety-committee",
      "term": "Drug Safety Committee",
      "acronym": "DSC",
      "definition": "A cross-functional committee responsible for reviewing safety data, making risk management decisions, and overseeing the company's pharmacovigilance activities.",
      "regulatorySource": "Company Governance, ICH E2E",
      "example": "The monthly DSC meeting reviews new signals, aggregate safety data, ongoing studies, and makes decisions about labeling changes, REMS modifications, or study protocol amendments.",
      "commonMistakes": "Having DSC meetings without clear decision-making authority or without appropriate cross-functional representation.",
      "inspectorQuestion": "Describe your DSC composition and charter. How are decisions documented and implemented?",
      "relatedTerms": [
        "safety-governance",
        "signal-management",
        "risk-management"
      ],
      "tags": [
        "governance",
        "decision-making",
        "oversight"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "aesi": {
      "id": "aesi",
      "term": "Adverse Event of Special Interest",
      "acronym": "AESI",
      "definition": "A predefined adverse event that requires enhanced monitoring and specific evaluation due to its potential association with the product or therapeutic class.",
      "regulatorySource": "ICH E2E, Risk Management Plans",
      "example": "For a new biologic, progressive multifocal leukoencephalopathy (PML) is designated as an AESI. Any PML report triggers immediate enhanced follow-up and expedited signal evaluation.",
      "commonMistakes": "Having overly broad AESI lists that dilute focus, or not operationalizing AESIs with specific monitoring procedures.",
      "inspectorQuestion": "How do you define AESIs for your products? What enhanced procedures are in place when an AESI is reported?",
      "relatedTerms": [
        "targeted-follow-up",
        "signal-detection",
        "risk-management"
      ],
      "tags": [
        "monitoring",
        "special-interest",
        "safety"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "targeted-follow-up": {
      "id": "targeted-follow-up",
      "term": "Targeted Follow-up",
      "acronym": "TFU",
      "definition": "A structured process to obtain specific additional information for certain types of adverse events to enable thorough medical assessment.",
      "regulatorySource": "Company SOPs, Risk Management Plans",
      "example": "For any reported case of anaphylaxis, targeted follow-up questions include: exact time of onset, all treatments administered, allergy history, confirmation of diagnosis, and outcome details.",
      "commonMistakes": "Using generic follow-up for all cases rather than event-specific questions that capture medically relevant details.",
      "inspectorQuestion": "Do you have targeted follow-up questionnaires? Show me how they're used and how completion rates are tracked.",
      "relatedTerms": [
        "aesi",
        "follow-up-report",
        "medical-information"
      ],
      "tags": [
        "follow-up",
        "quality",
        "medical"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "drug-utilization-study": {
      "id": "drug-utilization-study",
      "term": "Drug Utilization Study",
      "acronym": "DUS",
      "definition": "A study examining how a medicine is marketed, prescribed, and used in practice, providing context for safety data interpretation.",
      "regulatorySource": "EU GVP Module VIII",
      "example": "A DUS reveals that 30% of use is off-label in pediatric patients. This context is important when interpreting spontaneous pediatric adverse event reports.",
      "commonMistakes": "Interpreting adverse event data without considering actual usage patterns, potentially over- or underestimating risk.",
      "inspectorQuestion": "Do you conduct drug utilization studies? How do you use this data to inform your safety evaluation?",
      "relatedTerms": [
        "exposure-data",
        "signal-evaluation",
        "epidemiology"
      ],
      "tags": [
        "research",
        "utilization",
        "context"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "safety-signal": {
      "id": "safety-signal",
      "term": "Safety Signal",
      "acronym": null,
      "definition": "Information arising from one or multiple sources that suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event.",
      "regulatorySource": "EU GVP Module IX, ICH E2E",
      "example": "An unusual cluster of serious skin reactions is detected. This is a potential signal requiring validation to confirm whether it represents a true new risk.",
      "commonMistakes": "Treating every statistical fluctuation as a signal, or conversely, dismissing genuine signals as data noise.",
      "inspectorQuestion": "Define how you identify a signal. What threshold or criteria trigger signal validation activities?",
      "relatedTerms": [
        "signal-detection",
        "signal-validation",
        "disproportionality"
      ],
      "tags": [
        "signal",
        "safety",
        "detection"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "dmc": {
      "id": "dmc",
      "term": "Data Monitoring Committee",
      "acronym": "DMC",
      "definition": "An independent group of experts that monitors patient safety and treatment efficacy data during a clinical trial and can recommend trial modifications or termination.",
      "regulatorySource": "ICH E6, ICH E9",
      "example": "The DMC reviews unblinded interim analysis showing excess cardiac events in the treatment arm. They recommend stopping enrollment pending further analysis.",
      "commonMistakes": "DMC members having conflicts of interest, or the sponsor not acting promptly on DMC recommendations.",
      "inspectorQuestion": "Describe DMC involvement in your clinical trials. How do you ensure their independence and act on recommendations?",
      "relatedTerms": [
        "clinical-trial",
        "interim-analysis",
        "safety-monitoring"
      ],
      "tags": [
        "clinical-trial",
        "oversight",
        "monitoring"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "safety-update-report": {
      "id": "safety-update-report",
      "term": "Safety Update Report",
      "acronym": "SUR",
      "definition": "An interim safety report during clinical trials providing cumulative safety data and analysis at specified intervals or when requested.",
      "regulatorySource": "ICH E2F (DSUR), Company SOPs",
      "example": "A quarterly safety update to the IRB summarizes all SAEs, reviews causality trends, and provides an updated risk-benefit assessment for the ongoing study.",
      "commonMistakes": "Providing SURs with inadequate analysis or interpretation, presenting only data without safety conclusions.",
      "inspectorQuestion": "How do you prepare safety update reports? Who reviews and approves them before distribution?",
      "relatedTerms": [
        "dsur",
        "clinical-trial",
        "irb"
      ],
      "tags": [
        "reporting",
        "clinical-trial",
        "periodic"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "irb-notification": {
      "id": "irb-notification",
      "term": "IRB/EC Notification",
      "acronym": null,
      "definition": "The required reporting of safety information to Institutional Review Boards or Ethics Committees overseeing clinical trials.",
      "regulatorySource": "ICH E6, 21 CFR 312.32",
      "example": "A SUSAR requires notification to all IRBs overseeing sites where the product is being studied within the required timeframe (often 7-15 days).",
      "commonMistakes": "Not tracking IRB notification timelines separately from regulatory authority timelines, or failing to notify all relevant IRBs.",
      "inspectorQuestion": "How do you track IRB notifications for SUSARs? Demonstrate compliance for a recent case.",
      "relatedTerms": [
        "susar",
        "clinical-trial",
        "ethics-committee"
      ],
      "tags": [
        "clinical-trial",
        "notification",
        "oversight"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "clinical-overview": {
      "id": "clinical-overview",
      "term": "Clinical Overview",
      "acronym": null,
      "definition": "A critical analysis of clinical safety and efficacy data that integrates information from multiple sources into a coherent summary for regulatory submissions.",
      "regulatorySource": "ICH M4E, CTD Format",
      "example": "The clinical overview in Module 2.5 of a marketing application synthesizes safety data from Phase 1-3 trials, highlighting key risks, their management, and overall benefit-risk conclusions.",
      "commonMistakes": "Writing overviews that simply repeat study synopses rather than providing integrated critical analysis.",
      "inspectorQuestion": "How do you ensure the clinical overview accurately represents all available safety data?",
      "relatedTerms": [
        "integrated-safety-summary",
        "marketing-application",
        "benefit-risk"
      ],
      "tags": [
        "regulatory",
        "documentation",
        "submission"
      ],
      "categoryId": "medical-review",
      "categoryName": "Medical Review"
    },
    "expedited-reporting": {
      "id": "expedited-reporting",
      "term": "Expedited Reporting",
      "acronym": null,
      "definition": "The rapid submission of serious, unexpected adverse events to regulatory authorities within specified timeframes (typically 7 or 15 calendar days).",
      "regulatorySource": "ICH E2D, 21 CFR 314.80, EU GVP Module VI",
      "example": "A fatal unexpected adverse reaction requires 7-day expedited reporting. A serious unexpected non-fatal reaction requires 15-day expedited reporting to most regulatory authorities.",
      "commonMistakes": "Calculating business days instead of calendar days, or not accounting for different regional timeline requirements.",
      "inspectorQuestion": "Walk me through your expedited reporting process. How do you ensure cases are identified and submitted within required timeframes?",
      "relatedTerms": [
        "seven-day-report",
        "fifteen-day-report",
        "susar",
        "clock-start"
      ],
      "tags": [
        "reporting",
        "expedited",
        "regulatory"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "fifteen-day-report": {
      "id": "fifteen-day-report",
      "term": "15-Day Report",
      "acronym": null,
      "definition": "An expedited safety report submitted within 15 calendar days for serious, unexpected adverse reactions from post-marketing spontaneous sources.",
      "regulatorySource": "21 CFR 314.80, ICH E2D",
      "example": "Day 0: Company becomes aware of serious unexpected hepatotoxicity from a spontaneous report. Day 15 (or earlier): ICSR must be submitted to FDA and other relevant authorities.",
      "commonMistakes": "Waiting until Day 15 to submit when information is complete earlier. Regulations require submission 'as soon as possible but no later than 15 days.'",
      "inspectorQuestion": "What is your average submission time for 15-day reports? Show me your compliance metrics.",
      "relatedTerms": [
        "expedited-reporting",
        "serious-ae",
        "unexpected-ae"
      ],
      "tags": [
        "reporting",
        "timeline",
        "post-marketing"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "seven-day-report": {
      "id": "seven-day-report",
      "term": "7-Day Report",
      "acronym": null,
      "definition": "An expedited safety report submitted within 7 calendar days for fatal or life-threatening unexpected adverse reactions.",
      "regulatorySource": "ICH E2D, EU GVP Module VI",
      "example": "A patient dies from an unexpected serious adverse reaction. Initial report with available information must be submitted within 7 days, with follow-up within an additional 8 days.",
      "commonMistakes": "Not submitting within 7 days because complete information isn't available. Initial reports should be submitted with available data.",
      "inspectorQuestion": "How do you prioritize and expedite processing for potential 7-day cases?",
      "relatedTerms": [
        "expedited-reporting",
        "fatal",
        "life-threatening"
      ],
      "tags": [
        "reporting",
        "timeline",
        "urgent"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "susar": {
      "id": "susar",
      "term": "Suspected Unexpected Serious Adverse Reaction",
      "acronym": "SUSAR",
      "definition": "A serious adverse reaction from a clinical trial that is both suspected to be caused by the investigational product and is not consistent with the Investigator's Brochure.",
      "regulatorySource": "ICH E2A, EU CT Regulation",
      "example": "In a clinical trial, a patient develops Stevens-Johnson syndrome not listed in the IB. This SUSAR requires expedited reporting to regulators and notification to investigators/IRBs.",
      "commonMistakes": "Reporting all SAEs as SUSARs without proper expectedness assessment against the IB, or missing true SUSARs due to inadequate IB review.",
      "inspectorQuestion": "How do you determine expectedness for clinical trial events? Show me your IB and demonstrate the assessment process.",
      "relatedTerms": [
        "serious-ae",
        "unexpected-ae",
        "investigators-brochure",
        "clinical-trial"
      ],
      "tags": [
        "clinical-trial",
        "expedited",
        "reporting"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "cioms-form": {
      "id": "cioms-form",
      "term": "CIOMS Form",
      "acronym": "CIOMS I",
      "definition": "A standardized one-page form developed by the Council for International Organizations of Medical Sciences for reporting individual adverse reactions.",
      "regulatorySource": "CIOMS, Historical Standard",
      "example": "Before electronic E2B submissions became standard, the CIOMS I form was the international standard for paper-based expedited adverse reaction reporting.",
      "commonMistakes": "Using CIOMS forms when E2B electronic submission is required. Most major regulators now require electronic submission.",
      "inspectorQuestion": "When, if ever, do you still use CIOMS forms? What is your backup procedure if electronic submission fails?",
      "relatedTerms": [
        "e2b",
        "icsr",
        "expedited-reporting"
      ],
      "tags": [
        "form",
        "historical",
        "reporting"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "medwatch": {
      "id": "medwatch",
      "term": "MedWatch",
      "acronym": null,
      "definition": "The FDA's safety information and adverse event reporting program, including Form FDA 3500A for mandatory manufacturer reporting.",
      "regulatorySource": "FDA, 21 CFR 314.80",
      "example": "Pharmaceutical manufacturers submit expedited ICSRs to FDA through the MedWatch program using Form 3500A or E2B electronic transmission.",
      "commonMistakes": "Confusing Form 3500 (voluntary consumer reporting) with Form 3500A (mandatory manufacturer reporting).",
      "inspectorQuestion": "Describe your MedWatch submission process. How do you handle FDA acknowledgments and requests for information?",
      "relatedTerms": [
        "fda",
        "icsr",
        "faers"
      ],
      "tags": [
        "fda",
        "us",
        "reporting"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "faers": {
      "id": "faers",
      "term": "FDA Adverse Event Reporting System",
      "acronym": "FAERS",
      "definition": "FDA's database containing adverse event reports and medication error reports submitted by manufacturers, healthcare professionals, and consumers.",
      "regulatorySource": "FDA",
      "example": "FAERS data is publicly available and used by FDA for post-marketing safety surveillance. Signal detection algorithms analyze FAERS data for emerging safety concerns.",
      "commonMistakes": "Treating FAERS data as equivalent to clinical trial data. FAERS reports are unverified and subject to reporting biases.",
      "inspectorQuestion": "Do you monitor FAERS for signals related to your products? How do you use publicly available FAERS data?",
      "relatedTerms": [
        "medwatch",
        "signal-detection",
        "database"
      ],
      "tags": [
        "fda",
        "database",
        "surveillance"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "eudravigilance": {
      "id": "eudravigilance",
      "term": "EudraVigilance",
      "acronym": "EV",
      "definition": "The European system for managing and analyzing information on suspected adverse reactions to medicines authorized in the European Economic Area.",
      "regulatorySource": "EU Regulation 726/2004, EU GVP",
      "example": "MAHs submit ICSRs electronically to EudraVigilance. The system enables signal detection across the EU and facilitates data sharing between regulators.",
      "commonMistakes": "Submitting to national authorities instead of directly to EudraVigilance for centrally authorized products.",
      "inspectorQuestion": "Demonstrate your EudraVigilance submission process. How do you handle E2B acknowledgments and error messages?",
      "relatedTerms": [
        "ema",
        "e2b",
        "icsr",
        "evweb"
      ],
      "tags": [
        "eu",
        "database",
        "reporting"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "ack": {
      "id": "ack",
      "term": "Acknowledgment",
      "acronym": "ACK",
      "definition": "An electronic message from a regulatory authority confirming receipt of an E2B submission and indicating whether it passed validation.",
      "regulatorySource": "ICH E2B(R3), Gateway Standards",
      "example": "After E2B submission, the company receives ACK1 (receipt confirmation) and ACK2 (validation result). A negative ACK2 indicates errors requiring correction and resubmission.",
      "commonMistakes": "Not monitoring for ACKs or ignoring negative acknowledgments, leading to cases not being properly received by regulators.",
      "inspectorQuestion": "How do you track E2B acknowledgments? What is your process when you receive a negative ACK?",
      "relatedTerms": [
        "e2b",
        "gateway-submission",
        "validation"
      ],
      "tags": [
        "electronic",
        "submission",
        "technical"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "nullification": {
      "id": "nullification",
      "term": "Nullification",
      "acronym": null,
      "definition": "The process of voiding a previously submitted ICSR, typically when it is determined to be a duplicate or invalid.",
      "regulatorySource": "ICH E2B(R3), EU GVP Module VI",
      "example": "After submission, it's discovered that Case A and Case B are duplicates of the same event. Case B is nullified with reference to Case A as the master record.",
      "commonMistakes": "Using nullification to correct data errors instead of submitting follow-up reports. Nullification should only be used for truly invalid or duplicate cases.",
      "inspectorQuestion": "What criteria must be met to nullify a case? Show me your nullification SOP and recent examples.",
      "relatedTerms": [
        "duplicate-detection",
        "follow-up-report",
        "icsr"
      ],
      "tags": [
        "submission",
        "correction",
        "data-management"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "regulatory-authority": {
      "id": "regulatory-authority",
      "term": "Regulatory Authority",
      "acronym": "RA",
      "definition": "A government agency responsible for regulating medicines, including receiving safety reports and taking regulatory action to protect public health.",
      "regulatorySource": "Regional Regulations",
      "example": "Key regulatory authorities include FDA (US), EMA (EU), PMDA (Japan), MHRA (UK), and Health Canada. Each has specific reporting requirements and formats.",
      "commonMistakes": "Assuming all regulatory authorities have identical requirements. Regional variations in timelines, formats, and reportability exist.",
      "inspectorQuestion": "How do you track different regulatory authority requirements? How do you stay current when requirements change?",
      "relatedTerms": [
        "fda",
        "ema",
        "expedited-reporting"
      ],
      "tags": [
        "regulatory",
        "authority",
        "global"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "submission-tracking": {
      "id": "submission-tracking",
      "term": "Submission Tracking",
      "acronym": null,
      "definition": "The systematic monitoring of regulatory submission status, acknowledgments, due dates, and compliance metrics.",
      "regulatorySource": "Company SOPs, Quality Management",
      "example": "A dashboard shows: 15 expedited reports due this week, 3 pending ACKs, 2 negative ACKs requiring resubmission, 98% on-time submission rate YTD.",
      "commonMistakes": "Tracking only submission dates without monitoring acknowledgment status, potentially missing rejected submissions.",
      "inspectorQuestion": "Show me your submission tracking system. How do you ensure nothing falls through the cracks?",
      "relatedTerms": [
        "compliance-rate",
        "ack",
        "expedited-reporting"
      ],
      "tags": [
        "tracking",
        "compliance",
        "management"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "periodic-reporting": {
      "id": "periodic-reporting",
      "term": "Periodic Reporting",
      "acronym": null,
      "definition": "Safety reports submitted at regular intervals (e.g., annually) providing cumulative analysis of a product's safety profile.",
      "regulatorySource": "ICH E2C(R2), EU GVP Module VII",
      "example": "PSURs are submitted every 6 months for newly approved products, annually for established products, or at other intervals specified in the pharmacovigilance plan.",
      "commonMistakes": "Missing submission deadlines due to complex interval calculations or not tracking birth dates correctly.",
      "inspectorQuestion": "How do you manage periodic report submission schedules? Show me your tracking system.",
      "relatedTerms": [
        "psur",
        "pbrer",
        "dsur",
        "data-lock"
      ],
      "tags": [
        "reporting",
        "periodic",
        "aggregate"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "local-reporting": {
      "id": "local-reporting",
      "term": "Local Reporting Requirements",
      "acronym": null,
      "definition": "Country-specific adverse event reporting obligations that may differ from international standards in terms of reportability criteria, timelines, or format.",
      "regulatorySource": "National Regulations",
      "example": "Some countries require reporting of non-serious expected events, different timeline calculations, or local language translations not required by ICH standards.",
      "commonMistakes": "Applying only ICH standards without checking specific local requirements, leading to non-compliance in certain markets.",
      "inspectorQuestion": "How do you identify and track local reporting requirements? Give examples of requirements that differ from ICH standards.",
      "relatedTerms": [
        "regulatory-authority",
        "expedited-reporting",
        "global"
      ],
      "tags": [
        "local",
        "regional",
        "compliance"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "downstream-reporting": {
      "id": "downstream-reporting",
      "term": "Downstream Reporting",
      "acronym": null,
      "definition": "The process of forwarding adverse event reports to partners, licensees, or other stakeholders as required by contractual agreements.",
      "regulatorySource": "Safety Data Exchange Agreements",
      "example": "When the license holder receives an adverse event, they forward it to their licensing partner within the timeframe specified in their SDEA (typically 24-48 hours for serious cases).",
      "commonMistakes": "Not tracking downstream distribution or missing partner-specific formatting requirements.",
      "inspectorQuestion": "How do you manage downstream reporting to partners? Show me your tracking and reconciliation process.",
      "relatedTerms": [
        "sdea",
        "partner-company",
        "case-exchange"
      ],
      "tags": [
        "partnership",
        "distribution",
        "reporting"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "spontaneous-reporting-rate": {
      "id": "spontaneous-reporting-rate",
      "term": "Spontaneous Reporting Rate",
      "acronym": "SRR",
      "definition": "The frequency of adverse event reports relative to drug exposure, typically expressed as reports per patient-years of exposure or per units sold.",
      "regulatorySource": "Signal Detection, Epidemiology",
      "example": "If 100 reports are received and estimated exposure is 1 million patient-years, the reporting rate is 0.0001 or 10 per 100,000 patient-years.",
      "commonMistakes": "Interpreting reporting rates as incidence rates. Spontaneous reporting has significant underreporting and cannot establish true incidence.",
      "inspectorQuestion": "How do you calculate and use spontaneous reporting rates? What caveats do you apply when interpreting them?",
      "relatedTerms": [
        "underreporting",
        "exposure-data",
        "signal-detection"
      ],
      "tags": [
        "analysis",
        "rates",
        "epidemiology"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "underreporting": {
      "id": "underreporting",
      "term": "Underreporting",
      "acronym": null,
      "definition": "The phenomenon where only a fraction of actual adverse events are reported to spontaneous reporting systems, typically estimated at 1-10% of actual occurrences.",
      "regulatorySource": "Pharmacoepidemiology Literature",
      "example": "A serious adverse reaction may actually occur in 1 in 1,000 patients, but only 1 in 10,000 gets reported to the spontaneous system due to underreporting.",
      "commonMistakes": "Treating spontaneous report counts as actual case counts, leading to gross underestimation of risk.",
      "inspectorQuestion": "How do you account for underreporting in your safety analyses and signal evaluation?",
      "relatedTerms": [
        "spontaneous-report",
        "reporting-rate",
        "stimulated-reporting"
      ],
      "tags": [
        "limitation",
        "epidemiology",
        "analysis"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "stimulated-reporting": {
      "id": "stimulated-reporting",
      "term": "Stimulated Reporting",
      "acronym": null,
      "definition": "An increase in adverse event reporting due to external factors such as media attention, Dear Healthcare Provider letters, or regulatory actions.",
      "regulatorySource": "Signal Evaluation, Epidemiology",
      "example": "After a safety warning is publicized, reports of the mentioned adverse event increase dramatically - not because the event is occurring more often, but because awareness has increased.",
      "commonMistakes": "Interpreting increased reports after publicity as evidence of increased risk rather than increased reporting awareness.",
      "inspectorQuestion": "How do you distinguish true safety signals from stimulated reporting effects in your analyses?",
      "relatedTerms": [
        "underreporting",
        "media-attention",
        "signal-evaluation"
      ],
      "tags": [
        "bias",
        "analysis",
        "reporting"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "direct-reporting": {
      "id": "direct-reporting",
      "term": "Direct Reporting",
      "acronym": null,
      "definition": "Adverse event reports submitted directly by healthcare professionals or patients to regulatory authorities, bypassing the pharmaceutical company.",
      "regulatorySource": "EU Pharmacovigilance Legislation, FDA MedWatch",
      "example": "A patient reports an adverse reaction directly to FDA via MedWatch Form 3500. The FDA may forward this report to the manufacturer for additional information.",
      "commonMistakes": "Not having processes to receive and reconcile reports forwarded from regulatory authorities.",
      "inspectorQuestion": "How do you handle reports received from regulatory authorities that were originally submitted by HCPs or patients directly?",
      "relatedTerms": [
        "medwatch",
        "spontaneous-report",
        "regulatory-authority"
      ],
      "tags": [
        "reporting",
        "source",
        "regulatory"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "safety-report-submission": {
      "id": "safety-report-submission",
      "term": "Safety Report Submission",
      "acronym": null,
      "definition": "The formal transmission of adverse event information to regulatory authorities through approved channels and formats.",
      "regulatorySource": "ICH E2B(R3), Regional Requirements",
      "example": "Submission may occur via electronic gateway (E2B), regulatory portal (EudraVigilance, FAERS), or in some cases paper forms for regions without electronic capability.",
      "commonMistakes": "Using incorrect submission routes or formats for specific regulatory authorities.",
      "inspectorQuestion": "Describe your submission infrastructure. What backup procedures exist if primary submission routes fail?",
      "relatedTerms": [
        "e2b",
        "gateway-submission",
        "expedited-reporting"
      ],
      "tags": [
        "submission",
        "technical",
        "regulatory"
      ],
      "categoryId": "regulatory-reporting",
      "categoryName": "Regulatory Reporting"
    },
    "signal-detection": {
      "id": "signal-detection",
      "term": "Signal Detection",
      "acronym": null,
      "definition": "The systematic process of analyzing safety data to identify potential new risks or changes in known risks associated with a medicinal product.",
      "regulatorySource": "EU GVP Module IX, ICH E2E",
      "example": "Routine disproportionality analysis of the safety database identifies an unexpectedly high reporting ratio for cardiac arrhythmia. This triggers signal validation activities.",
      "commonMistakes": "Relying solely on statistical methods without clinical review, or conversely, ignoring statistical signals without proper evaluation.",
      "inspectorQuestion": "Describe your signal detection methodology. What data sources and analytical methods do you use?",
      "relatedTerms": [
        "disproportionality",
        "signal-validation",
        "data-mining"
      ],
      "tags": [
        "signal",
        "detection",
        "analysis"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "signal-validation": {
      "id": "signal-validation",
      "term": "Signal Validation",
      "acronym": null,
      "definition": "The process of evaluating whether a detected signal represents a genuine new safety concern warranting further analysis.",
      "regulatorySource": "EU GVP Module IX",
      "example": "A statistical signal for 'cardiac arrest' is validated by reviewing individual case quality, checking for duplicates, assessing biological plausibility, and comparing with external data sources.",
      "commonMistakes": "Skipping validation and moving directly to labeling changes, or dismissing signals without adequate evaluation.",
      "inspectorQuestion": "Walk me through a recent signal validation. What criteria do you use to determine if a signal is validated?",
      "relatedTerms": [
        "signal-detection",
        "signal-evaluation",
        "validated-signal"
      ],
      "tags": [
        "signal",
        "validation",
        "process"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "signal-evaluation": {
      "id": "signal-evaluation",
      "term": "Signal Evaluation",
      "acronym": null,
      "definition": "The comprehensive assessment of a validated signal including analysis of all available data to characterize the risk and determine appropriate actions.",
      "regulatorySource": "EU GVP Module IX",
      "example": "Evaluation of a hepatotoxicity signal includes: case series review, literature analysis, mechanism assessment, population risk factors, dose relationship, and comparison with similar drugs.",
      "commonMistakes": "Limiting evaluation to spontaneous data without incorporating clinical trial data, literature, and epidemiological studies.",
      "inspectorQuestion": "Show me a signal evaluation report. How do you integrate data from multiple sources?",
      "relatedTerms": [
        "signal-validation",
        "benefit-risk",
        "risk-characterization"
      ],
      "tags": [
        "signal",
        "evaluation",
        "assessment"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "disproportionality": {
      "id": "disproportionality",
      "term": "Disproportionality Analysis",
      "acronym": null,
      "definition": "A statistical method comparing the observed frequency of a drug-event combination against the expected frequency based on overall reporting patterns in a database.",
      "regulatorySource": "EU GVP Module IX, Pharmacoepidemiology",
      "example": "PRR (Proportional Reporting Ratio) of 3.5 for Drug X and hepatitis means this combination is reported 3.5 times more frequently than expected based on database patterns.",
      "commonMistakes": "Interpreting disproportionality as proof of causation. It indicates a statistical signal requiring clinical evaluation, not confirmed causality.",
      "inspectorQuestion": "What disproportionality methods do you use? How do you set thresholds for signal detection?",
      "relatedTerms": [
        "prr",
        "ror",
        "signal-detection",
        "data-mining"
      ],
      "tags": [
        "statistics",
        "analysis",
        "methodology"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "prr": {
      "id": "prr",
      "term": "Proportional Reporting Ratio",
      "acronym": "PRR",
      "definition": "A disproportionality measure comparing the proportion of a specific event for a drug versus the proportion for all other drugs in the database.",
      "regulatorySource": "EU GVP Module IX, EudraVigilance",
      "example": "If 10% of Drug X reports mention rhabdomyolysis but only 1% of all other drug reports mention it, PRR = 10/1 = 10, suggesting a potential signal.",
      "commonMistakes": "Using PRR without considering case counts. A PRR of 10 based on 2 cases is less meaningful than PRR of 3 based on 500 cases.",
      "inspectorQuestion": "What PRR threshold do you use for signal detection? How do you account for sample size?",
      "relatedTerms": [
        "disproportionality",
        "ror",
        "signal-detection"
      ],
      "tags": [
        "statistics",
        "metric",
        "signal"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "ror": {
      "id": "ror",
      "term": "Reporting Odds Ratio",
      "acronym": "ROR",
      "definition": "A disproportionality measure that compares the odds of a specific event being reported for a drug versus the odds for all other drugs.",
      "regulatorySource": "Pharmacoepidemiology Literature",
      "example": "ROR = (Drug X with Event A / Drug X without Event A) / (Other drugs with Event A / Other drugs without Event A). ROR > 1 suggests potential association.",
      "commonMistakes": "Confusing ROR with relative risk. ROR uses reporting odds, not true occurrence rates.",
      "inspectorQuestion": "How do you interpret ROR values? What confidence intervals do you consider meaningful?",
      "relatedTerms": [
        "disproportionality",
        "prr",
        "signal-detection"
      ],
      "tags": [
        "statistics",
        "metric",
        "analysis"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "signal-tracking": {
      "id": "signal-tracking",
      "term": "Signal Tracking",
      "acronym": null,
      "definition": "The systematic documentation and monitoring of signals through their lifecycle from detection through evaluation and final outcome.",
      "regulatorySource": "EU GVP Module IX",
      "example": "A signal tracking log documents: detection date, source, initial assessment, validation outcome, evaluation status, recommended actions, and final disposition.",
      "commonMistakes": "Not maintaining comprehensive signal documentation, leading to gaps in regulatory inspection readiness.",
      "inspectorQuestion": "Show me your signal tracking system. How do you ensure all signals are followed to conclusion?",
      "relatedTerms": [
        "signal-management",
        "prac",
        "regulatory-compliance"
      ],
      "tags": [
        "tracking",
        "management",
        "documentation"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "prac": {
      "id": "prac",
      "term": "Pharmacovigilance Risk Assessment Committee",
      "acronym": "PRAC",
      "definition": "The EMA committee responsible for assessing and monitoring safety issues for human medicines, including signal assessment and risk management recommendations.",
      "regulatorySource": "EU Regulation 726/2004",
      "example": "PRAC reviews signals detected in EudraVigilance, assesses PSUR findings, and makes recommendations that may lead to label changes, restrictions, or withdrawals.",
      "commonMistakes": "Not adequately preparing for or responding to PRAC requests for information or assessment reports.",
      "inspectorQuestion": "How do you prepare for PRAC signal assessments? Describe your interaction with PRAC.",
      "relatedTerms": [
        "ema",
        "signal-evaluation",
        "referral"
      ],
      "tags": [
        "eu",
        "committee",
        "regulatory"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "emerging-safety-issue": {
      "id": "emerging-safety-issue",
      "term": "Emerging Safety Issue",
      "acronym": "ESI",
      "definition": "A safety issue that requires urgent reporting to regulators based on new information that may affect the benefit-risk balance of a product.",
      "regulatorySource": "EU GVP Module VI",
      "example": "A cluster of fatalities from a previously unknown adverse reaction is detected. This emerging safety issue is reported to regulators within 24 hours of identification.",
      "commonMistakes": "Not recognizing emerging safety issues promptly, or over-reporting minor issues as emergent.",
      "inspectorQuestion": "How do you identify emerging safety issues? Walk me through a recent example.",
      "relatedTerms": [
        "urgent-safety-restriction",
        "signal-management",
        "benefit-risk"
      ],
      "tags": [
        "urgent",
        "safety",
        "regulatory"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "urgent-safety-restriction": {
      "id": "urgent-safety-restriction",
      "term": "Urgent Safety Restriction",
      "acronym": "USR",
      "definition": "A provisional change to product information initiated by an MAH due to new safety information, implemented before regulatory approval.",
      "regulatorySource": "EU Variation Regulation",
      "example": "New data shows serious risk of hepatotoxicity. The MAH implements an urgent safety restriction adding a contraindication, then notifies regulators within 24 hours.",
      "commonMistakes": "Using USR inappropriately for non-urgent changes, or not following up with the required Type II variation.",
      "inspectorQuestion": "Describe a situation where you implemented an urgent safety restriction. What was the timeline?",
      "relatedTerms": [
        "emerging-safety-issue",
        "safety-variation",
        "contraindication"
      ],
      "tags": [
        "urgent",
        "labeling",
        "regulatory"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "case-series": {
      "id": "case-series",
      "term": "Case Series Analysis",
      "acronym": null,
      "definition": "A detailed clinical review of multiple individual cases sharing common characteristics to identify patterns and support signal evaluation.",
      "regulatorySource": "EU GVP Module IX, Signal Evaluation",
      "example": "Fifteen cases of pancreatitis are identified. Case series analysis examines: patient demographics, time to onset, concomitant drugs, dechallenge/rechallenge, and outcomes to characterize the signal.",
      "commonMistakes": "Treating case series as epidemiological studies. Case series can generate hypotheses but cannot establish incidence or comparative risk.",
      "inspectorQuestion": "Show me a case series analysis you conducted. What clinical patterns did you identify?",
      "relatedTerms": [
        "signal-evaluation",
        "clinical-review",
        "pattern-recognition"
      ],
      "tags": [
        "analysis",
        "clinical",
        "signal"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "signal-prioritization": {
      "id": "signal-prioritization",
      "term": "Signal Prioritization",
      "acronym": null,
      "definition": "The process of ranking detected signals based on factors such as strength of evidence, potential impact, and public health importance to allocate evaluation resources.",
      "regulatorySource": "EU GVP Module IX",
      "example": "With 10 potential signals detected, prioritization ranks a fatal cardiac signal highest, followed by signals with strong disproportionality, while weak statistical noise is deprioritized.",
      "commonMistakes": "Not having clear prioritization criteria, leading to inconsistent resource allocation.",
      "inspectorQuestion": "How do you prioritize signals for evaluation? What criteria do you use?",
      "relatedTerms": [
        "signal-detection",
        "signal-evaluation",
        "resource-allocation"
      ],
      "tags": [
        "management",
        "prioritization",
        "decision"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "negative-signal": {
      "id": "negative-signal",
      "term": "Refuted Signal",
      "acronym": null,
      "definition": "A potential signal that, after thorough evaluation, is determined not to represent a true safety concern and requires no further action.",
      "regulatorySource": "EU GVP Module IX",
      "example": "A statistical signal for stroke is identified. Evaluation reveals the reports were confounded by underlying disease, with no plausible drug mechanism. The signal is closed as refuted.",
      "commonMistakes": "Closing signals without adequate documentation of evaluation rationale, or prematurely closing signals that warrant ongoing monitoring.",
      "inspectorQuestion": "How do you document refuted signals? What level of evaluation is required before closure?",
      "relatedTerms": [
        "signal-evaluation",
        "signal-closure",
        "documentation"
      ],
      "tags": [
        "signal",
        "outcome",
        "closure"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "confirmed-signal": {
      "id": "confirmed-signal",
      "term": "Confirmed Signal",
      "acronym": null,
      "definition": "A validated signal where evaluation has established sufficient evidence of a causal association requiring risk management action.",
      "regulatorySource": "EU GVP Module IX",
      "example": "Evaluation of a hepatotoxicity signal confirms: consistent case pattern, biological plausibility, positive dechallenge, supporting literature. Label update is recommended.",
      "commonMistakes": "Requiring the same level of proof as a randomized trial. Signal confirmation is based on weight of evidence, not absolute certainty.",
      "inspectorQuestion": "Walk me through a confirmed signal. What evidence supported confirmation?",
      "relatedTerms": [
        "signal-evaluation",
        "labeling",
        "risk-management"
      ],
      "tags": [
        "signal",
        "outcome",
        "confirmed"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "external-data-sources": {
      "id": "external-data-sources",
      "term": "External Data Sources",
      "acronym": null,
      "definition": "Safety data from sources outside the company's own database, including regulatory databases, literature, registries, and epidemiological studies.",
      "regulatorySource": "EU GVP Module IX",
      "example": "Signal evaluation incorporates: EudraVigilance data, FAERS data, published case reports, observational study results, and competitor product safety information.",
      "commonMistakes": "Relying solely on internal data for signal evaluation without consulting external sources.",
      "inspectorQuestion": "What external data sources do you use for signal detection and evaluation?",
      "relatedTerms": [
        "eudravigilance",
        "faers",
        "literature-screening"
      ],
      "tags": [
        "data",
        "external",
        "sources"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "data-mining": {
      "id": "data-mining",
      "term": "Data Mining",
      "acronym": null,
      "definition": "The application of statistical and computational techniques to large safety databases to identify potential safety signals automatically.",
      "regulatorySource": "EU GVP Module IX, FDA AERS",
      "example": "Bayesian data mining algorithms (BCPNN, MGPS) scan EudraVigilance nightly to identify new drug-event combinations with unexpectedly high reporting frequency.",
      "commonMistakes": "Treating data mining results as definitive signals rather than hypotheses requiring clinical validation.",
      "inspectorQuestion": "What data mining methods do you use? How do you validate data mining outputs?",
      "relatedTerms": [
        "disproportionality",
        "signal-detection",
        "algorithm"
      ],
      "tags": [
        "methodology",
        "statistics",
        "automated"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "signal-communication": {
      "id": "signal-communication",
      "term": "Signal Communication",
      "acronym": null,
      "definition": "The process of informing relevant stakeholders (regulators, healthcare professionals, patients) about confirmed safety signals and any resulting actions.",
      "regulatorySource": "EU GVP Module XV",
      "example": "Following confirmation of a serious hepatotoxicity signal, communication includes: regulatory notification, DHPC to healthcare professionals, patient information update, and label revision.",
      "commonMistakes": "Delaying communication or providing inconsistent messages to different stakeholders.",
      "inspectorQuestion": "How do you coordinate signal communication to different stakeholders? Show me a recent example.",
      "relatedTerms": [
        "dhpc",
        "rmp",
        "regulatory-notification"
      ],
      "tags": [
        "communication",
        "stakeholder",
        "regulatory"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "dhpc": {
      "id": "dhpc",
      "term": "Direct Healthcare Professional Communication",
      "acronym": "DHPC",
      "definition": "A communication sent directly to healthcare professionals to inform them of important safety information that may affect how they prescribe or use a medicine.",
      "regulatorySource": "EU GVP Module XV",
      "example": "A DHPC is sent to cardiologists informing them of a newly identified risk of QT prolongation, with recommendations for ECG monitoring and contraindicated combinations.",
      "commonMistakes": "Sending DHPCs without regulatory agreement on content, or using inappropriate distribution channels.",
      "inspectorQuestion": "Describe your DHPC development and approval process. How do you ensure appropriate distribution?",
      "relatedTerms": [
        "signal-communication",
        "safety-variation",
        "hcp"
      ],
      "tags": [
        "communication",
        "hcp",
        "safety"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "periodic-signal-report": {
      "id": "periodic-signal-report",
      "term": "Signal Detection Report",
      "acronym": null,
      "definition": "Regular documentation of signal detection activities, methods used, signals identified, and their status.",
      "regulatorySource": "EU GVP Module IX, PSMF",
      "example": "Monthly signal detection report documents: databases screened, methods applied, new signals identified, status of ongoing signals, and signals closed during the period.",
      "commonMistakes": "Not maintaining documentation of signal detection activities, particularly negative results showing no signals detected.",
      "inspectorQuestion": "Show me your signal detection documentation. How do you prove you performed signal detection when no signals were found?",
      "relatedTerms": [
        "signal-detection",
        "psmf",
        "documentation"
      ],
      "tags": [
        "documentation",
        "periodic",
        "compliance"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "signal-management-plan": {
      "id": "signal-management-plan",
      "term": "Signal Management Plan",
      "acronym": null,
      "definition": "A documented plan describing the procedures, responsibilities, and timelines for signal detection, validation, evaluation, and action.",
      "regulatorySource": "EU GVP Module IX",
      "example": "The signal management plan specifies: detection methods, frequency of review, validation criteria, evaluation procedures, escalation pathways, and decision-making responsibilities.",
      "commonMistakes": "Having a generic plan that doesn't account for product-specific considerations or resource constraints.",
      "inspectorQuestion": "Walk me through your signal management plan. How is it customized for different products?",
      "relatedTerms": [
        "signal-detection",
        "pv-system",
        "sop"
      ],
      "tags": [
        "planning",
        "documentation",
        "process"
      ],
      "categoryId": "signal-management",
      "categoryName": "Signal Management"
    },
    "psur": {
      "id": "psur",
      "term": "Periodic Safety Update Report",
      "acronym": "PSUR",
      "definition": "A comprehensive assessment of the risk-benefit balance of a medicinal product submitted at defined intervals throughout its marketed life.",
      "regulatorySource": "ICH E2C(R2), EU GVP Module VII",
      "example": "The annual PSUR for Drug X includes: estimated exposure, cumulative adverse reaction tables, signal evaluation summary, benefit-risk analysis, and proposed actions.",
      "commonMistakes": "Treating PSURs as simple data compilations rather than analytical documents requiring benefit-risk conclusions.",
      "inspectorQuestion": "Walk me through your PSUR preparation process. How do you conduct the benefit-risk evaluation?",
      "relatedTerms": [
        "pbrer",
        "data-lock",
        "benefit-risk"
      ],
      "tags": [
        "periodic",
        "reporting",
        "aggregate"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "pbrer": {
      "id": "pbrer",
      "term": "Periodic Benefit-Risk Evaluation Report",
      "acronym": "PBRER",
      "definition": "The ICH E2C(R2) format for periodic safety reports that emphasizes benefit-risk evaluation, replacing the previous PSUR format internationally.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "PBRER sections include: worldwide marketing status, update on regulatory actions, estimated exposure, safety data summary, signal and risk evaluation, benefit evaluation, and integrated benefit-risk analysis.",
      "commonMistakes": "Using old PSUR format when PBRER is required, or not including adequate benefit assessment.",
      "inspectorQuestion": "How do you ensure your PBRER meets all ICH E2C(R2) requirements?",
      "relatedTerms": [
        "psur",
        "benefit-risk",
        "ich"
      ],
      "tags": [
        "periodic",
        "format",
        "international"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "dsur": {
      "id": "dsur",
      "term": "Development Safety Update Report",
      "acronym": "DSUR",
      "definition": "An annual safety report for investigational drugs submitted during clinical development to regulatory authorities and ethics committees.",
      "regulatorySource": "ICH E2F",
      "example": "The DSUR summarizes all clinical trial safety data from the past year, analyzes emerging safety findings, and updates the benefit-risk assessment for continued development.",
      "commonMistakes": "Not including relevant safety data from all ongoing trials globally, or providing inadequate analysis of aggregate safety findings.",
      "inspectorQuestion": "Show me your DSUR preparation timeline. How do you ensure all global trial data is captured?",
      "relatedTerms": [
        "clinical-trial",
        "investigational-drug",
        "annual-report"
      ],
      "tags": [
        "clinical-trial",
        "periodic",
        "development"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "pader": {
      "id": "pader",
      "term": "Periodic Adverse Drug Experience Report",
      "acronym": "PADER",
      "definition": "The FDA-specific periodic safety report format required for approved drugs, similar to PSUR but with US-specific requirements.",
      "regulatorySource": "21 CFR 314.80",
      "example": "The annual PADER to FDA includes all US adverse experience reports, a narrative discussion of notable cases, and any labeling changes during the period.",
      "commonMistakes": "Using PSUR format directly without addressing FDA-specific PADER requirements.",
      "inspectorQuestion": "How do you handle differences between PSUR/PBRER and PADER requirements?",
      "relatedTerms": [
        "fda",
        "psur",
        "periodic-reporting"
      ],
      "tags": [
        "fda",
        "us",
        "periodic"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "ibd": {
      "id": "ibd",
      "term": "International Birth Date",
      "acronym": "IBD",
      "definition": "The date of first marketing authorization for a medicinal product anywhere in the world, used to calculate PSUR submission intervals.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "Drug X was first approved in Switzerland on June 15, 2010. This IBD determines that PSURs are due in December (6-month cycle) and June (annual) regardless of when other countries approved.",
      "commonMistakes": "Using regional approval dates instead of the global IBD for PSUR timing, leading to inconsistent reporting periods.",
      "inspectorQuestion": "How do you determine and track IBDs? How do you handle products with different formulations?",
      "relatedTerms": [
        "psur",
        "data-lock",
        "reporting-interval"
      ],
      "tags": [
        "date",
        "psur",
        "timeline"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "dlu": {
      "id": "dlu",
      "term": "Data Lock Point",
      "acronym": "DLP",
      "definition": "The cutoff date for including data in a periodic safety report, after which no new data is added to that report.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "For a PSUR with DLP of December 31, all cases with awareness dates through December 31 are included. A case received on December 30 but entered on January 2 is still included.",
      "commonMistakes": "Using case entry date rather than awareness date for DLP determination.",
      "inspectorQuestion": "How do you manage cases that arrive close to DLP? What is your cut-off procedure?",
      "relatedTerms": [
        "data-lock",
        "psur",
        "awareness-date"
      ],
      "tags": [
        "date",
        "cutoff",
        "reporting"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "line-listing": {
      "id": "line-listing",
      "term": "Line Listing",
      "acronym": null,
      "definition": "A tabular presentation of individual case data, with each row representing one case and columns containing key data elements.",
      "regulatorySource": "ICH E2C(R2), EU GVP Module VII",
      "example": "A PSUR line listing shows: case ID, country, age/sex, adverse event terms, seriousness, outcome, causality, and relevant dates for each case in the reporting period.",
      "commonMistakes": "Including excessive detail that obscures important information, or not organizing line listings logically by event type or seriousness.",
      "inspectorQuestion": "How do you generate and quality check line listings? What data elements are included?",
      "relatedTerms": [
        "psur",
        "tabulation",
        "case-data"
      ],
      "tags": [
        "format",
        "data",
        "presentation"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "summary-tabulation": {
      "id": "summary-tabulation",
      "term": "Summary Tabulation",
      "acronym": null,
      "definition": "Aggregate tables presenting case counts by various parameters such as adverse event, seriousness, outcome, or system organ class.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "A summary tabulation shows: 150 total cases in the period, 45 serious (30%), distributed across SOCs with Cardiac disorders (25 cases) being most frequent.",
      "commonMistakes": "Not providing adequate context for numbers, such as comparison to previous periods or baseline rates.",
      "inspectorQuestion": "How do you interpret trends in summary tabulations? What triggers further investigation?",
      "relatedTerms": [
        "line-listing",
        "psur",
        "aggregate-analysis"
      ],
      "tags": [
        "format",
        "aggregate",
        "tables"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "exposure-data": {
      "id": "exposure-data",
      "term": "Patient Exposure Data",
      "acronym": null,
      "definition": "Estimates of the number of patients or patient-time exposed to a medicinal product, providing context for interpreting adverse event data.",
      "regulatorySource": "ICH E2C(R2), EU GVP Module VII",
      "example": "Exposure data shows: 500,000 patients treated in the period, approximately 250,000 patient-years of exposure based on average treatment duration of 6 months.",
      "commonMistakes": "Using different exposure methodologies inconsistently, or not clearly stating assumptions and limitations.",
      "inspectorQuestion": "How do you estimate patient exposure? What data sources do you use?",
      "relatedTerms": [
        "psur",
        "reporting-rate",
        "drug-utilization-study"
      ],
      "tags": [
        "exposure",
        "denominator",
        "analysis"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "cumulative-data": {
      "id": "cumulative-data",
      "term": "Cumulative Summary",
      "acronym": null,
      "definition": "The total of all safety data from first approval through the current data lock point, providing historical context.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "Since launch in 2010, cumulative data includes 25,000 adverse event reports, with estimated cumulative exposure of 5 million patient-years.",
      "commonMistakes": "Not maintaining accurate cumulative counts, leading to inconsistencies between PSURs.",
      "inspectorQuestion": "How do you maintain cumulative safety data? How do you reconcile numbers across reports?",
      "relatedTerms": [
        "psur",
        "data-lock",
        "historical"
      ],
      "tags": [
        "cumulative",
        "historical",
        "aggregate"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "interval-data": {
      "id": "interval-data",
      "term": "Interval Data",
      "acronym": null,
      "definition": "Safety data from the period between the previous and current data lock points, representing new information since the last report.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "Interval data for the annual PSUR shows 3,500 new cases reported between January 1 and December 31, compared to 3,200 in the previous interval.",
      "commonMistakes": "Including cumulative data when interval data is required, or vice versa.",
      "inspectorQuestion": "How do you generate interval-specific data? How do you track period-over-period changes?",
      "relatedTerms": [
        "cumulative-data",
        "psur",
        "reporting-period"
      ],
      "tags": [
        "interval",
        "period",
        "comparative"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "eurd": {
      "id": "eurd",
      "term": "EU Reference Date",
      "acronym": "EURD",
      "definition": "The date in the EU that determines the harmonized submission schedule for PSURs, as listed in the EURD list maintained by EMA.",
      "regulatorySource": "EU GVP Module VII",
      "example": "The EURD list specifies that all products containing ibuprofen have an EU reference date of June 1, ensuring synchronized PSUR submissions across MAHs.",
      "commonMistakes": "Using the company's IBD instead of the EURD for EU PSUR timing.",
      "inspectorQuestion": "How do you track EURD requirements? How do you handle products not on the EURD list?",
      "relatedTerms": [
        "psur",
        "ibd",
        "ema"
      ],
      "tags": [
        "eu",
        "date",
        "harmonization"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "single-assessment": {
      "id": "single-assessment",
      "term": "Single Assessment",
      "acronym": null,
      "definition": "The EU procedure where one member state assesses a PSUR on behalf of all member states where the product is authorized.",
      "regulatorySource": "EU GVP Module VII",
      "example": "Germany is the lead member state for assessing Drug X PSURs. Their assessment and recommendations apply across all EU member states through the single assessment procedure.",
      "commonMistakes": "Submitting to individual member states instead of using the centralized single assessment procedure.",
      "inspectorQuestion": "How do you interact with lead member states during PSUR assessment? How do you implement recommendations?",
      "relatedTerms": [
        "psur",
        "eu",
        "lead-member-state"
      ],
      "tags": [
        "eu",
        "assessment",
        "procedure"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "benefit-risk-analysis": {
      "id": "benefit-risk-analysis",
      "term": "Benefit-Risk Analysis (Aggregate)",
      "acronym": null,
      "definition": "A structured evaluation in periodic reports weighing the therapeutic benefits against known and emerging risks to conclude on overall product value.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "The PBRER concludes: 'Despite the newly identified hepatotoxicity risk (estimated 1:10,000), the product's proven efficacy in reducing mortality in severe disease maintains a favorable benefit-risk balance with enhanced monitoring.'",
      "commonMistakes": "Providing vague benefit-risk conclusions without specific supporting data and reasoning.",
      "inspectorQuestion": "Walk me through your benefit-risk analysis methodology. How do you quantify and weigh factors?",
      "relatedTerms": [
        "psur",
        "pbrer",
        "risk-management"
      ],
      "tags": [
        "analysis",
        "benefit-risk",
        "conclusion"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "proposed-actions": {
      "id": "proposed-actions",
      "term": "Proposed Product Information Changes",
      "acronym": null,
      "definition": "Recommendations in a periodic report for updating product labeling or risk management measures based on safety findings.",
      "regulatorySource": "ICH E2C(R2)",
      "example": "Based on PSUR findings, proposed actions include: adding 'hepatotoxicity' to Section 4.4 Warnings, updating Section 4.8 with incidence data, and recommending liver function monitoring.",
      "commonMistakes": "Not including specific proposed text for labeling changes, or proposing changes without adequate supporting evidence.",
      "inspectorQuestion": "How do you determine when findings warrant labeling changes? Who approves proposed actions?",
      "relatedTerms": [
        "psur",
        "labeling",
        "safety-variation"
      ],
      "tags": [
        "action",
        "labeling",
        "recommendation"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "addendum-report": {
      "id": "addendum-report",
      "term": "Addendum Report",
      "acronym": null,
      "definition": "A supplementary document submitted after a periodic report to provide additional information, updated analyses, or responses to regulatory questions.",
      "regulatorySource": "EU GVP Module VII",
      "example": "Following PRAC assessment questions about hepatotoxicity cases, an addendum provides: additional case details, updated case series analysis, and proposed risk minimization measures.",
      "commonMistakes": "Submitting new data that should have been in the original report as an addendum, rather than truly supplementary information.",
      "inspectorQuestion": "When do you prepare addendum reports? How do you track and respond to regulatory assessment requests?",
      "relatedTerms": [
        "psur",
        "prac",
        "regulatory-response"
      ],
      "tags": [
        "supplementary",
        "response",
        "regulatory"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "psur-repository": {
      "id": "psur-repository",
      "term": "PSUR Repository",
      "acronym": null,
      "definition": "The EU electronic system for submission and storage of PSURs, enabling centralized access and assessment.",
      "regulatorySource": "EU GVP Module VII",
      "example": "MAHs submit PSURs electronically through the common European submission portal to the PSUR repository, where assessors from lead member states access them.",
      "commonMistakes": "Not following repository technical specifications, leading to submission failures.",
      "inspectorQuestion": "Describe your PSUR repository submission process. How do you confirm successful submission?",
      "relatedTerms": [
        "psur",
        "eu",
        "electronic-submission"
      ],
      "tags": [
        "eu",
        "system",
        "submission"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "safety-specification": {
      "id": "safety-specification",
      "term": "Safety Specification",
      "acronym": null,
      "definition": "A summary of the identified risks, potential risks, and missing information for a medicinal product, forming the basis for pharmacovigilance planning.",
      "regulatorySource": "EU GVP Module V, ICH E2E",
      "example": "The safety specification lists: Identified risks (hepatotoxicity), Potential risks (cardiac effects based on mechanism), Missing information (long-term use, pediatric populations).",
      "commonMistakes": "Not updating the safety specification when new information emerges or risks are reclassified.",
      "inspectorQuestion": "How do you maintain the safety specification? How do you determine when to move a potential risk to identified?",
      "relatedTerms": [
        "rmp",
        "identified-risk",
        "potential-risk"
      ],
      "tags": [
        "risk",
        "planning",
        "documentation"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "asa-report": {
      "id": "asa-report",
      "term": "Annual Safety Report",
      "acronym": "ASR",
      "definition": "A yearly safety report required by some regulatory authorities, summarizing safety data and any relevant safety issues.",
      "regulatorySource": "Regional Requirements",
      "example": "Japan requires Annual Safety Reports for approved products, summarizing Japanese and global safety data with analysis relevant to the Japanese population.",
      "commonMistakes": "Assuming PSUR meets all regional annual reporting requirements without checking specific local formats.",
      "inspectorQuestion": "What regional annual reports do you prepare? How do they differ from PSURs?",
      "relatedTerms": [
        "psur",
        "regional-requirements",
        "periodic-reporting"
      ],
      "tags": [
        "regional",
        "annual",
        "reporting"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "clinical-trial-safety-report": {
      "id": "clinical-trial-safety-report",
      "term": "Periodic Safety Reporting for Clinical Trials",
      "acronym": null,
      "definition": "Regular safety reports during clinical development providing aggregate analysis of trial safety data to regulators and ethics committees.",
      "regulatorySource": "ICH E6, Regional CT Regulations",
      "example": "Quarterly safety reports to IRBs summarize: SAEs by treatment arm, emerging safety patterns, and updated risk-benefit assessment for continuing the trial.",
      "commonMistakes": "Providing reports with inadequate blinded analysis or without appropriate statistical context.",
      "inspectorQuestion": "How do you prepare periodic clinical trial safety reports? Who reviews and approves them?",
      "relatedTerms": [
        "dsur",
        "clinical-trial",
        "irb-notification"
      ],
      "tags": [
        "clinical-trial",
        "periodic",
        "safety"
      ],
      "categoryId": "aggregate-reporting",
      "categoryName": "Aggregate Reporting"
    },
    "rmp": {
      "id": "rmp",
      "term": "Risk Management Plan",
      "acronym": "RMP",
      "definition": "A comprehensive document describing the safety profile, pharmacovigilance activities, and risk minimization measures for a medicinal product.",
      "regulatorySource": "EU GVP Module V",
      "example": "The RMP for a new anticoagulant includes: safety specification identifying bleeding risk, pharmacovigilance plan for additional data collection, and risk minimization measures including an HCP guide.",
      "commonMistakes": "Creating static RMPs that aren't updated as new safety information emerges.",
      "inspectorQuestion": "How often do you review and update your RMPs? What triggers an RMP update?",
      "relatedTerms": [
        "safety-specification",
        "pharmacovigilance-plan",
        "risk-minimization"
      ],
      "tags": [
        "risk",
        "planning",
        "eu"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "rems": {
      "id": "rems",
      "term": "Risk Evaluation and Mitigation Strategy",
      "acronym": "REMS",
      "definition": "A US FDA-required drug safety program to ensure benefits outweigh risks, which may include medication guides, communication plans, or elements to assure safe use.",
      "regulatorySource": "FDA, FDAAA 2007",
      "example": "The REMS for an opioid includes: prescriber certification, patient counseling requirements, pharmacy enrollment, and dispensing restrictions to mitigate misuse risk.",
      "commonMistakes": "Treating REMS as a one-time submission rather than an ongoing program requiring monitoring and assessment.",
      "inspectorQuestion": "Describe your REMS program. How do you assess its effectiveness?",
      "relatedTerms": [
        "etasu",
        "medication-guide",
        "risk-minimization"
      ],
      "tags": [
        "fda",
        "us",
        "risk"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "etasu": {
      "id": "etasu",
      "term": "Elements to Assure Safe Use",
      "acronym": "ETASU",
      "definition": "Components of a REMS program that impose access restrictions, such as prescriber/pharmacy certification, patient registries, or dispensing requirements.",
      "regulatorySource": "FDA REMS Guidance",
      "example": "ETASU for a teratogenic drug requires: pregnancy testing before each prescription, prescriber enrollment, pharmacy certification, and mandatory patient registry enrollment.",
      "commonMistakes": "Implementing ETASU without adequate infrastructure to track compliance and assess effectiveness.",
      "inspectorQuestion": "How do you monitor ETASU compliance? What metrics do you track?",
      "relatedTerms": [
        "rems",
        "restricted-distribution",
        "pregnancy-registry"
      ],
      "tags": [
        "fda",
        "restriction",
        "safety"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "identified-risk": {
      "id": "identified-risk",
      "term": "Identified Risk",
      "acronym": null,
      "definition": "A risk for which there is sufficient evidence of an association with the medicinal product based on clinical trial data, post-marketing experience, or nonclinical studies.",
      "regulatorySource": "EU GVP Module V, ICH E2E",
      "example": "Hepatotoxicity is an identified risk for Drug X based on: clinical trial incidence of 0.5%, 50 post-marketing reports with positive dechallenge, and supporting hepatocyte toxicity studies.",
      "commonMistakes": "Classifying risks as identified based on theoretical concerns rather than actual evidence of association.",
      "inspectorQuestion": "What evidence threshold do you use to classify a risk as identified?",
      "relatedTerms": [
        "potential-risk",
        "safety-specification",
        "rmp"
      ],
      "tags": [
        "risk",
        "classification",
        "evidence"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "potential-risk": {
      "id": "potential-risk",
      "term": "Potential Risk",
      "acronym": null,
      "definition": "A risk where there is a basis for concern but insufficient evidence to establish a causal relationship, such as class effects or nonclinical findings.",
      "regulatorySource": "EU GVP Module V, ICH E2E",
      "example": "Cardiac toxicity is a potential risk based on: drug class association, in vitro hERG findings, but no clinical cases observed in trials of 2,000 patients.",
      "commonMistakes": "Including every theoretical possibility as a potential risk, diluting focus on meaningful concerns.",
      "inspectorQuestion": "How do you determine which concerns warrant classification as potential risks?",
      "relatedTerms": [
        "identified-risk",
        "safety-specification",
        "class-effect"
      ],
      "tags": [
        "risk",
        "classification",
        "theoretical"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "missing-information": {
      "id": "missing-information",
      "term": "Missing Information",
      "acronym": null,
      "definition": "Gaps in knowledge about the safety of a medicine in certain populations or situations, requiring further data collection.",
      "regulatorySource": "EU GVP Module V",
      "example": "Missing information includes: use in pregnancy (excluded from trials), long-term safety beyond 2 years, and safety in severe hepatic impairment.",
      "commonMistakes": "Not planning specific activities to address missing information, leaving gaps unresolved indefinitely.",
      "inspectorQuestion": "What activities do you conduct to address missing information? How do you prioritize?",
      "relatedTerms": [
        "safety-specification",
        "pass",
        "registry"
      ],
      "tags": [
        "risk",
        "gaps",
        "information"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "pharmacovigilance-plan": {
      "id": "pharmacovigilance-plan",
      "term": "Pharmacovigilance Plan",
      "acronym": null,
      "definition": "The section of an RMP describing activities to identify, characterize, or quantify risks, including routine and additional pharmacovigilance activities.",
      "regulatorySource": "EU GVP Module V",
      "example": "The pharmacovigilance plan specifies: routine signal detection, a PASS to characterize hepatotoxicity incidence, and a pregnancy registry to collect use-in-pregnancy data.",
      "commonMistakes": "Having vague plans without specific timelines, methods, or milestones.",
      "inspectorQuestion": "Show me your pharmacovigilance plan. How do you track progress on planned activities?",
      "relatedTerms": [
        "rmp",
        "pass",
        "additional-monitoring"
      ],
      "tags": [
        "planning",
        "pv",
        "activities"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "pass": {
      "id": "pass",
      "term": "Post-Authorization Safety Study",
      "acronym": "PASS",
      "definition": "A study conducted after authorization to obtain further information on a medicine's safety, identify risks, or measure effectiveness of risk minimization.",
      "regulatorySource": "EU GVP Module VIII",
      "example": "A PASS using healthcare databases aims to estimate the incidence of hepatotoxicity in routine clinical practice and identify patient risk factors.",
      "commonMistakes": "Designing PASS that cannot answer the specific safety questions due to inadequate sample size or data sources.",
      "inspectorQuestion": "Describe your PASS program. How do you select study designs and data sources?",
      "relatedTerms": [
        "rmp",
        "observational-study",
        "risk-characterization"
      ],
      "tags": [
        "study",
        "post-marketing",
        "safety"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "paes": {
      "id": "paes",
      "term": "Post-Authorization Efficacy Study",
      "acronym": "PAES",
      "definition": "A study conducted after authorization to obtain further information on a medicine's effectiveness in routine clinical practice.",
      "regulatorySource": "EU Regulation 726/2004",
      "example": "A PAES evaluates whether the efficacy observed in clinical trials translates to real-world effectiveness when the drug is used in typical clinical practice.",
      "commonMistakes": "Not distinguishing between PASS (safety) and PAES (efficacy) when designing post-authorization studies.",
      "inspectorQuestion": "Do you conduct PAES? How do PAES results inform your benefit-risk assessment?",
      "relatedTerms": [
        "pass",
        "real-world-evidence",
        "effectiveness"
      ],
      "tags": [
        "study",
        "efficacy",
        "post-marketing"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "risk-minimization-measures": {
      "id": "risk-minimization-measures",
      "term": "Risk Minimization Measures",
      "acronym": "RMM",
      "definition": "Interventions intended to prevent or reduce the probability of an adverse reaction occurring or its severity if it does occur.",
      "regulatorySource": "EU GVP Module XVI",
      "example": "Risk minimization measures for a teratogenic drug include: contraindication in pregnancy, pregnancy prevention program, contraception requirements, and pregnancy testing protocols.",
      "commonMistakes": "Implementing RMMs without a plan to evaluate their effectiveness.",
      "inspectorQuestion": "How do you assess the effectiveness of your risk minimization measures?",
      "relatedTerms": [
        "rmp",
        "additional-rmm",
        "routine-rmm"
      ],
      "tags": [
        "risk",
        "minimization",
        "intervention"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "routine-rmm": {
      "id": "routine-rmm",
      "term": "Routine Risk Minimization",
      "acronym": null,
      "definition": "Standard risk minimization through product labeling, including SmPC, package leaflet, and appropriate pack size.",
      "regulatorySource": "EU GVP Module XVI",
      "example": "Routine risk minimization includes: contraindications in Section 4.3, warnings in Section 4.4, adverse reactions in Section 4.8, and appropriate dosing instructions.",
      "commonMistakes": "Assuming routine labeling is sufficient for all risks without assessing if additional measures are needed.",
      "inspectorQuestion": "How do you assess whether routine risk minimization is adequate?",
      "relatedTerms": [
        "additional-rmm",
        "labeling",
        "smpc"
      ],
      "tags": [
        "routine",
        "labeling",
        "minimization"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "additional-rmm": {
      "id": "additional-rmm",
      "term": "Additional Risk Minimization Measures",
      "acronym": "aRMM",
      "definition": "Risk minimization interventions beyond routine labeling, such as educational materials, prescriber guides, or controlled access programs.",
      "regulatorySource": "EU GVP Module XVI",
      "example": "Additional RMM for a high-risk biologic includes: prescriber training program, patient alert card, HCP guide with monitoring protocols, and pharmacy-level controls.",
      "commonMistakes": "Creating materials that duplicate labeling rather than providing actionable tools for risk management.",
      "inspectorQuestion": "What additional RMMs do you have in place? How do you distribute and track their use?",
      "relatedTerms": [
        "educational-materials",
        "patient-card",
        "hcp-guide"
      ],
      "tags": [
        "additional",
        "educational",
        "minimization"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "educational-materials": {
      "id": "educational-materials",
      "term": "Educational Materials",
      "acronym": null,
      "definition": "Documents or tools designed to inform healthcare professionals and/or patients about specific risks and how to minimize them.",
      "regulatorySource": "EU GVP Module XVI",
      "example": "Educational materials for an injectable drug include: HCP guide on injection technique and monitoring, patient guide on self-administration, and injection site reaction management.",
      "commonMistakes": "Creating materials that are too lengthy or complex for the target audience to use effectively.",
      "inspectorQuestion": "How do you develop and test educational materials? How do you ensure they reach the target audience?",
      "relatedTerms": [
        "additional-rmm",
        "patient-card",
        "hcp-guide"
      ],
      "tags": [
        "educational",
        "materials",
        "communication"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "patient-alert-card": {
      "id": "patient-alert-card",
      "term": "Patient Alert Card",
      "acronym": null,
      "definition": "A card given to patients containing critical safety information they should share with all healthcare providers involved in their care.",
      "regulatorySource": "EU GVP Module XVI",
      "example": "The patient alert card for an anticoagulant states: 'I am taking [drug name]. This affects blood clotting. Please consider this in emergencies or before any procedures.'",
      "commonMistakes": "Including too much information, reducing the likelihood that patients will carry and use the card.",
      "inspectorQuestion": "How do you ensure patients receive and carry alert cards? How do you measure usage?",
      "relatedTerms": [
        "educational-materials",
        "additional-rmm",
        "patient-safety"
      ],
      "tags": [
        "patient",
        "card",
        "safety"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "controlled-access": {
      "id": "controlled-access",
      "term": "Controlled Access Program",
      "acronym": null,
      "definition": "A distribution system that restricts access to a medicine to ensure it is only prescribed by qualified prescribers and dispensed to appropriate patients.",
      "regulatorySource": "EU GVP Module XVI, FDA REMS",
      "example": "The controlled access program requires: certified prescribers, enrolled pharmacies, patient consent acknowledging risks, and verification of safety requirements before dispensing.",
      "commonMistakes": "Implementing controls that create barriers to legitimate patient access without proportionate safety benefit.",
      "inspectorQuestion": "Describe your controlled access program. How do you balance safety restrictions with patient access?",
      "relatedTerms": [
        "etasu",
        "restricted-distribution",
        "rems"
      ],
      "tags": [
        "access",
        "restriction",
        "program"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "pregnancy-prevention-program": {
      "id": "pregnancy-prevention-program",
      "term": "Pregnancy Prevention Program",
      "acronym": "PPP",
      "definition": "A comprehensive risk minimization program for teratogenic medicines to prevent fetal exposure through pregnancy testing, contraception, and patient counseling.",
      "regulatorySource": "EU GVP Module XVI",
      "example": "The PPP requires: pregnancy test before each prescription, two forms of contraception, monthly prescriptions only, patient acknowledgment forms, and mandatory contraceptive counseling.",
      "commonMistakes": "Not monitoring compliance with PPP requirements or failing to track pregnancy outcomes despite the program.",
      "inspectorQuestion": "How do you monitor PPP compliance? How do you handle pregnancies that occur?",
      "relatedTerms": [
        "teratogenicity",
        "pregnancy-registry",
        "additional-rmm"
      ],
      "tags": [
        "pregnancy",
        "prevention",
        "teratogenic"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "rmm-effectiveness": {
      "id": "rmm-effectiveness",
      "term": "Risk Minimization Effectiveness",
      "acronym": null,
      "definition": "The measurement of whether risk minimization measures achieve their intended goals of reducing risk occurrence or severity.",
      "regulatorySource": "EU GVP Module XVI",
      "example": "Effectiveness evaluation shows: 85% of prescribers report using the HCP guide, pregnancy rate in treated women is 0.1% (target <0.5%), and hepatotoxicity monitoring compliance is 90%.",
      "commonMistakes": "Measuring only distribution of materials rather than behavioral change and actual risk reduction.",
      "inspectorQuestion": "How do you measure RMM effectiveness? What metrics indicate success or need for improvement?",
      "relatedTerms": [
        "additional-rmm",
        "pass",
        "metrics"
      ],
      "tags": [
        "effectiveness",
        "measurement",
        "evaluation"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "black-triangle": {
      "id": "black-triangle",
      "term": "Black Triangle",
      "acronym": "‚ñº",
      "definition": "A symbol used in the EU to identify medicines under additional monitoring, indicating the need for enhanced adverse event reporting.",
      "regulatorySource": "EU Regulation 726/2004",
      "example": "A newly approved medicine displays ‚ñº in its labeling, signaling to healthcare professionals and patients that adverse event reporting is particularly important.",
      "commonMistakes": "Assuming black triangle indicates the medicine is unsafe, rather than simply under enhanced monitoring.",
      "inspectorQuestion": "How do you communicate the meaning of the black triangle to healthcare professionals and patients?",
      "relatedTerms": [
        "additional-monitoring",
        "new-drug",
        "adverse-event-reporting"
      ],
      "tags": [
        "eu",
        "monitoring",
        "symbol"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "medication-guide": {
      "id": "medication-guide",
      "term": "Medication Guide",
      "acronym": "MedGuide",
      "definition": "FDA-required patient labeling that provides information about drug risks to help patients use medicines safely.",
      "regulatorySource": "21 CFR 208",
      "example": "The Medication Guide for an antidepressant includes the boxed warning about suicidality in young adults, symptoms to watch for, and when to contact a healthcare provider.",
      "commonMistakes": "Not ensuring medication guides are distributed with each prescription as required.",
      "inspectorQuestion": "How do you ensure medication guides reach patients? How do you monitor distribution?",
      "relatedTerms": [
        "rems",
        "patient-information",
        "fda"
      ],
      "tags": [
        "fda",
        "patient",
        "labeling"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "psmf": {
      "id": "psmf",
      "term": "Pharmacovigilance System Master File",
      "acronym": "PSMF",
      "definition": "A detailed description of the pharmacovigilance system used by an MAH, maintained at the QPPV location and available for inspection.",
      "regulatorySource": "EU GVP Module II",
      "example": "The PSMF describes: organizational structure, QPPV responsibilities, database details, process flows for case handling, signal management, and contractual arrangements with service providers.",
      "commonMistakes": "Not keeping the PSMF current as processes, personnel, or systems change.",
      "inspectorQuestion": "Show me your PSMF. When was it last updated? How do you ensure it reflects current operations?",
      "relatedTerms": [
        "qppv",
        "pv-system",
        "inspection"
      ],
      "tags": [
        "documentation",
        "system",
        "eu"
      ],
      "categoryId": "risk-management",
      "categoryName": "Risk Management"
    },
    "pv-inspection": {
      "id": "pv-inspection",
      "term": "Pharmacovigilance Inspection",
      "acronym": null,
      "definition": "An official examination by a regulatory authority of a company's pharmacovigilance system, processes, and documentation to verify compliance with regulations.",
      "regulatorySource": "EU GVP Module III, 21 CFR 312/314",
      "example": "EMA conducts a routine pharmacovigilance inspection at the QPPV site, reviewing the PSMF, case processing records, signal management documentation, and PSUR procedures.",
      "commonMistakes": "Treating inspections as adversarial events rather than opportunities to demonstrate a robust PV system.",
      "inspectorQuestion": "Describe your previous inspection history. What findings were identified and how were they resolved?",
      "relatedTerms": [
        "inspection-readiness",
        "finding",
        "capa"
      ],
      "tags": [
        "inspection",
        "regulatory",
        "compliance"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "inspection-readiness": {
      "id": "inspection-readiness",
      "term": "Inspection Readiness",
      "acronym": null,
      "definition": "The state of preparedness to undergo a regulatory inspection at any time, including organized documentation, trained staff, and current processes.",
      "regulatorySource": "EU GVP Module III, Company SOPs",
      "example": "Inspection readiness activities include: PSMF currency verification, documentation organization, mock inspection exercises, and staff training on inspection procedures.",
      "commonMistakes": "Only preparing when an inspection is announced rather than maintaining continuous readiness.",
      "inspectorQuestion": "How do you maintain inspection readiness? When was your last mock inspection?",
      "relatedTerms": [
        "pv-inspection",
        "mock-inspection",
        "psmf"
      ],
      "tags": [
        "preparation",
        "readiness",
        "compliance"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "mock-inspection": {
      "id": "mock-inspection",
      "term": "Mock Inspection",
      "acronym": null,
      "definition": "A simulated regulatory inspection conducted internally or by external consultants to assess readiness and identify areas for improvement.",
      "regulatorySource": "Best Practice",
      "example": "Annual mock inspections simulate real inspection scenarios: document requests, staff interviews, process walkthroughs, and case reviews to identify gaps before real inspections.",
      "commonMistakes": "Conducting superficial mock inspections that don't challenge the organization like a real inspection would.",
      "inspectorQuestion": "What was the scope of your last mock inspection? What findings emerged?",
      "relatedTerms": [
        "inspection-readiness",
        "gap-assessment",
        "audit"
      ],
      "tags": [
        "preparation",
        "simulation",
        "assessment"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "inspection-finding": {
      "id": "inspection-finding",
      "term": "Inspection Finding",
      "acronym": null,
      "definition": "An observation of non-compliance or deficiency identified during a regulatory inspection, categorized by severity (critical, major, minor).",
      "regulatorySource": "EU GVP Module III, EMA Inspection Procedures",
      "example": "A major finding: 'The company failed to submit 5 expedited reports within required timeframes during the inspection period, with delays ranging from 2-10 days.'",
      "commonMistakes": "Disputing findings without valid justification, or providing inadequate response and CAPA.",
      "inspectorQuestion": "If I identify a finding during this inspection, what is your process for responding?",
      "relatedTerms": [
        "critical-finding",
        "capa",
        "inspection-response"
      ],
      "tags": [
        "finding",
        "non-compliance",
        "classification"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "critical-finding": {
      "id": "critical-finding",
      "term": "Critical Finding",
      "acronym": null,
      "definition": "A severe inspection observation indicating that pharmacovigilance processes fundamentally failed to ensure patient safety or regulatory compliance.",
      "regulatorySource": "EU GVP Module III, EMA Classification",
      "example": "Critical finding: 'The company has no functioning signal detection process. Safety signals in published literature were not identified or evaluated for a period of 18 months.'",
      "commonMistakes": "Not recognizing the severity of critical findings or failing to implement immediate corrective measures.",
      "inspectorQuestion": "Have you ever received a critical finding? What would your immediate response be?",
      "relatedTerms": [
        "inspection-finding",
        "major-finding",
        "urgent-action"
      ],
      "tags": [
        "critical",
        "severity",
        "finding"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "major-finding": {
      "id": "major-finding",
      "term": "Major Finding",
      "acronym": null,
      "definition": "An inspection observation indicating significant non-compliance that could potentially affect patient safety or reliability of pharmacovigilance data.",
      "regulatorySource": "EU GVP Module III",
      "example": "Major finding: 'QC processes do not adequately verify case data accuracy. Review of 20 cases found 6 with significant data entry errors affecting seriousness or causality coding.'",
      "commonMistakes": "Providing superficial CAPA that addresses symptoms rather than root causes of major findings.",
      "inspectorQuestion": "How do you differentiate major from minor findings in your response prioritization?",
      "relatedTerms": [
        "inspection-finding",
        "critical-finding",
        "minor-finding"
      ],
      "tags": [
        "major",
        "severity",
        "finding"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "inspection-response": {
      "id": "inspection-response",
      "term": "Inspection Response",
      "acronym": null,
      "definition": "The formal written reply to an inspection report, addressing each finding with root cause analysis, corrective actions, and preventive measures.",
      "regulatorySource": "EU GVP Module III, Regional Requirements",
      "example": "Inspection response due within 30 days addresses each finding with: root cause analysis, immediate corrections taken, long-term preventive actions, implementation timeline, and effectiveness metrics.",
      "commonMistakes": "Providing vague responses without specific timelines, responsible persons, and measurable outcomes.",
      "inspectorQuestion": "Who prepares your inspection responses? How do you ensure timely and adequate submission?",
      "relatedTerms": [
        "inspection-finding",
        "capa",
        "root-cause"
      ],
      "tags": [
        "response",
        "capa",
        "regulatory"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "bimo-inspection": {
      "id": "bimo-inspection",
      "term": "Bioresearch Monitoring Inspection",
      "acronym": "BIMO",
      "definition": "FDA's program for inspecting clinical trials, including sponsor oversight of safety reporting, investigator compliance, and IRB operations.",
      "regulatorySource": "FDA BIMO Program",
      "example": "BIMO inspection of the sponsor examines: SAE reporting procedures, safety monitoring, protocol compliance, and oversight of clinical sites for a Phase III trial.",
      "commonMistakes": "Not maintaining adequate documentation of sponsor oversight activities at clinical sites.",
      "inspectorQuestion": "Describe your sponsor oversight program. How do you monitor site compliance with safety reporting?",
      "relatedTerms": [
        "clinical-trial",
        "fda",
        "sponsor-oversight"
      ],
      "tags": [
        "fda",
        "clinical-trial",
        "inspection"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "gvp-compliance": {
      "id": "gvp-compliance",
      "term": "GVP Compliance",
      "acronym": null,
      "definition": "Adherence to Good Pharmacovigilance Practice as defined in EU guidance modules covering all aspects of pharmacovigilance operations.",
      "regulatorySource": "EU GVP Modules I-XVI",
      "example": "GVP compliance requires: qualified personnel, documented procedures, validated systems, timely reporting, signal management, RMP maintenance, and auditable records.",
      "commonMistakes": "Treating GVP as a checklist rather than a comprehensive quality framework.",
      "inspectorQuestion": "How do you assess and ensure ongoing GVP compliance across your organization?",
      "relatedTerms": [
        "eu",
        "quality-system",
        "regulatory-compliance"
      ],
      "tags": [
        "eu",
        "gvp",
        "compliance"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "internal-audit": {
      "id": "internal-audit",
      "term": "Internal Audit",
      "acronym": null,
      "definition": "A systematic, independent examination of pharmacovigilance activities conducted by the company's quality function to ensure compliance and identify improvement opportunities.",
      "regulatorySource": "ICH Q10, EU GVP Module I",
      "example": "Annual internal audit of expedited reporting examines: timeliness metrics, case selection, data quality, and regulatory compliance across a sample of cases.",
      "commonMistakes": "Auditing to show compliance rather than genuinely assessing process effectiveness and identifying risks.",
      "inspectorQuestion": "Show me your internal audit schedule. How do you select audit topics and scope?",
      "relatedTerms": [
        "quality-assurance",
        "audit-finding",
        "self-assessment"
      ],
      "tags": [
        "audit",
        "internal",
        "quality"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "audit-trail-review": {
      "id": "audit-trail-review",
      "term": "Audit Trail Review",
      "acronym": null,
      "definition": "Examination of the electronic record of changes to safety database entries to verify data integrity and identify unauthorized modifications.",
      "regulatorySource": "21 CFR Part 11, EU GVP",
      "example": "Audit trail review reveals: all changes are attributable to specific users, timestamps are accurate, original values are preserved, and change reasons are documented.",
      "commonMistakes": "Only reviewing audit trails when problems are suspected rather than routinely as part of quality monitoring.",
      "inspectorQuestion": "How frequently do you review audit trails? What would trigger an intensive review?",
      "relatedTerms": [
        "audit-trail",
        "data-integrity",
        "system-validation"
      ],
      "tags": [
        "electronic",
        "review",
        "integrity"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "vendor-audit": {
      "id": "vendor-audit",
      "term": "Vendor Audit",
      "acronym": null,
      "definition": "An assessment of third-party service providers performing pharmacovigilance activities to verify capability, compliance, and quality.",
      "regulatorySource": "EU GVP Module I, ICH Q10",
      "example": "Pre-contract vendor audit of a CRO examines: PV qualifications, training records, system validation, SOPs, capacity, and previous inspection history.",
      "commonMistakes": "Conducting superficial vendor audits that don't adequately assess PV-specific competencies.",
      "inspectorQuestion": "How do you qualify and audit PV service providers? What criteria must they meet?",
      "relatedTerms": [
        "outsourcing",
        "qualification",
        "oversight"
      ],
      "tags": [
        "vendor",
        "audit",
        "oversight"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "for-cause-inspection": {
      "id": "for-cause-inspection",
      "term": "For-Cause Inspection",
      "acronym": null,
      "definition": "A regulatory inspection triggered by specific concerns, such as safety issues, compliance complaints, or signals of potential violations.",
      "regulatorySource": "EU GVP Module III, FDA Compliance",
      "example": "A for-cause inspection is initiated after multiple late expedited reports are detected in regulatory databases, suggesting systemic compliance issues.",
      "commonMistakes": "Not treating for-cause inspections with appropriate urgency or failing to understand the triggering concern.",
      "inspectorQuestion": "What circumstances might trigger a for-cause inspection of your operations?",
      "relatedTerms": [
        "pv-inspection",
        "compliance-concern",
        "regulatory-action"
      ],
      "tags": [
        "inspection",
        "triggered",
        "concern"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "document-request": {
      "id": "document-request",
      "term": "Document Request",
      "acronym": null,
      "definition": "A formal request from inspectors for specific documents, records, or data during a pharmacovigilance inspection.",
      "regulatorySource": "Inspection Procedures",
      "example": "Inspector requests: 'Please provide 10 recent expedited case files with source documents, the signal detection procedure, and QPPV job description within 2 hours.'",
      "commonMistakes": "Not having an organized document management system enabling rapid retrieval during inspections.",
      "inspectorQuestion": "How quickly can you retrieve requested documents? Show me your document management system.",
      "relatedTerms": [
        "inspection-readiness",
        "document-control",
        "retrieval"
      ],
      "tags": [
        "inspection",
        "documents",
        "retrieval"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "staff-interview": {
      "id": "staff-interview",
      "term": "Staff Interview",
      "acronym": null,
      "definition": "Conversations between inspectors and company personnel to verify understanding of procedures, roles, and responsibilities.",
      "regulatorySource": "Inspection Procedures",
      "example": "Inspector interviews a case processor: 'Walk me through how you would process this case from receipt to submission. What would you do if you identified a potential signal?'",
      "commonMistakes": "Not preparing staff for interviews, leading to nervous or inaccurate responses.",
      "inspectorQuestion": "How do you prepare staff for potential inspection interviews?",
      "relatedTerms": [
        "inspection-readiness",
        "training",
        "competency"
      ],
      "tags": [
        "inspection",
        "interview",
        "personnel"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "inspection-closeout": {
      "id": "inspection-closeout",
      "term": "Inspection Close-out",
      "acronym": null,
      "definition": "The final meeting at the end of an inspection where preliminary findings are discussed and next steps are outlined.",
      "regulatorySource": "Inspection Procedures",
      "example": "At close-out, the inspector summarizes: 'We identified 2 major and 3 minor observations. The formal report will be issued within 30 days. You'll have 30 days to respond.'",
      "commonMistakes": "Not taking detailed notes during close-out, missing important context for response preparation.",
      "inspectorQuestion": "Who attends your inspection close-out meetings? How do you document and act on preliminary findings?",
      "relatedTerms": [
        "pv-inspection",
        "inspection-finding",
        "inspection-response"
      ],
      "tags": [
        "inspection",
        "meeting",
        "findings"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "regulatory-action": {
      "id": "regulatory-action",
      "term": "Regulatory Action",
      "acronym": null,
      "definition": "Measures taken by regulatory authorities in response to compliance issues, ranging from warning letters to product withdrawal.",
      "regulatorySource": "Regional Regulations",
      "example": "Following critical inspection findings, regulatory actions could include: warning letter, consent decree, import alert, marketing suspension, or license revocation.",
      "commonMistakes": "Underestimating the potential consequences of pharmacovigilance non-compliance.",
      "inspectorQuestion": "What regulatory actions are you aware of in your therapeutic area? How do you prevent similar issues?",
      "relatedTerms": [
        "warning-letter",
        "compliance",
        "enforcement"
      ],
      "tags": [
        "regulatory",
        "enforcement",
        "consequence"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "warning-letter": {
      "id": "warning-letter",
      "term": "Warning Letter",
      "acronym": null,
      "definition": "An official FDA communication citing significant regulatory violations that must be addressed to avoid further enforcement action.",
      "regulatorySource": "FDA Enforcement",
      "example": "FDA warning letter cites: 'Failure to submit 15-day reports for serious, unexpected adverse reactions as required by 21 CFR 314.80(c)(1)(i).'",
      "commonMistakes": "Not treating warning letters with appropriate urgency or providing inadequate response.",
      "inspectorQuestion": "How would your organization respond to a warning letter? Who would be involved?",
      "relatedTerms": [
        "fda",
        "regulatory-action",
        "enforcement"
      ],
      "tags": [
        "fda",
        "enforcement",
        "communication"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "483-observation": {
      "id": "483-observation",
      "term": "FDA Form 483",
      "acronym": "483",
      "definition": "The form FDA uses to document inspectional observations of conditions that may constitute violations of regulations.",
      "regulatorySource": "FDA Compliance",
      "example": "Form 483 observation: 'Written procedures for handling adverse drug experiences are not followed. Specifically, 12 of 50 reviewed expedited reports were submitted late.'",
      "commonMistakes": "Not providing timely and comprehensive response to 483 observations.",
      "inspectorQuestion": "Describe your process for responding to FDA Form 483 observations.",
      "relatedTerms": [
        "fda",
        "inspection-finding",
        "inspection-response"
      ],
      "tags": [
        "fda",
        "observation",
        "form"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    },
    "continuous-improvement": {
      "id": "continuous-improvement",
      "term": "Continuous Improvement",
      "acronym": "CI",
      "definition": "The ongoing effort to enhance pharmacovigilance processes, systems, and outcomes through systematic evaluation and implementation of improvements.",
      "regulatorySource": "ICH Q10, Quality Management",
      "example": "Continuous improvement activities include: trend analysis of QC metrics, process efficiency reviews, technology upgrades, and implementation of regulatory guidance updates.",
      "commonMistakes": "Treating improvement as a one-time project rather than an ongoing organizational commitment.",
      "inspectorQuestion": "Give examples of recent process improvements in your PV operations. How do you identify improvement opportunities?",
      "relatedTerms": [
        "quality-assurance",
        "capa",
        "metrics"
      ],
      "tags": [
        "quality",
        "improvement",
        "ongoing"
      ],
      "categoryId": "audits-inspections",
      "categoryName": "Audits & Inspections"
    }
  },
  "metadata": {
    "version": "1.0.0",
    "buildDate": "2026-02-07T18:01:26.424Z",
    "totalTerms": 200
  }
};
const SCENARIOS_DATA = {
  "metadata": {
    "version": "1.0.0",
    "totalScenarios": 15,
    "categories": [
      "reporting",
      "inspection",
      "case-intake",
      "case-assessment"
    ]
  },
  "scenarios": [
    {
      "id": "intake-001",
      "title": "The Monday Morning Voicemail",
      "category": "case-intake",
      "categoryName": "Case Intake",
      "difficulty": "beginner",
      "icon": "üìû",
      "estimatedTime": "5 min",
      "description": "Practice identifying valid cases from consumer phone reports",
      "learningObjectives": [
        "Identify the four minimum criteria for a valid case",
        "Recognize valid cases from consumer sources",
        "Determine Day 0 and reporting requirements"
      ],
      "briefing": {
        "role": "Drug Safety Associate",
        "context": "You've just arrived at your desk on Monday morning. The voicemail light is blinking. You press play and hear a message from a concerned family member.",
        "task": "Determine if this voicemail contains a valid adverse event case and what actions are required."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "The Voicemail",
          "contentType": "voicemail",
          "content": "Hi, this is Margaret Chen calling about my father. He's 78 years old and started taking Cardizol about two weeks ago for his blood pressure. Yesterday he fainted while getting out of bed and hit his head on the nightstand. We took him to the emergency room and the doctor there said it might be related to his new blood pressure medicine. He's okay now but I'm worried. Can someone please call me back? My number is 555-867-5309. Thank you.",
          "metadata": {
            "received": "Monday 8:47 AM",
            "duration": "45 seconds",
            "callerID": "555-867-5309"
          },
          "question": "Does this voicemail contain a valid adverse event case?",
          "options": [
            {
              "id": "A",
              "text": "Yes - all four minimum criteria are met",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "No - the patient is not identifiable (no name given for father)",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "No - the reporter is not a healthcare professional",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "No - we need medical records to confirm the event",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This voicemail contains all four minimum elements required for a valid case:",
              "points": [
                {
                  "label": "Identifiable Reporter",
                  "detail": "Margaret Chen with callback number 555-867-5309",
                  "status": "met"
                },
                {
                  "label": "Identifiable Patient",
                  "detail": "78-year-old male (father) - name is NOT required",
                  "status": "met"
                },
                {
                  "label": "Suspect Product",
                  "detail": "Cardizol (blood pressure medication)",
                  "status": "met"
                },
                {
                  "label": "Adverse Event",
                  "detail": "Syncope (fainting) with fall and head injury",
                  "status": "met"
                }
              ],
              "inspectorTip": "Inspectors frequently test whether staff understand that patient NAME is not required. Age, gender, or initials alone make a patient identifiable."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "The patient IS identifiable. Remember, a patient can be identified by ANY of these qualifiers: name, initials, date of birth, age, gender, or patient ID number. In this case, '78-year-old father' (age + gender + relationship) is sufficient."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "The reporter does NOT need to be a healthcare professional for a case to be valid. Consumers, patients, family members, lawyers, and others can all be valid reporters. The key is that they must be IDENTIFIABLE, not medically qualified."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Medical confirmation is NOT required for case validity. A valid case requires only the four minimum elements. While medical records can enhance a case, they are not required. Process this as a valid case and seek medical confirmation as follow-up."
            }
          },
          "hints": [
            "Remember the four minimum criteria: identifiable reporter, identifiable patient, suspect product, adverse event",
            "Consider: Can you contact the reporter? Can you distinguish this patient from others?"
          ],
          "relatedTerms": [
            "valid-case",
            "minimum-information",
            "identifiable-patient",
            "identifiable-reporter",
            "consumer-report"
          ]
        },
        {
          "id": "step-2",
          "title": "Seriousness Assessment",
          "contentType": "info",
          "content": "Good work! You've correctly identified this as a valid case. Now let's assess seriousness. The ER physician mentioned the syncope might be related to the medication. The patient was taken to the emergency room and treated there.",
          "question": "Based on the information provided, is this case SERIOUS?",
          "options": [
            {
              "id": "A",
              "text": "Yes - the patient was hospitalized (ER visit with treatment)",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "Yes - syncope is always a serious event",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "No - the patient recovered and is okay now",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Cannot determine - need more information about the ER visit",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This case meets the HOSPITALIZATION criterion for seriousness.",
              "points": [
                {
                  "label": "Key Point",
                  "detail": "ER visit with treatment/admission qualifies as hospitalization",
                  "status": "info"
                },
                {
                  "label": "Remember",
                  "detail": "Seriousness is regulatory classification, different from clinical severity",
                  "status": "info"
                }
              ],
              "inspectorTip": "Be careful to distinguish ER visits (observation only, sent home) from actual admissions. When in doubt, follow up to clarify admission status."
            },
            "B": {
              "title": "Partially correct, but wrong reasoning",
              "explanation": "While this IS serious, syncope is NOT automatically serious. The seriousness determination must be based on the regulatory criteria (death, life-threatening, hospitalization, disability, congenital anomaly, important medical event). Here, it's the HOSPITALIZATION that makes it serious."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Recovery does not change seriousness classification. If a case meets ANY seriousness criterion at the time of the event, it remains classified as serious regardless of outcome. 'Recovered' is the OUTCOME, not the seriousness."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "We have enough information to determine seriousness. The ER visit/hospitalization mentioned in the voicemail is sufficient to classify this as serious. While we may want additional details for a complete report, we can make the seriousness determination now."
            }
          },
          "hints": [
            "Review the six seriousness criteria: death, life-threatening, hospitalization, disability, congenital anomaly, important medical event",
            "Consider what happened to the patient that meets any of these criteria"
          ],
          "relatedTerms": [
            "serious-ae",
            "seriousness-criteria",
            "hospitalization",
            "severity"
          ]
        },
        {
          "id": "step-3",
          "title": "Reporting Timeline",
          "contentType": "info",
          "content": "Excellent! You've determined this is a valid, serious case. The voicemail was left at 8:47 AM today (Monday). You're listening to it now at 9:15 AM. Cardizol is your company's product, and syncope is NOT listed in the product labeling as a known adverse reaction.",
          "question": "What is Day 0 for this case, and what type of report is required?",
          "options": [
            {
              "id": "A",
              "text": "Day 0 is today (Monday). 15-day expedited report required.",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "Day 0 is yesterday (Sunday) when the event occurred. 15-day report required.",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Day 0 is today (Monday). 7-day expedited report required.",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Day 0 is today (Monday). Periodic reporting only - not expedited.",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Day 0 is when the COMPANY first becomes aware, not when the event occurred.",
              "points": [
                {
                  "label": "Day 0",
                  "detail": "Monday (today) - when voicemail was received",
                  "status": "met"
                },
                {
                  "label": "Seriousness",
                  "detail": "Serious (hospitalization criterion)",
                  "status": "met"
                },
                {
                  "label": "Expectedness",
                  "detail": "Unexpected (syncope not in labeling)",
                  "status": "met"
                },
                {
                  "label": "Report Type",
                  "detail": "15-day expedited (serious + unexpected + non-fatal)",
                  "status": "info"
                }
              ],
              "inspectorTip": "Inspectors often ask about Day 0 determination. Be prepared to explain: 'Day 0 is the date of first company awareness, which was [date] when [source of information].'"
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Day 0 is NOT when the event occurred. Day 0 is when the COMPANY first became aware of the information. The event occurred Sunday, but the company learned about it Monday via voicemail. Day 0 = Monday."
            },
            "C": {
              "title": "Close, but not quite",
              "explanation": "7-day reporting is reserved for FATAL or LIFE-THREATENING cases only. This case is serious (hospitalization) and unexpected, but it is not fatal or life-threatening. Therefore, it requires a 15-day expedited report."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "This case requires EXPEDITED reporting. Periodic reporting applies to expected serious cases or non-serious cases. This case is UNEXPECTED (syncope not in labeling) AND SERIOUS (hospitalization). Serious + Unexpected = Expedited reporting required."
            }
          },
          "hints": [
            "Day 0 relates to company awareness, not event occurrence",
            "Consider: Is this case serious? Is it expected or unexpected? What report timeline applies?"
          ],
          "relatedTerms": [
            "day-zero",
            "clock-start",
            "expedited-reporting",
            "fifteen-day-report",
            "unexpected-ae"
          ]
        }
      ],
      "debrief": {
        "summary": "You successfully processed a consumer-reported adverse event from voicemail, correctly identifying it as a valid, serious, unexpected case requiring 15-day expedited reporting.",
        "keyTakeaways": [
          "Patient NAME is not required - age, gender, or other identifiers are sufficient",
          "Consumer reports are fully valid if the four minimum criteria are met",
          "Day 0 is company awareness date, not event date",
          "Serious + Unexpected = Expedited reporting (15-day unless fatal/life-threatening)"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "intake-003",
      "title": "The Literature Alert",
      "category": "case-intake",
      "categoryName": "Case Intake",
      "difficulty": "intermediate",
      "icon": "üìö",
      "estimatedTime": "6 min",
      "description": "Identify reportable cases from published medical literature",
      "learningObjectives": [
        "Recognize adverse events in published case reports",
        "Understand literature monitoring obligations",
        "Determine when literature constitutes a valid case"
      ],
      "briefing": {
        "role": "Drug Safety Scientist",
        "context": "Your weekly literature monitoring alert has arrived. You need to review abstracts flagged by the search algorithm for potential adverse event cases involving your company's products.",
        "task": "Evaluate each literature hit and determine appropriate action."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "The Case Report",
          "contentType": "case",
          "content": "Title: 'Acute Hepatotoxicity Associated with Viralex: A Case Report'\n\nAbstract: A 54-year-old female with chronic hepatitis C was started on Viralex 400mg daily. After 6 weeks of treatment, she presented with jaundice, fatigue, and elevated transaminases (ALT 1,250 U/L, AST 980 U/L). Viralex was discontinued and she was treated with supportive care. Liver function normalized over 8 weeks. The authors conclude that Viralex may cause idiosyncratic hepatotoxicity and recommend liver function monitoring.\n\nViralex is your company's product.",
          "metadata": {
            "journal": "Journal of Clinical Hepatology",
            "published": "March 2024"
          },
          "question": "Does this literature article represent a valid ICSR that must be captured?",
          "options": [
            {
              "id": "A",
              "text": "Yes - this is a valid case with all minimum criteria met",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "No - literature articles are not considered spontaneous reports",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "No - the patient has underlying liver disease (hepatitis C), so it's confounded",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Yes, but only if we can contact the author for more details first",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Published literature describing adverse events with identifiable patients must be captured as ICSRs.",
              "points": [
                {
                  "label": "Identifiable Reporter",
                  "detail": "The article authors serve as reporters",
                  "status": "met"
                },
                {
                  "label": "Identifiable Patient",
                  "detail": "54-year-old female - age and gender provided",
                  "status": "met"
                },
                {
                  "label": "Suspect Product",
                  "detail": "Viralex 400mg (your company's product)",
                  "status": "met"
                },
                {
                  "label": "Adverse Event",
                  "detail": "Hepatotoxicity with specific clinical details",
                  "status": "met"
                }
              ],
              "inspectorTip": "Literature monitoring is a regulatory requirement. MAHs must have systematic processes to identify and capture AE cases from worldwide medical literature."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Literature reports ARE a source of valid ICSRs. ICH E2D specifically includes published literature as a reportable source. MAHs are required to monitor scientific literature for adverse event reports."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Confounding factors don't make a case invalid - they're part of the assessment. The case must still be captured; the underlying hepatitis C would be documented as relevant medical history and considered in causality assessment."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "You don't need author contact before capturing the case. The published information is sufficient for a valid ICSR. Author follow-up is recommended for additional details but isn't required for initial capture."
            }
          },
          "hints": [
            "Think about what sources are considered reportable under ICH E2D",
            "Apply the four minimum criteria to the information in the abstract"
          ],
          "relatedTerms": [
            "literature-report",
            "valid-case",
            "minimum-information",
            "literature-screening"
          ]
        },
        {
          "id": "step-2",
          "title": "Assessing the Case",
          "contentType": "info",
          "content": "You've correctly identified this as a valid case. Now assess it further. The patient was hospitalized (implied by 'treated with supportive care' for acute hepatotoxicity). Hepatotoxicity IS listed in Section 4.8 of Viralex's SmPC as an uncommon adverse reaction.",
          "question": "What is the reporting requirement for this case?",
          "options": [
            {
              "id": "A",
              "text": "15-day expedited report - serious and unexpected",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "15-day expedited report - serious, unexpected severity (Grade 3-4)",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Periodic reporting only - serious but expected (listed)",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "No reporting required - literature cases are informational only",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "While 'hepatotoxicity' is listed, the SEVERITY described exceeds what's in the label.",
              "points": [
                {
                  "label": "Seriousness",
                  "detail": "Serious - hospitalization required",
                  "status": "met"
                },
                {
                  "label": "Expectedness",
                  "detail": "The TERM is listed, but this severity (ALT >30x ULN) likely exceeds label description",
                  "status": "info"
                },
                {
                  "label": "Key Principle",
                  "detail": "Expectedness considers nature AND severity - severe manifestations of listed events can be unexpected",
                  "status": "info"
                }
              ],
              "inspectorTip": "Don't just match terms literally. If the label says 'transaminase elevation' but this case shows fulminant hepatic failure, the severity makes it unexpected even though the term matches."
            },
            "A": {
              "title": "Close but incomplete reasoning",
              "explanation": "The conclusion is correct (15-day expedited), but the reasoning matters. 'Hepatotoxicity' IS listed in the label. What makes this unexpected is the SEVERITY - the extreme transaminase elevation and clinical presentation exceed typical label descriptions."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Simply matching the term 'hepatotoxicity' isn't sufficient. Expectedness must consider severity and clinical presentation. This severe, acute presentation with ALT >30x ULN likely exceeds what's described in the SmPC."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Literature cases have the same reporting requirements as any other valid ICSR. The source doesn't change the regulatory obligations."
            }
          },
          "hints": [
            "Expectedness isn't just about whether the term appears in the label",
            "Consider whether the severity/presentation matches what's described in the SmPC"
          ],
          "relatedTerms": [
            "expectedness",
            "unexpected-ae",
            "expedited-reporting",
            "seriousness-criteria"
          ]
        },
        {
          "id": "step-3",
          "title": "Day Zero Determination",
          "contentType": "info",
          "content": "The article was published in the March 2024 issue. Your literature monitoring vendor delivered the alert to your inbox on March 15th (Friday). You're reviewing it today, March 18th (Monday).",
          "question": "What is Day 0 for this case?",
          "options": [
            {
              "id": "A",
              "text": "March 2024 - when the article was published",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "March 15th - when the alert was delivered to company email",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "March 18th - when you actually reviewed and identified the case",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "The date when the patient's event actually occurred (6 weeks into treatment)",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Day 0 is when the information reached the company, regardless of when it was reviewed.",
              "points": [
                {
                  "label": "Key Principle",
                  "detail": "Company awareness = when information is received, not when it's reviewed",
                  "status": "info"
                },
                {
                  "label": "Implication",
                  "detail": "You should have reviewed Friday's alerts before Monday to meet timelines",
                  "status": "warning"
                },
                {
                  "label": "Best Practice",
                  "detail": "Literature alerts should be reviewed within 24 hours of receipt",
                  "status": "info"
                }
              ],
              "inspectorTip": "Inspectors will ask about your literature monitoring frequency and review timelines. Delays between receipt and review can cause late submissions."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "Publication date isn't the awareness date. Your company didn't have access to the article when it was published - you became aware when your monitoring system delivered it."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "The information reached your company on March 15th. The fact that you didn't review it until the 18th doesn't change when awareness occurred. This is a common source of late submissions."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Day 0 is never the date of the actual adverse event. It's always the date of company awareness of the reportable information."
            }
          },
          "hints": [
            "When did the information first reach any company system or employee?",
            "Does it matter when you personally opened and read the email?"
          ],
          "relatedTerms": [
            "day-zero",
            "awareness-date",
            "clock-start",
            "literature-report"
          ]
        }
      ],
      "debrief": {
        "summary": "You successfully identified and assessed a literature-sourced adverse event case, understanding that published case reports are valid ICSR sources with standard reporting requirements.",
        "keyTakeaways": [
          "Literature case reports are valid ICSR sources requiring capture",
          "Article authors serve as identifiable reporters",
          "Expectedness considers BOTH term AND severity - severe presentations can be unexpected",
          "Day 0 is when the literature alert reached your company, not publication date or review date",
          "Timely literature review is critical to meet reporting deadlines"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "intake-004",
      "title": "The Medical Information Call",
      "category": "case-intake",
      "categoryName": "Case Intake",
      "difficulty": "beginner",
      "icon": "‚òéÔ∏è",
      "estimatedTime": "5 min",
      "description": "Identify embedded adverse events in product inquiries",
      "learningObjectives": [
        "Recognize adverse events embedded in general inquiries",
        "Understand Medical Information's role in AE identification",
        "Apply minimum criteria to conversational information"
      ],
      "briefing": {
        "role": "Medical Information Specialist",
        "context": "You work in the Medical Information department. A physician has called with what seems like a routine product question.",
        "task": "Determine if this call contains reportable adverse event information."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "The Phone Call",
          "contentType": "interview",
          "content": "Physician: 'Hi, I'm Dr. Patterson from Memorial Hospital. I have a quick question about Cardizem dosing. One of my patients - she's 67 - has been on your drug for about 3 months now and she's been complaining of persistent dizziness. I'm wondering if I should adjust the dose or if this is something that usually goes away on its own. What do you typically recommend?'",
          "metadata": {
            "caller": "Dr. Patterson",
            "affiliation": "Memorial Hospital",
            "callType": "Product Inquiry"
          },
          "question": "Does this call contain a reportable adverse event?",
          "options": [
            {
              "id": "A",
              "text": "No - this is just a dosing question, not an AE report",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "No - dizziness is too common and non-specific to report",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Yes - this contains an embedded AE requiring capture",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Maybe - need to ask the physician if they want to report it",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This inquiry contains an embedded adverse event that must be captured, regardless of the caller's intent.",
              "points": [
                {
                  "label": "Identifiable Reporter",
                  "detail": "Dr. Patterson, Memorial Hospital",
                  "status": "met"
                },
                {
                  "label": "Identifiable Patient",
                  "detail": "67-year-old female",
                  "status": "met"
                },
                {
                  "label": "Suspect Product",
                  "detail": "Cardizem (your company's product)",
                  "status": "met"
                },
                {
                  "label": "Adverse Event",
                  "detail": "Persistent dizziness",
                  "status": "met"
                }
              ],
              "inspectorTip": "Medical Information staff must be trained to recognize embedded AEs. The physician's intent (asking about dosing) doesn't change the fact that they described an adverse event."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "The PRIMARY purpose of the call was a dosing question, but the physician described an adverse event (persistent dizziness) in the process. Both the question AND the AE must be addressed."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "The nature or commonality of the event doesn't determine whether it should be captured. ALL valid adverse events must be recorded, whether common or rare, serious or non-serious."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "You don't need the reporter's permission or intent to report. If minimum criteria are met, the case must be captured. The physician doesn't get to decide whether it's a reportable event."
            }
          },
          "hints": [
            "Focus on what information was communicated, not the caller's intent",
            "Apply the four minimum criteria to what you heard"
          ],
          "relatedTerms": [
            "medical-information-request",
            "valid-case",
            "minimum-information",
            "spontaneous-report"
          ]
        },
        {
          "id": "step-2",
          "title": "Gathering Information",
          "contentType": "info",
          "content": "You've correctly identified this as a reportable AE. Now you need to gather additional information while the physician is still on the line. You can answer their dosing question AND collect AE details.",
          "question": "Which of these is the MOST important additional information to request?",
          "options": [
            {
              "id": "A",
              "text": "The patient's full name and date of birth",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Permission to report this to regulatory authorities",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "When the dizziness started and any actions taken",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "The physician's medical license number",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Onset timing and actions taken are clinically valuable and help assess the case.",
              "points": [
                {
                  "label": "Onset Date",
                  "detail": "Helps establish time-to-onset and temporal relationship",
                  "status": "info"
                },
                {
                  "label": "Actions Taken",
                  "detail": "Dose changes, discontinuation, or treatments provide important context",
                  "status": "info"
                },
                {
                  "label": "What Else To Ask",
                  "detail": "Outcome, concomitant medications, medical history if time permits",
                  "status": "info"
                }
              ],
              "inspectorTip": "You already have the four minimum criteria. Additional questions should focus on clinical relevance and assessment value, not administrative details."
            },
            "A": {
              "title": "Not the priority",
              "explanation": "Patient name is NOT required for a valid case - you already have age and gender. While additional identifiers can be helpful, clinical details about the event itself are more important for safety assessment."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "You don't need permission to report adverse events. Regulatory reporting is a legal obligation. Asking for permission might suggest the reporter can opt out, which isn't accurate."
            },
            "D": {
              "title": "Not the priority",
              "explanation": "Reporter license numbers aren't required and aren't particularly useful for case assessment. Focus on information that helps understand the adverse event."
            }
          },
          "hints": [
            "You already have the minimum criteria - what CLINICAL information would enhance the case?",
            "Think about what would help with causality assessment"
          ],
          "relatedTerms": [
            "time-to-onset",
            "dechallenge",
            "follow-up-report",
            "case-processing"
          ]
        }
      ],
      "debrief": {
        "summary": "You successfully identified an embedded adverse event in a medical information call and understood how to prioritize information gathering.",
        "keyTakeaways": [
          "AEs can be embedded in routine product inquiries - always listen carefully",
          "Reporter intent doesn't determine reportability - if minimum criteria are met, capture the case",
          "Patient name is NOT required - age and gender are sufficient identifiers",
          "Prioritize clinically relevant information (onset, actions, outcome) over administrative details",
          "Medical Information staff are often the first point of contact for spontaneous reports"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "assessment-002",
      "title": "Causality Challenge",
      "category": "case-assessment",
      "categoryName": "Case Assessment",
      "difficulty": "advanced",
      "icon": "üî¨",
      "estimatedTime": "8 min",
      "description": "Apply causality assessment principles to complex cases",
      "learningObjectives": [
        "Apply causality assessment criteria systematically",
        "Understand dechallenge, rechallenge, and temporal relationships",
        "Distinguish between different causality categories"
      ],
      "briefing": {
        "role": "Drug Safety Physician",
        "context": "You're reviewing cases that require medical assessment of causality. Each case has different evidence patterns that affect the causality determination.",
        "task": "Assess the causality for each case using standard criteria."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Case 1: The Clear Picture",
          "contentType": "case",
          "content": "A 45-year-old male started Dermaclear cream for psoriasis. Within 3 days, he developed a localized rash at the application site. He stopped using the cream and the rash resolved in 5 days. Two weeks later, he tried the cream again (didn't realize it was the cause), and the rash recurred within 2 days in the same location. He stopped again and it resolved.",
          "highlight": "Positive dechallenge AND positive rechallenge",
          "question": "What is the most appropriate causality assessment?",
          "options": [
            {
              "id": "A",
              "text": "Certain/Definite - positive rechallenge confirms causation",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "Probable - strong evidence but rechallenge could be coincidence",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Possible - temporal relationship only",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Unlikely - localized reactions are usually not drug-related",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Positive rechallenge is the strongest evidence for causality and typically supports a 'Certain' or 'Definite' assessment.",
              "points": [
                {
                  "label": "Temporal Relationship",
                  "detail": "Appropriate timing (3 days, then 2 days on rechallenge)",
                  "status": "met"
                },
                {
                  "label": "Dechallenge",
                  "detail": "Positive - rash resolved when cream stopped",
                  "status": "met"
                },
                {
                  "label": "Rechallenge",
                  "detail": "Positive - rash recurred when cream restarted",
                  "status": "met"
                },
                {
                  "label": "Biological Plausibility",
                  "detail": "Topical product causing localized skin reaction is plausible",
                  "status": "met"
                }
              ],
              "inspectorTip": "Positive rechallenge is relatively rare because it's usually unethical to intentionally re-expose patients. When it occurs inadvertently (as here), it provides compelling evidence."
            },
            "B": {
              "title": "Too conservative",
              "explanation": "With positive rechallenge, 'Probable' is too cautious. Rechallenge reproducing the same reaction at the same site is strong confirmation of causality."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "'Possible' would be appropriate with only temporal relationship. This case has much more: positive dechallenge AND positive rechallenge."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "The rechallenge clearly demonstrates causality. Localized reactions to topical products are actually a well-recognized phenomenon."
            }
          },
          "hints": [
            "Rechallenge is considered the strongest evidence for causality",
            "What happened when the patient stopped AND restarted the product?"
          ],
          "relatedTerms": [
            "rechallenge",
            "dechallenge",
            "causality-assessment",
            "who-umc"
          ]
        },
        {
          "id": "step-2",
          "title": "Case 2: The Confounded Case",
          "contentType": "case",
          "content": "A 72-year-old male with diabetes, hypertension, and coronary artery disease started Lipitor 40mg for hyperlipidemia. Six months later, he was hospitalized for acute myocardial infarction (MI). He was on multiple medications including metformin, lisinopril, and aspirin. The patient had a 40-year smoking history.",
          "highlight": "Multiple confounding factors, pre-existing cardiovascular disease",
          "question": "What is the most appropriate causality assessment for Lipitor ‚Üí MI?",
          "options": [
            {
              "id": "A",
              "text": "Certain - he was taking Lipitor when the MI occurred",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Probable - 6 months is an appropriate timeframe",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Unlikely - pre-existing CAD and risk factors more likely explain the MI",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Unassessable - too many confounding factors",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "The pre-existing coronary artery disease and multiple risk factors provide a more plausible explanation than the statin.",
              "points": [
                {
                  "label": "Alternative Etiology",
                  "detail": "Known CAD, diabetes, hypertension, 40-year smoking history",
                  "status": "info"
                },
                {
                  "label": "Biological Plausibility",
                  "detail": "Statins REDUCE MI risk - causation is implausible",
                  "status": "info"
                },
                {
                  "label": "Temporal Relationship",
                  "detail": "6 months is very long; MI is an acute event",
                  "status": "info"
                },
                {
                  "label": "Assessment",
                  "detail": "Alternative explanation is more compelling than drug causation",
                  "status": "met"
                }
              ],
              "inspectorTip": "'Unlikely' doesn't mean the case isn't captured - it's still a valid ICSR. Causality assessment documents your medical judgment about the relationship."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "'Certain' requires positive rechallenge or definitive evidence. Temporal association alone, especially with confounding factors and implausible mechanism, is insufficient."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "'Probable' requires reasonable temporal relationship, no likely alternative cause, and plausible mechanism. Here, the patient's underlying disease is a much more likely cause."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "'Unassessable' is for cases where data is insufficient to make any judgment. Here, we have enough information - it points toward alternative etiology."
            }
          },
          "hints": [
            "Consider the patient's underlying conditions and risk factors",
            "Think about whether the drug mechanism makes the event more or less likely"
          ],
          "relatedTerms": [
            "alternative-etiology",
            "causality-assessment",
            "biological-plausibility",
            "confounding"
          ]
        },
        {
          "id": "step-3",
          "title": "Case 3: The Timing Question",
          "contentType": "case",
          "content": "A 38-year-old female received her first dose of Immunex (a new biologic) via IV infusion. Within 30 minutes of infusion completion, she developed flushing, difficulty breathing, and hypotension requiring epinephrine. Symptoms resolved after treatment. She had no known allergies. The event occurred during her first-ever exposure to this drug.",
          "highlight": "First dose, immediate onset (30 minutes), infusion reaction pattern",
          "question": "What is the most appropriate causality assessment?",
          "options": [
            {
              "id": "A",
              "text": "Possible - could be coincidental anxiety reaction",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Probable - strong temporal relationship and known reaction type",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Certain - because it required epinephrine treatment",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Probable/Likely - temporal relationship, plausible mechanism, no alternative cause",
              "isCorrect": true
            }
          ],
          "correctAnswer": "D",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This case meets criteria for 'Probable' - strong evidence without rechallenge confirmation.",
              "points": [
                {
                  "label": "Temporal Relationship",
                  "detail": "30 minutes post-infusion - classic timing for infusion reactions",
                  "status": "met"
                },
                {
                  "label": "Biological Plausibility",
                  "detail": "Biologics commonly cause infusion/hypersensitivity reactions",
                  "status": "met"
                },
                {
                  "label": "No Alternative Cause",
                  "detail": "No known allergies, no other new exposures",
                  "status": "met"
                },
                {
                  "label": "Why Not Certain?",
                  "detail": "No rechallenge (and none should be attempted for anaphylaxis)",
                  "status": "info"
                }
              ],
              "inspectorTip": "For immediate hypersensitivity reactions, 'Probable' is typically the highest appropriate assessment without rechallenge. Rechallenge would be unethical for anaphylaxis."
            },
            "A": {
              "title": "Too conservative",
              "explanation": "The clinical presentation (flushing, breathing difficulty, hypotension requiring epinephrine) is not consistent with anxiety. This is a classic anaphylactoid/hypersensitivity reaction."
            },
            "B": {
              "title": "Correct assessment but incomplete reasoning",
              "explanation": "The answer is right, but option D better explains WHY it's probable - the combination of temporal relationship, plausible mechanism, AND absence of alternative cause."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "'Certain' requires positive rechallenge. The severity of treatment needed doesn't determine causality category - it determines seriousness."
            }
          },
          "hints": [
            "Immediate reactions after first dose of biologics are a known phenomenon",
            "What would be required to upgrade from 'Probable' to 'Certain'?"
          ],
          "relatedTerms": [
            "time-to-onset",
            "biological-plausibility",
            "causality-assessment",
            "life-threatening"
          ]
        }
      ],
      "debrief": {
        "summary": "You've practiced applying causality assessment principles across cases with varying evidence patterns, from certain (rechallenge positive) to unlikely (clear alternative etiology).",
        "keyTakeaways": [
          "Positive rechallenge is the strongest evidence supporting 'Certain' causality",
          "Alternative etiologies must be considered - underlying disease may better explain events",
          "Biological plausibility matters - does the drug mechanism make the event more or less likely?",
          "Temporal relationship alone isn't sufficient - consider all available evidence",
          "'Unlikely' or 'Unrelated' doesn't mean the case isn't captured - causality is separate from validity"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "assessment-003",
      "title": "Expectedness Evaluation",
      "category": "case-assessment",
      "categoryName": "Case Assessment",
      "difficulty": "intermediate",
      "icon": "üìã",
      "estimatedTime": "6 min",
      "description": "Determine expectedness using Reference Safety Information",
      "learningObjectives": [
        "Apply expectedness criteria beyond simple term matching",
        "Understand that severity affects expectedness",
        "Use the RSI/SmPC correctly for expectedness determination"
      ],
      "briefing": {
        "role": "Drug Safety Associate",
        "context": "You're assessing expectedness for several cases. You have access to the product's SmPC Section 4.8 (Adverse Reactions) for reference.",
        "task": "Determine whether each adverse event is expected (listed) or unexpected (unlisted) based on the RSI."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Case 1: Term Matching",
          "contentType": "case",
          "content": "SmPC Section 4.8 states: 'Common (‚â•1/100): headache, nausea, dizziness. Uncommon (‚â•1/1,000): rash, pruritus. Rare (‚â•1/10,000): hepatic enzyme elevation.'\n\nThe reported event is: Patient experienced moderate nausea for 2 days after starting treatment.",
          "question": "Is 'moderate nausea for 2 days' expected or unexpected?",
          "options": [
            {
              "id": "A",
              "text": "Expected - 'nausea' is listed as a Common adverse reaction",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "Unexpected - the duration (2 days) is not specified in the label",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Unexpected - 'moderate' severity is not mentioned",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Cannot determine without more information",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "The term 'nausea' is listed in Section 4.8. The moderate severity and 2-day duration are within normal expectations for this type of event.",
              "points": [
                {
                  "label": "Term Match",
                  "detail": "'Nausea' explicitly appears in Section 4.8",
                  "status": "met"
                },
                {
                  "label": "Severity",
                  "detail": "'Moderate' is typical for listed GI events unless label specifies otherwise",
                  "status": "info"
                },
                {
                  "label": "Duration",
                  "detail": "2 days is not unusual; doesn't change expectedness",
                  "status": "info"
                }
              ],
              "inspectorTip": "For straightforward term matches with typical presentations, the event is expected. Don't over-complicate expectedness with minor variations in presentation."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Labels don't typically specify durations for every adverse reaction. A 2-day duration for nausea is not unusual or extreme enough to make an otherwise listed term unexpected."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Labels don't always specify severity levels. 'Moderate' nausea is well within the expected range for a listed GI adverse reaction. Only extreme or unusual severity might change expectedness."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "You have sufficient information. The term matches, the presentation is typical - this is a straightforward expected event."
            }
          },
          "hints": [
            "Look for the exact term in Section 4.8",
            "Consider whether the presentation is unusual or extreme"
          ],
          "relatedTerms": [
            "expectedness",
            "listed",
            "smpc",
            "rsi"
          ]
        },
        {
          "id": "step-2",
          "title": "Case 2: Severity Mismatch",
          "contentType": "case",
          "content": "Same SmPC: 'Rare (‚â•1/10,000): hepatic enzyme elevation'\n\nThe reported event is: Patient developed fulminant hepatic failure requiring liver transplant. Initial presentation included ALT 3,500 U/L (normal <40), AST 2,800 U/L, total bilirubin 18 mg/dL, and INR 4.2.",
          "highlight": "Label says 'enzyme elevation' - case shows hepatic failure requiring transplant",
          "question": "Is this case expected or unexpected?",
          "options": [
            {
              "id": "A",
              "text": "Expected - hepatic events are listed in Section 4.8",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Unexpected - the severity far exceeds what is described in the label",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Expected - 'hepatic enzyme elevation' covers all liver events",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Unexpected - because it's listed as 'Rare'",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "While hepatic effects are mentioned, this severity (fulminant failure, transplant needed) far exceeds 'enzyme elevation.'",
              "points": [
                {
                  "label": "Label Language",
                  "detail": "'Hepatic enzyme elevation' suggests laboratory finding, not clinical hepatic failure",
                  "status": "info"
                },
                {
                  "label": "Case Severity",
                  "detail": "Fulminant failure, encephalopathy features (INR 4.2), transplant required",
                  "status": "info"
                },
                {
                  "label": "Key Principle",
                  "detail": "Expectedness considers NATURE, SEVERITY, SPECIFICITY, and OUTCOME",
                  "status": "met"
                }
              ],
              "inspectorTip": "This is exactly the type of case regulators want to know about quickly. The label mentions mild liver effects; this is a completely different clinical entity."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "You can't simply match 'liver' to 'liver.' The label describes enzyme elevation (a lab finding); this case is fulminant hepatic failure (life-threatening organ failure). These are clinically very different."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "'Hepatic enzyme elevation' does NOT cover all liver events. It specifically describes elevated lab values, not clinical liver failure. The ICH E2D definition of expectedness includes severity and outcome."
            },
            "D": {
              "title": "Wrong reasoning",
              "explanation": "Frequency (Rare, Common, etc.) doesn't determine expectedness. Even rare events are 'expected' if they're listed. This is unexpected because of SEVERITY, not frequency."
            }
          },
          "hints": [
            "Compare the label language to what actually happened",
            "Is 'enzyme elevation' the same as 'hepatic failure'?"
          ],
          "relatedTerms": [
            "unexpected-ae",
            "expectedness",
            "rsi",
            "serious-ae"
          ]
        },
        {
          "id": "step-3",
          "title": "Case 3: The Unlisted Event",
          "contentType": "case",
          "content": "Same SmPC Section 4.8: 'Common: headache, nausea, dizziness. Uncommon: rash, pruritus. Rare: hepatic enzyme elevation.'\n\nThe reported event is: Patient developed severe aplastic anemia requiring hospitalization and blood transfusions.",
          "question": "Is aplastic anemia expected or unexpected?",
          "options": [
            {
              "id": "A",
              "text": "Expected - blood disorders are a known class effect",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Unexpected - aplastic anemia is not listed in Section 4.8",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Cannot determine - need to check Section 4.4 Warnings",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Expected - all serious events are expected for marketed drugs",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Aplastic anemia does not appear anywhere in the provided Section 4.8. If it's not listed, it's unexpected.",
              "points": [
                {
                  "label": "Section 4.8 Review",
                  "detail": "Lists headache, nausea, dizziness, rash, pruritus, hepatic enzyme elevation",
                  "status": "info"
                },
                {
                  "label": "Aplastic Anemia",
                  "detail": "Not mentioned - therefore UNEXPECTED",
                  "status": "met"
                },
                {
                  "label": "Reporting Implication",
                  "detail": "Serious + Unexpected = Expedited reporting required",
                  "status": "info"
                }
              ],
              "inspectorTip": "Always document your expectedness assessment with reference to the specific RSI version and section you reviewed."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "Class effects don't automatically make events 'expected' for a specific product. Expectedness is determined by what's in THIS product's labeling, not what's known about similar drugs."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "For expectedness determination, Section 4.8 (Adverse Reactions) is the primary reference. Warnings in 4.4 may provide context but the adverse reactions section is definitive for expectedness."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "This is incorrect. 'Expected' has a specific regulatory meaning - the event must be listed in the RSI. Not all serious events are expected; many serious events are unexpected."
            }
          },
          "hints": [
            "Scan Section 4.8 for the term or similar terms",
            "If it's not there, what does that mean for expectedness?"
          ],
          "relatedTerms": [
            "unlisted",
            "unexpected-ae",
            "expectedness",
            "expedited-reporting"
          ]
        }
      ],
      "debrief": {
        "summary": "You've learned that expectedness goes beyond simple term matching - severity, specificity, and outcome all factor into the determination.",
        "keyTakeaways": [
          "Expectedness is determined by the Reference Safety Information (RSI/SmPC Section 4.8)",
          "Simple term matches with typical presentations are expected",
          "Severity matters - extreme presentations can make listed terms unexpected",
          "'Enzyme elevation' ‚â† 'hepatic failure' - clinical significance differs",
          "If the term isn't in Section 4.8, it's unexpected regardless of class effects",
          "Serious + Unexpected = Expedited reporting"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "intake-002",
      "title": "The Ambiguous Email",
      "category": "case-intake",
      "categoryName": "Case Intake",
      "difficulty": "intermediate",
      "icon": "üìß",
      "estimatedTime": "6 min",
      "description": "Evaluate a tricky email that may or may not contain a valid case",
      "learningObjectives": [
        "Recognize borderline valid/invalid case scenarios",
        "Apply minimum criteria to ambiguous situations",
        "Understand when to seek clarification"
      ],
      "briefing": {
        "role": "Drug Safety Associate",
        "context": "You receive an email forwarded from Medical Information. The original sender's details are partially visible.",
        "task": "Determine if this email contains a valid case and what follow-up may be needed."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "The Email",
          "contentType": "email",
          "content": "Subject: Question about Nexapril\n\nHi,\n\nI've been reading online about Nexapril side effects. My neighbor mentioned she had some dizziness when she started taking it last month. Is this common? Should she be worried?\n\nThanks,\nCurious Patient",
          "metadata": {
            "from": "curious_patient_2024@email.com",
            "to": "medinfo@pharmacompany.com",
            "date": "Tuesday 2:30 PM"
          },
          "question": "Does this email contain a valid adverse event case?",
          "options": [
            {
              "id": "A",
              "text": "Yes - we have reporter, patient, product, and event",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "No - the patient (neighbor) is not identifiable",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "No - the reporter is asking a question, not reporting an event",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Yes, but it's non-serious so no action needed",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This email does NOT meet minimum criteria because the patient is not identifiable.",
              "points": [
                {
                  "label": "Identifiable Reporter",
                  "detail": "Email address available - criterion MET",
                  "status": "met"
                },
                {
                  "label": "Identifiable Patient",
                  "detail": "'My neighbor' with no qualifying details - NOT MET",
                  "status": "notmet"
                },
                {
                  "label": "Suspect Product",
                  "detail": "Nexapril - criterion MET",
                  "status": "met"
                },
                {
                  "label": "Adverse Event",
                  "detail": "Dizziness - criterion MET",
                  "status": "met"
                }
              ],
              "inspectorTip": "Three out of four criteria isn't enough. However, you should attempt to obtain the missing information through follow-up before closing the case as invalid."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "While we do have a reporter, product, and event, the PATIENT is not identifiable. 'My neighbor' without any qualifying information (age, gender, initials) does not meet the identifiable patient criterion."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "The format of communication (question vs. statement) doesn't matter. What matters is whether the content contains the four minimum elements. This email DOES describe an adverse event (dizziness) with a suspect product (Nexapril) - it just lacks an identifiable patient."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Two problems: First, the case isn't valid because the patient isn't identifiable. Second, even if it were valid, seriousness doesn't determine whether a case needs to be processed - all valid cases must be captured."
            }
          },
          "hints": [
            "Go through each of the four minimum criteria systematically",
            "What specific information do we have about the patient?"
          ],
          "relatedTerms": [
            "valid-case",
            "minimum-information",
            "identifiable-patient",
            "follow-up-report"
          ]
        },
        {
          "id": "step-2",
          "title": "Next Steps",
          "contentType": "info",
          "content": "You've correctly identified that the patient is not identifiable. However, we have three of four criteria met. What should you do next?",
          "question": "What is the appropriate action for this email?",
          "options": [
            {
              "id": "A",
              "text": "Close as invalid - missing minimum criteria",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Enter as valid case anyway - we have most information",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Attempt follow-up to obtain patient identifiers, then reassess validity",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Forward to Medical Information - this is just a product question",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "When you have partial minimum criteria, you should attempt to obtain the missing information before determining the case is invalid.",
              "points": [
                {
                  "label": "Best Practice",
                  "detail": "Contact reporter to ask for patient age, gender, or other identifier",
                  "status": "info"
                },
                {
                  "label": "Documentation",
                  "detail": "Document your follow-up attempts even if unsuccessful",
                  "status": "info"
                }
              ],
              "inspectorTip": "Inspectors will ask: 'What efforts did you make to obtain the missing information?' Simply closing cases as invalid without follow-up attempts is a common inspection finding."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "Closing immediately without attempting follow-up is not best practice. With three of four criteria met, a simple follow-up question could yield a valid case. Document your attempts to obtain information."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "You cannot enter an invalid case as valid. The minimum criteria exist for regulatory reasons. However, you should attempt to OBTAIN the missing information first."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Even though this came as a question, it contains potential adverse event information (dizziness with Nexapril). This requires safety assessment, not just medical information response."
            }
          },
          "hints": [
            "Think about what an inspector would expect to see in your records",
            "What simple question could you ask to potentially make this case valid?"
          ],
          "relatedTerms": [
            "minimum-information",
            "follow-up-report",
            "source-document"
          ]
        }
      ],
      "debrief": {
        "summary": "You correctly identified a case missing minimum criteria and understood the importance of follow-up attempts before determining invalidity.",
        "keyTakeaways": [
          "Three out of four minimum criteria is NOT sufficient for validity",
          "Always attempt to obtain missing information before closing as invalid",
          "Document all follow-up attempts, even unsuccessful ones",
          "Questions can contain embedded adverse event reports"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "assessment-001",
      "title": "Serious vs. Severe Challenge",
      "category": "case-assessment",
      "categoryName": "Case Assessment",
      "difficulty": "intermediate",
      "icon": "‚öñÔ∏è",
      "estimatedTime": "7 min",
      "description": "Master the critical distinction between severity and seriousness",
      "learningObjectives": [
        "Distinguish between serious (regulatory) and severe (clinical intensity)",
        "Apply all six seriousness criteria correctly",
        "Recognize Important Medical Events"
      ],
      "briefing": {
        "role": "Drug Safety Case Processor",
        "context": "Your QC reviewer has flagged several cases where previous processors made seriousness determination errors. This is a common problem area.",
        "task": "Correctly classify each case and understand the reasoning."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Case 1: The Severe Headache",
          "contentType": "case",
          "content": "A 34-year-old female reports SEVERE headache lasting 3 days after starting Study Drug. She rated pain as 9/10 and was unable to work for 2 days. She took OTC ibuprofen at home and the headache eventually resolved. She did not seek any medical attention.",
          "highlight": "SEVERE headache, 9/10 pain, missed work",
          "question": "Is this case SERIOUS per regulatory criteria?",
          "options": [
            {
              "id": "A",
              "text": "Yes - severe symptoms indicate seriousness",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Yes - inability to work constitutes disability",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "No - none of the six seriousness criteria are met",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Yes - this should be classified as an Important Medical Event",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct! This is SEVERE but NOT SERIOUS.",
              "explanation": "This is one of the most important distinctions in pharmacovigilance. Let's check each criterion:",
              "points": [
                {
                  "label": "Death",
                  "detail": "No",
                  "status": "notmet"
                },
                {
                  "label": "Life-threatening",
                  "detail": "No - not at immediate risk of death",
                  "status": "notmet"
                },
                {
                  "label": "Hospitalization",
                  "detail": "No - treated at home with OTC meds",
                  "status": "notmet"
                },
                {
                  "label": "Disability",
                  "detail": "No - temporary work absence ‚â† persistent disability",
                  "status": "notmet"
                },
                {
                  "label": "Congenital anomaly",
                  "detail": "No",
                  "status": "notmet"
                },
                {
                  "label": "Important Medical Event",
                  "detail": "No - self-limited, no intervention needed",
                  "status": "notmet"
                }
              ],
              "inspectorTip": "SEVERITY (mild/moderate/severe) describes INTENSITY. SERIOUSNESS is a regulatory classification. They are completely independent concepts. A severe headache can be non-serious; a mild rash requiring hospitalization is serious."
            },
            "A": {
              "title": "This is the most common mistake!",
              "explanation": "SEVERE ‚â† SERIOUS. 'Severe' describes the intensity of symptoms on a clinical scale (mild/moderate/severe). 'Serious' is a regulatory classification with six specific criteria. This headache is severe in intensity but does NOT meet any seriousness criteria."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Missing work temporarily is NOT regulatory 'disability.' The disability criterion requires PERSISTENT or SIGNIFICANT disruption of ability to conduct normal life functions. Missing 2 days of work from a self-limited headache does not meet this threshold."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Important Medical Event (IME) requires medical judgment that the event may jeopardize the patient or require intervention to prevent a serious outcome. A headache that resolved with OTC medication does not meet this bar."
            }
          },
          "hints": [
            "Remember: severity and seriousness are different concepts",
            "Go through each of the six seriousness criteria systematically"
          ],
          "relatedTerms": [
            "serious-ae",
            "severity",
            "seriousness-criteria",
            "disability",
            "important-medical-event"
          ]
        },
        {
          "id": "step-2",
          "title": "Case 2: The Allergic Reaction",
          "contentType": "case",
          "content": "A 52-year-old male developed mild hives and throat tightness 30 minutes after first dose of Study Drug. His wife administered his personal EpiPen. Symptoms resolved within 20 minutes. He did NOT go to the hospital since symptoms resolved quickly at home.",
          "highlight": "Mild hives, throat tightness, EpiPen used, NO hospitalization",
          "question": "Is this case SERIOUS?",
          "options": [
            {
              "id": "A",
              "text": "No - patient was not hospitalized and recovered quickly",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "No - symptoms were described as mild",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Yes - this was life-threatening (anaphylaxis requiring epinephrine)",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Cannot determine without confirmation from a physician",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This is SERIOUS under the LIFE-THREATENING criterion, despite the mild symptoms and lack of hospitalization.",
              "points": [
                {
                  "label": "Critical Reasoning",
                  "detail": "Throat tightness + need for emergency epinephrine = potential anaphylaxis",
                  "status": "info"
                },
                {
                  "label": "Life-threatening Definition",
                  "detail": "Patient was at immediate risk of death WITHOUT the EpiPen intervention",
                  "status": "met"
                },
                {
                  "label": "Key Insight",
                  "detail": "Outcome doesn't determine seriousness - it's about risk at time of event",
                  "status": "info"
                }
              ],
              "inspectorTip": "Don't be fooled by good outcomes or mild symptom descriptions. Always ask: 'What would have happened WITHOUT intervention?' If the answer is 'possible death,' it's life-threatening."
            },
            "A": {
              "title": "Careful! Hospitalization is only ONE of six criteria.",
              "explanation": "Lack of hospitalization doesn't mean the case isn't serious. There are SIX seriousness criteria. This case meets the LIFE-THREATENING criterion regardless of hospitalization status."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Again, severity (mild) is different from seriousness. The hives may have been mild, but throat tightness suggesting airway compromise requiring epinephrine is a life-threatening situation."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "You have enough information. EpiPen use for throat tightness strongly suggests anaphylaxis, which is life-threatening by definition. You don't need physician confirmation to make this assessment."
            }
          },
          "hints": [
            "Consider what would have happened if no intervention occurred",
            "Hospitalization is just one of six criteria - check them all"
          ],
          "relatedTerms": [
            "life-threatening",
            "serious-ae",
            "seriousness-criteria"
          ]
        },
        {
          "id": "step-3",
          "title": "Case 3: The Lab Finding",
          "contentType": "case",
          "content": "Routine monitoring during a Phase 3 clinical trial reveals Grade 3 neutropenia (ANC 600/ŒºL) in an asymptomatic 45-year-old patient. The patient feels fine with no symptoms. Study drug was held per protocol. Repeat labs 1 week later showed ANC normalized at 2,500/ŒºL. Patient never developed fever or infection.",
          "highlight": "Grade 3 lab abnormality, asymptomatic, drug held, labs normalized",
          "question": "Is this case SERIOUS?",
          "options": [
            {
              "id": "A",
              "text": "No - patient was asymptomatic and labs normalized",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "No - this is just a lab finding, not a clinical event",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Yes - Grade 3 = Serious by definition",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Yes - this is an Important Medical Event requiring intervention",
              "isCorrect": true
            }
          ],
          "correctAnswer": "D",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This qualifies as SERIOUS under the Important Medical Event (IME) criterion.",
              "points": [
                {
                  "label": "IME Reasoning",
                  "detail": "Without holding the drug, severe neutropenia could progress to febrile neutropenia, sepsis, or death",
                  "status": "met"
                },
                {
                  "label": "Intervention Required",
                  "detail": "Study drug was held - this intervention prevented a potentially serious outcome",
                  "status": "met"
                },
                {
                  "label": "Key Question",
                  "detail": "Did we have to DO something to prevent a bad outcome? YES = consider IME",
                  "status": "info"
                }
              ],
              "inspectorTip": "Asymptomatic lab abnormalities that require action (dose hold, treatment, additional monitoring) often qualify as IME. The intervention is what prevented the serious outcome."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "The fact that labs normalized is BECAUSE the drug was held. The intervention prevented a potentially serious outcome. That's exactly the IME criterion - 'requires intervention to prevent a serious outcome.'"
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Lab findings can absolutely be adverse events. Grade 3 neutropenia is a clinically significant finding that required action and carries real risk of serious infection."
            },
            "C": {
              "title": "Close but wrong reasoning",
              "explanation": "This IS serious, but NOT because 'Grade 3 = Serious.' CTCAE grades measure severity, not regulatory seriousness. Some Grade 3 events may not be serious; some Grade 1 events may be serious. The correct reasoning is IME."
            }
          },
          "hints": [
            "Consider why the drug was held - what were they trying to prevent?",
            "Think about the Important Medical Event criterion"
          ],
          "relatedTerms": [
            "important-medical-event",
            "serious-ae",
            "ctcae",
            "seriousness-criteria"
          ]
        }
      ],
      "debrief": {
        "summary": "You've mastered one of the most challenging concepts in pharmacovigilance - distinguishing between severity and seriousness, and applying the six criteria correctly.",
        "keyTakeaways": [
          "SEVERE ‚â† SERIOUS - they are completely independent concepts",
          "Life-threatening means immediate risk of death at time of event, regardless of outcome",
          "Important Medical Event requires medical judgment - ask 'what would happen without intervention?'",
          "CTCAE grades (1-5) do NOT automatically map to regulatory seriousness",
          "Asymptomatic lab findings CAN be serious if they require intervention"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "reporting-001",
      "title": "Timeline Determination",
      "category": "reporting",
      "categoryName": "Regulatory Reporting",
      "difficulty": "intermediate",
      "icon": "‚è±Ô∏è",
      "estimatedTime": "6 min",
      "description": "Practice determining correct reporting timelines for different scenarios",
      "learningObjectives": [
        "Correctly identify Day 0 in various scenarios",
        "Distinguish between 7-day and 15-day expedited reports",
        "Understand when periodic reporting applies"
      ],
      "briefing": {
        "role": "Drug Safety Specialist",
        "context": "You're reviewing several cases to determine appropriate reporting timelines. Each case has different characteristics affecting the timeline.",
        "task": "Determine the correct Day 0 and reporting requirement for each case."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Case 1: The Sales Rep Report",
          "contentType": "case",
          "content": "A sales representative had lunch with a physician on Thursday. During the conversation, the physician mentioned that one of her patients died last week from liver failure while taking your company's drug Hepatox. The sales rep thought this was just conversation and didn't report it until the following Monday when she returned to the office and mentioned it to her manager.",
          "question": "What is Day 0 for this case?",
          "options": [
            {
              "id": "A",
              "text": "Thursday - when the sales rep first heard about it",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "Monday - when the sales rep reported it to her manager",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Last week - when the patient actually died",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Monday - when Drug Safety first received the information",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Day 0 is THURSDAY - when ANY company employee first became aware of the information.",
              "points": [
                {
                  "label": "Critical Point",
                  "detail": "Company awareness includes ALL employees, not just Drug Safety",
                  "status": "info"
                },
                {
                  "label": "Implication",
                  "detail": "The 7-day clock started Thursday - this case is already late!",
                  "status": "warning"
                },
                {
                  "label": "Training Issue",
                  "detail": "Sales reps must be trained to report safety information immediately",
                  "status": "info"
                }
              ],
              "inspectorTip": "This scenario is a classic inspection finding. Inspectors will ask: 'How do you train field staff on adverse event reporting? What is your escalation timeline from field to Drug Safety?'"
            },
            "B": {
              "title": "Not quite right",
              "explanation": "The sales rep IS a company employee. Company awareness began Thursday when she heard the information, not Monday when she chose to report it internally."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Day 0 is company awareness date, not event date. While the death occurred 'last week,' the company didn't know about it until Thursday."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Drug Safety receipt is not what determines Day 0. ANY company employee's awareness counts. This is why field force training on AE reporting is critical."
            }
          },
          "hints": [
            "Consider who is a 'company employee' for awareness purposes",
            "When did the company first learn of this event through any channel?"
          ],
          "relatedTerms": [
            "day-zero",
            "awareness-date",
            "clock-start"
          ]
        },
        {
          "id": "step-2",
          "title": "Case 1 Follow-up: Report Type",
          "contentType": "info",
          "content": "You've correctly identified Day 0 as Thursday. The case involves: Death (serious), and liver failure is NOT listed in the product labeling (unexpected). The product is a marketed drug.",
          "question": "What type of report is required and what is the timeline?",
          "options": [
            {
              "id": "A",
              "text": "7-day expedited report - fatal unexpected case",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "15-day expedited report - serious unexpected case",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "7-day expedited report for death, then 15-day for additional info",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Periodic report - need to investigate causality first",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Fatal or life-threatening unexpected cases require 7-day expedited reporting.",
              "points": [
                {
                  "label": "Seriousness",
                  "detail": "Death = Serious (most serious outcome)",
                  "status": "met"
                },
                {
                  "label": "Expectedness",
                  "detail": "Unexpected (liver failure not in labeling)",
                  "status": "met"
                },
                {
                  "label": "Timeline",
                  "detail": "7 calendar days for fatal/life-threatening unexpected",
                  "status": "info"
                },
                {
                  "label": "This Case",
                  "detail": "Day 0 was Thursday - 7 days = following Wednesday deadline",
                  "status": "warning"
                }
              ],
              "inspectorTip": "For fatal cases, initial reports should be submitted even with limited information. Follow-up reports add details as they become available."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "15-day timeline applies to serious unexpected cases that are NOT fatal or life-threatening. Since this is a fatal case, the more urgent 7-day timeline applies."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "There's only one initial report with one timeline. For fatal unexpected cases, it's 7 days. Follow-up reports with additional information are submitted within 15 days of receiving new information."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "You don't wait for causality investigation before expedited reporting. If a case is serious and unexpected, it must be reported within the expedited timeline. Causality assessment is part of the report but doesn't delay submission."
            }
          },
          "hints": [
            "What's the timeline for fatal cases?",
            "Does expectedness matter for determining 7-day vs 15-day?"
          ],
          "relatedTerms": [
            "seven-day-report",
            "fifteen-day-report",
            "expedited-reporting",
            "fatal"
          ]
        },
        {
          "id": "step-3",
          "title": "Case 2: The Expected SAE",
          "contentType": "case",
          "content": "A patient taking your anticoagulant drug Bleedex was hospitalized for GI bleeding. GI bleeding is listed in Section 4.8 of the SmPC as a 'Common' adverse reaction. The case was reported by the treating physician.",
          "question": "What reporting is required?",
          "options": [
            {
              "id": "A",
              "text": "7-day expedited report - hospitalization is serious",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "15-day expedited report - serious case from HCP",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Periodic reporting only - serious but expected (listed)",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "No reporting required - expected events don't need reports",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Serious EXPECTED (listed) cases go into periodic reports, not expedited reports.",
              "points": [
                {
                  "label": "Seriousness",
                  "detail": "Serious - hospitalization criterion met",
                  "status": "met"
                },
                {
                  "label": "Expectedness",
                  "detail": "Expected/Listed - GI bleeding is in Section 4.8",
                  "status": "met"
                },
                {
                  "label": "Reporting",
                  "detail": "Periodic (PSUR) - not expedited",
                  "status": "info"
                },
                {
                  "label": "Key Rule",
                  "detail": "Expedited reporting = Serious + UNEXPECTED",
                  "status": "info"
                }
              ],
              "inspectorTip": "Even though this doesn't require expedited reporting, the case must still be entered into your safety database and included in your next PSUR. All valid cases must be captured."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "7-day reports are only for fatal or life-threatening unexpected cases. This case, while serious (hospitalization), is expected (listed in labeling)."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "15-day expedited reports require the case to be BOTH serious AND unexpected. This case is serious but expected (GI bleeding is listed). Reporter type (HCP) doesn't change this."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "ALL valid cases must be captured in the safety database, regardless of expectedness. This case doesn't require expedited reporting but must still be processed and will appear in periodic reports."
            }
          },
          "hints": [
            "What two criteria must both be met for expedited reporting?",
            "Is GI bleeding listed in the product labeling?"
          ],
          "relatedTerms": [
            "expectedness",
            "listed",
            "psur",
            "periodic-reporting",
            "serious-ae"
          ]
        }
      ],
      "debrief": {
        "summary": "You've practiced determining reporting timelines based on seriousness, expectedness, and company awareness dates - critical skills for regulatory compliance.",
        "keyTakeaways": [
          "Day 0 = ANY company employee's awareness, not just Drug Safety",
          "7-day reports: Fatal or life-threatening + unexpected",
          "15-day reports: Serious + unexpected (non-fatal, non-life-threatening)",
          "Periodic reports: Serious + expected (listed)",
          "All valid cases must be captured regardless of reporting timeline"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "inspection-001",
      "title": "The Inspector's Questions",
      "category": "inspection",
      "categoryName": "Inspection Readiness",
      "difficulty": "advanced",
      "icon": "üîç",
      "estimatedTime": "8 min",
      "description": "Practice responding to common inspector questions with confidence",
      "learningObjectives": [
        "Respond confidently to typical inspector questions",
        "Understand what inspectors are looking for",
        "Use documentation to support your answers"
      ],
      "briefing": {
        "role": "Drug Safety Manager",
        "context": "An EMA GVP inspection is underway at your site. The inspector has reviewed documents and now wants to discuss your procedures with you.",
        "task": "Answer the inspector's questions clearly, confidently, and accurately."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Question 1: Day Zero Discrepancy",
          "contentType": "interview",
          "content": "Inspector: 'I've been reviewing your expedited cases. Case XYZ-2024-0847 shows the event occurred on March 3rd, but Day 0 is recorded as March 5th. There's a 2-day discrepancy. Can you explain this?'",
          "metadata": {
            "inspector": "Dr. Helena Virtanen",
            "role": "EMA GVP Inspector",
            "demeanor": "Professional, detail-oriented"
          },
          "question": "How do you respond?",
          "options": [
            {
              "id": "A",
              "text": "That's an error - Day 0 should match the event date. I'll have it corrected immediately.",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Day 0 is the date of first company awareness, not the event date. We received this report on March 5th, which is documented in our source records.",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "I'm not sure about this specific case. Let me check with my team and get back to you.",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "The reporter didn't contact us until March 5th, so we couldn't have known about it earlier.",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Excellent response!",
              "explanation": "You correctly and confidently explained the Day 0 definition while offering to show documentation.",
              "points": [
                {
                  "label": "What You Did Right",
                  "detail": "Stated the regulatory definition clearly and accurately",
                  "status": "met"
                },
                {
                  "label": "What You Did Right",
                  "detail": "Referenced documentation to support your answer",
                  "status": "met"
                },
                {
                  "label": "Bonus",
                  "detail": "You could offer: 'Would you like me to show you the source document confirming March 5th receipt?'",
                  "status": "info"
                }
              ],
              "inspectorTip": "Inspectors often ask about dates because they're testing your understanding of clock-start rules. Confidence + documentation = credibility."
            },
            "A": {
              "title": "Dangerous response!",
              "explanation": "Never agree to 'correct' something that isn't wrong! The date WAS correct. This response would: 1) Create a data integrity issue, 2) Undermine your credibility, 3) Show you don't understand Day 0 definition."
            },
            "C": {
              "title": "Understandable but problematic",
              "explanation": "As Drug Safety Manager, you should know this fundamental concept. Deferring on basic questions makes inspectors concerned about staff competency and may lead to deeper investigation."
            },
            "D": {
              "title": "Correct concept but weak delivery",
              "explanation": "The underlying reasoning is correct, but this sounds defensive. Better to lead with the regulatory definition ('Day 0 is company awareness date...') then provide the facts."
            }
          },
          "hints": [
            "Think about what Day 0 actually means - is it event date or awareness date?",
            "How can you support your answer with documentation?"
          ],
          "relatedTerms": [
            "day-zero",
            "awareness-date",
            "pv-inspection",
            "audit-trail"
          ]
        },
        {
          "id": "step-2",
          "title": "Question 2: Process Walkthrough",
          "contentType": "interview",
          "content": "Inspector: 'I'd like to understand your expedited reporting process. Can you walk me through how a case gets from initial receipt to regulatory submission?'",
          "question": "What's the best approach to answering this question?",
          "options": [
            {
              "id": "A",
              "text": "Describe the process from memory, covering all the key steps",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Retrieve your SOP and walk through it step-by-step, referencing a real example case",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Provide a high-level overview of the general principles involved",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Ask if they would prefer to speak with the case processors who do this daily",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Perfect approach!",
              "explanation": "Using your SOP plus a real example demonstrates that documented procedures actually reflect practice.",
              "points": [
                {
                  "label": "Why This Works",
                  "detail": "Shows SOPs are practical and actually followed",
                  "status": "met"
                },
                {
                  "label": "Why This Works",
                  "detail": "Demonstrates traceability from procedure to practice",
                  "status": "met"
                },
                {
                  "label": "How To Execute",
                  "detail": "1) Retrieve SOP, 2) Select recent case, 3) Walk through each step showing how it was applied, 4) Show documentation at each stage",
                  "status": "info"
                }
              ],
              "inspectorTip": "When asked about ANY process, offer to show the SOP and walk through a real example. This is always stronger than verbal explanation alone."
            },
            "A": {
              "title": "Risky approach",
              "explanation": "Reciting from memory may miss steps or - worse - differ from your documented SOP. If your verbal description doesn't match your written procedure, the inspector will note an inconsistency."
            },
            "C": {
              "title": "Too vague",
              "explanation": "Inspectors want to see YOUR specific procedures, not textbook concepts. High-level overviews don't demonstrate that you have adequate processes in place."
            },
            "D": {
              "title": "Acceptable but suboptimal",
              "explanation": "It's okay to involve specialists for technical details, but as Manager you should demonstrate YOUR understanding first. Completely deflecting may raise concerns."
            }
          },
          "hints": [
            "Think about what would make your answer most credible",
            "How can you prove your documented procedures match actual practice?"
          ],
          "relatedTerms": [
            "sop",
            "inspection-readiness",
            "pv-inspection",
            "quality-control"
          ]
        },
        {
          "id": "step-3",
          "title": "Question 3: The Compliance Gap",
          "contentType": "interview",
          "content": "Inspector: 'I've reviewed your submission metrics. I notice that in Q3, your 15-day compliance rate dropped to 89%. Three cases were submitted late, ranging from 2 to 5 days overdue. Can you explain what happened?'",
          "question": "How should you respond?",
          "options": [
            {
              "id": "A",
              "text": "I wasn't aware of that. Let me look into it and get back to you with details.",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "We had staffing issues during that quarter due to unexpected turnover, which affected our processing capacity.",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Yes, we identified this issue. I can show you our deviation reports, root cause analysis, and the CAPA we implemented. Our Q4 rate returned to 100%.",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "89% is still quite good performance. The late cases were only minor delays and all were ultimately submitted.",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Excellent response!",
              "explanation": "You acknowledged the issue, showed you have a quality system that detected it, and demonstrated corrective action was taken.",
              "points": [
                {
                  "label": "What Impressed The Inspector",
                  "detail": "You were already aware of the issue (proactive monitoring)",
                  "status": "met"
                },
                {
                  "label": "What Impressed The Inspector",
                  "detail": "You documented it properly (deviation reports)",
                  "status": "met"
                },
                {
                  "label": "What Impressed The Inspector",
                  "detail": "You investigated and fixed it (RCA + CAPA)",
                  "status": "met"
                },
                {
                  "label": "What Impressed The Inspector",
                  "detail": "You can demonstrate effectiveness (Q4 = 100%)",
                  "status": "met"
                }
              ],
              "inspectorTip": "Inspectors expect issues to occur occasionally. What they're assessing is: Do you detect issues? Do you investigate? Do you fix them? Can you prove the fix worked?"
            },
            "A": {
              "title": "Problematic response",
              "explanation": "As Drug Safety Manager, you should be aware of your compliance metrics. Not knowing about a compliance gap raises serious concerns about management oversight."
            },
            "B": {
              "title": "Incomplete response",
              "explanation": "This explains WHY it happened but doesn't show you handled it properly. Where's the deviation report? The CAPA? The evidence it was fixed? This sounds like an excuse without documentation."
            },
            "D": {
              "title": "Very problematic response",
              "explanation": "NEVER minimize compliance issues to an inspector. 89% means you failed to meet regulatory timelines. Inspectors are not impressed by 'it's still pretty good' - they expect 100% compliance with reporting timelines."
            }
          },
          "hints": [
            "Think about what a robust quality system should have done with this issue",
            "What documentation would demonstrate you handled this properly?"
          ],
          "relatedTerms": [
            "compliance-rate",
            "capa",
            "deviation",
            "root-cause",
            "inspection-finding"
          ]
        }
      ],
      "debrief": {
        "summary": "You've practiced handling common inspector questions, learning that confidence comes from knowledge, documentation, and demonstrating an effective quality system.",
        "keyTakeaways": [
          "Know fundamental definitions (Day 0, seriousness criteria) without hesitation",
          "Never agree to 'fix' something without first verifying it's actually wrong",
          "Use SOPs + real examples when explaining processes",
          "Own your issues - show you detected, investigated, and corrected them",
          "Never minimize compliance gaps to inspectors"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "intake-005",
      "title": "The Social Media Post",
      "category": "case-intake",
      "categoryName": "Case Intake",
      "difficulty": "intermediate",
      "icon": "üì±",
      "estimatedTime": "6 min",
      "description": "Identify reportable adverse events from social media monitoring",
      "learningObjectives": [
        "Recognize adverse events in social media content",
        "Understand digital and social media monitoring obligations",
        "Apply minimum criteria when reporter identity is unclear"
      ],
      "briefing": {
        "role": "Drug Safety Social Media Monitor",
        "context": "Your company's social media monitoring vendor has flagged several posts mentioning your product Nexapril. You need to review the flagged posts and determine which require action.",
        "task": "Evaluate each social media post and determine if it contains a valid adverse event case."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "The Patient Forum Post",
          "contentType": "email",
          "content": "Post from user 'HeartHealthMom2024' on PatientConnect forum:\n\n'Has anyone else experienced terrible muscle cramps since starting Nexapril? I've been on it for 6 weeks and the cramps in my legs are so bad I can barely sleep. My doctor said to keep taking it but I'm miserable. I'm 52F if that matters. Thinking of stopping on my own.'",
          "metadata": {
            "platform": "PatientConnect Forum",
            "posted": "2 hours ago",
            "username": "HeartHealthMom2024"
          },
          "question": "Does this forum post contain a valid ICSR?",
          "options": [
            {
              "id": "A",
              "text": "Yes - all four minimum criteria are identifiable",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "No - the reporter uses a pseudonym, not their real name",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "No - we cannot contact the reporter to verify information",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Potentially - but we need to attempt contact to confirm identifiability",
              "isCorrect": true
            }
          ],
          "correctAnswer": "D",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Social media posts require careful evaluation. While we have a suspect product, event, and patient details, reporter identifiability through a pseudonym is uncertain.",
              "points": [
                {
                  "label": "Suspect Product",
                  "detail": "Nexapril (your company's product)",
                  "status": "met"
                },
                {
                  "label": "Adverse Event",
                  "detail": "Muscle cramps / myalgia",
                  "status": "met"
                },
                {
                  "label": "Identifiable Patient",
                  "detail": "52-year-old female - sufficient even without name",
                  "status": "met"
                },
                {
                  "label": "Identifiable Reporter",
                  "detail": "Username only - attempt contact through platform if possible",
                  "status": "warning"
                }
              ],
              "inspectorTip": "EMA Module VI requires MAHs to monitor digital media. When AE information is found, you must make one reasonable attempt to obtain reporter contact details. Document all attempts."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "While three criteria are clearly met, the reporter identity is ambiguous. A pseudonym alone may not make a reporter identifiable. Best practice is to attempt contact through the platform's messaging system before determining validity."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "A real name is NOT required for an identifiable reporter. However, the reporter must be contactable or distinguishable. Some regulators accept usernames if the platform allows messaging. You should attempt contact first."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Many platforms DO allow private messaging. You should make a reasonable attempt to contact the poster before concluding the reporter is unidentifiable. The key is documenting your effort."
            }
          },
          "hints": [
            "Think about what makes a reporter 'identifiable' - is a name always required?",
            "What does EMA guidance say about social media monitoring and contact attempts?"
          ],
          "relatedTerms": [
            "identifiable-reporter",
            "valid-case",
            "minimum-information",
            "solicited-report"
          ]
        },
        {
          "id": "step-2",
          "title": "The Twitter/X Mention",
          "contentType": "email",
          "content": "Tweet from @frustrated_dad:\n\n'@NexaprilOfficial your drug is garbage. My wife took it and now has problems. Never buying your products again. #BigPharmaFails'",
          "metadata": {
            "platform": "Twitter/X",
            "posted": "Yesterday"
          },
          "question": "Does this tweet require case processing?",
          "options": [
            {
              "id": "A",
              "text": "Yes - contains an AE report that must be captured immediately",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "No - it's too vague, no specific adverse event is described",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "No - Twitter complaints are not reportable sources",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Yes - any mention of 'problems' constitutes an adverse event",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "While this tweet mentions your product and implies something negative happened, 'problems' is not a specific adverse event. The minimum criteria are not met.",
              "points": [
                {
                  "label": "Identifiable Reporter",
                  "detail": "Possibly - Twitter handle exists",
                  "status": "warning"
                },
                {
                  "label": "Identifiable Patient",
                  "detail": "Wife - no age, gender beyond female",
                  "status": "warning"
                },
                {
                  "label": "Suspect Product",
                  "detail": "Nexapril - identified",
                  "status": "met"
                },
                {
                  "label": "Adverse Event",
                  "detail": "'Problems' is NOT a specific AE - too vague",
                  "status": "notmet"
                }
              ],
              "inspectorTip": "Not every negative mention is a valid case. 'Problems,' 'side effects,' or 'issues' without specifics don't constitute an identifiable adverse event. However, document that you reviewed and assessed the post."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "While vigilance is good, 'problems' is not a specific adverse event. Without knowing WHAT happened (rash? headache? hospitalization?), we cannot capture a meaningful case."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Social media IS a reportable source if valid AE information is present. The issue here isn't the platform - it's that no specific adverse event was described."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "The word 'problems' alone does not constitute an adverse event. You need a specific, identifiable event."
            }
          },
          "hints": [
            "Apply the four minimum criteria - is there a specific adverse event described?",
            "What level of detail is needed for an 'identifiable' adverse event?"
          ],
          "relatedTerms": [
            "adverse-event",
            "minimum-information",
            "valid-case"
          ]
        },
        {
          "id": "step-3",
          "title": "The YouTube Comment",
          "contentType": "email",
          "content": "Comment on a health education YouTube video about hypertension:\n\nUser 'Sarah M.' wrote: 'I'm a nurse practitioner and I had a patient last month who developed angioedema within hours of their first Nexapril dose. Lips and tongue swelled up badly. We had to give epinephrine and admit to ICU for monitoring. She recovered but it was terrifying. I've since switched all my patients to a different class.'",
          "metadata": {
            "platform": "YouTube",
            "posted": "3 days ago"
          },
          "question": "What is the appropriate classification and action for this post?",
          "options": [
            {
              "id": "A",
              "text": "Valid non-serious case - patient recovered, capture in periodic report",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Valid serious case - attempt contact, capture as ICSR, assess for expedited reporting",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Not valid - this is secondhand information from a public platform",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Valid case but low priority - angioedema is a known ACE inhibitor effect",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This contains a clear, detailed adverse event report that meets all minimum criteria and describes a serious case.",
              "points": [
                {
                  "label": "Identifiable Reporter",
                  "detail": "Sarah M., nurse practitioner - HCP reporter with partial name",
                  "status": "met"
                },
                {
                  "label": "Identifiable Patient",
                  "detail": "Female patient (gender from 'she') - seen last month",
                  "status": "met"
                },
                {
                  "label": "Suspect Product",
                  "detail": "Nexapril, first dose",
                  "status": "met"
                },
                {
                  "label": "Adverse Event",
                  "detail": "Angioedema requiring epinephrine and ICU admission",
                  "status": "met"
                },
                {
                  "label": "Seriousness",
                  "detail": "Life-threatening (required epinephrine) AND hospitalization (ICU)",
                  "status": "info"
                }
              ],
              "inspectorTip": "HCP-reported cases from any source carry the same regulatory weight. This case needs expedited assessment. Attempt YouTube contact for follow-up details."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "This IS a valid case, but it IS serious. Angioedema requiring epinephrine meets the life-threatening criterion, and ICU admission meets hospitalization."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "A nurse practitioner describing their own patient's experience is a firsthand HCP report, regardless of where it's posted."
            },
            "D": {
              "title": "Partially correct but dangerous reasoning",
              "explanation": "While angioedema is known for the ACE inhibitor class, that affects EXPECTEDNESS, not priority. This is still a serious case requiring proper processing."
            }
          },
          "hints": [
            "Apply minimum criteria AND assess seriousness",
            "Does the reporter's profession matter?"
          ],
          "relatedTerms": [
            "serious-ae",
            "life-threatening",
            "hospitalization",
            "identifiable-reporter",
            "hcp-report"
          ]
        }
      ],
      "debrief": {
        "summary": "You've practiced evaluating adverse event reports from social media and digital platforms, learning to apply minimum criteria to non-traditional reporting sources.",
        "keyTakeaways": [
          "Social media monitoring is a regulatory requirement for MAHs",
          "Not every negative mention is a valid case - specific AE details are needed",
          "Pseudonymous reporters may require contact attempts before determining validity",
          "HCP reports from social media carry the same weight as traditional reports",
          "Always document your assessment, even when posts don't meet case criteria",
          "Attempt one reasonable contact through the platform before closing as non-valid"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "intake-006",
      "title": "The Clinical Trial SAE",
      "category": "case-intake",
      "categoryName": "Case Intake",
      "difficulty": "advanced",
      "icon": "üß™",
      "estimatedTime": "7 min",
      "description": "Process a Serious Adverse Event from a clinical trial setting",
      "learningObjectives": [
        "Understand SAE reporting differences between clinical trials and post-market",
        "Apply unblinding considerations for expedited reporting",
        "Determine investigator vs. sponsor causality assessment roles"
      ],
      "briefing": {
        "role": "Drug Safety Scientist (Sponsor)",
        "context": "You're working on a Phase III randomized, double-blind, placebo-controlled trial for Neurobalance (treatment for epilepsy). The CRO has just faxed an urgent SAE report from a trial site.",
        "task": "Process this SAE and determine appropriate regulatory actions."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "The SAE Report",
          "contentType": "case",
          "content": "SAE Form received from Site 042 (Dr. Yamamoto, Principal Investigator):\n\nSubject: NB-3042-118, 29-year-old male\nEvent: Stevens-Johnson Syndrome (SJS)\nOnset: Day 14 of treatment\nEvent Description: Subject developed widespread blistering skin lesions, mucosal involvement, and fever (39.2¬∞C). Admitted to burn unit. Currently receiving IV fluids and wound care.\nInvestigator Assessment: Related to study drug\nTreatment arm: BLINDED\nConcomitant meds: Levetiracetam 500mg BID (ongoing background therapy)\nSAE form received by sponsor: Today at 2:30 PM",
          "metadata": {
            "study": "NB-PHASE3-001",
            "site": "042",
            "faxTime": "Today 2:30 PM"
          },
          "question": "What is the FIRST critical action you should take?",
          "options": [
            {
              "id": "A",
              "text": "Request unblinding to determine if subject received active drug or placebo",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "Wait for pathology confirmation of SJS before processing",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Report to regulatory authorities immediately - SJS is always reportable",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Contact the investigator to change their causality assessment - SJS could be from levetiracetam",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "In a blinded trial, unblinding is the critical first step to determine expedited reporting obligations.",
              "points": [
                {
                  "label": "Why Unblinding",
                  "detail": "Cannot determine if SUSAR without knowing treatment assignment",
                  "status": "info"
                },
                {
                  "label": "SJS Assessment",
                  "detail": "Serious (hospitalization, potentially life-threatening), unexpected (not in IB)",
                  "status": "info"
                },
                {
                  "label": "If Active Drug",
                  "detail": "SUSAR - requires 7-day expedited report (life-threatening unexpected)",
                  "status": "info"
                },
                {
                  "label": "If Placebo",
                  "detail": "SAE but not a SUSAR for your drug - different reporting path",
                  "status": "info"
                }
              ],
              "inspectorTip": "Sponsors must have clear SOPs for emergency unblinding. The decision to unblind for expedited reporting purposes should be documented with justification and timestamp."
            },
            "B": {
              "title": "Dangerous delay",
              "explanation": "You cannot wait for pathology confirmation before processing an SAE. The clinical description is sufficient to begin processing. The regulatory clock starts when you receive the report."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "You need to know the treatment assignment first. If on placebo, this isn't a SUSAR for your product."
            },
            "D": {
              "title": "Inappropriate action",
              "explanation": "NEVER pressure an investigator to change their causality assessment. The investigator's assessment is their independent clinical judgment. The sponsor makes a SEPARATE causality assessment."
            }
          },
          "hints": [
            "In a blinded trial, what do you need to know before determining SUSAR status?",
            "Consider the regulatory definition of SUSAR and what information is required"
          ],
          "relatedTerms": [
            "susar",
            "serious-ae",
            "unblinding",
            "expedited-reporting"
          ]
        },
        {
          "id": "step-2",
          "title": "The Unblinding Result",
          "contentType": "info",
          "content": "Unblinding reveals: Subject NB-3042-118 was randomized to NEUROBALANCE 200mg BID (active drug).\n\nThe Investigator's Brochure (IB) lists: headache, dizziness, somnolence, nausea, and mild rash (maculopapular). Stevens-Johnson Syndrome is NOT listed in the IB.",
          "question": "How should this case be classified for regulatory reporting?",
          "options": [
            {
              "id": "A",
              "text": "Expected SAE - rash is listed in the IB, SJS is a type of rash",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "SUSAR - serious, unexpected, and suspected to be related",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Expected SAE - SJS is a known risk of anti-epileptic drugs (class effect)",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Cannot classify yet - need sponsor causality assessment before determining SUSAR",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "This is a textbook SUSAR - Suspected Unexpected Serious Adverse Reaction.",
              "points": [
                {
                  "label": "Serious",
                  "detail": "Hospitalization (burn unit), potentially life-threatening",
                  "status": "met"
                },
                {
                  "label": "Unexpected",
                  "detail": "SJS is NOT in the IB (only 'mild rash' is listed)",
                  "status": "met"
                },
                {
                  "label": "Suspected Relationship",
                  "detail": "Investigator assessed as related - sufficient for SUSAR",
                  "status": "met"
                },
                {
                  "label": "Reporting Timeline",
                  "detail": "7 calendar days (life-threatening) or 15 days (serious non-fatal)",
                  "status": "info"
                }
              ],
              "inspectorTip": "For clinical trials, expectedness is assessed against the IB (Investigator's Brochure), not the SmPC. This is a key difference from post-market reporting."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "'Mild rash (maculopapular)' does NOT cover Stevens-Johnson Syndrome. SJS is a completely different clinical entity."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Class effects do NOT determine expectedness for YOUR specific product. Expectedness is based solely on what's in YOUR IB."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "The investigator's assessment of 'related' is sufficient. If EITHER investigator OR sponsor considers it related, it qualifies as suspected."
            }
          },
          "hints": [
            "Where do you look to determine expectedness in a clinical trial?",
            "Does 'mild rash' in the IB cover all skin reactions?"
          ],
          "relatedTerms": [
            "susar",
            "unexpected-ae",
            "investigator-brochure",
            "expectedness"
          ]
        },
        {
          "id": "step-3",
          "title": "The Reporting Timeline",
          "contentType": "info",
          "content": "You've correctly identified this as a SUSAR. The SAE form was received today (Wednesday) at 2:30 PM. The treating dermatologist has described the case as 'potentially life-threatening given >15% body surface area involvement and mucosal involvement.'",
          "question": "What is the reporting timeline for this SUSAR?",
          "options": [
            {
              "id": "A",
              "text": "15 calendar days from today - standard SUSAR timeline",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "7 calendar days from today - life-threatening SUSAR",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "24 hours - this is an immediately reportable event",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "7 calendar days, but only to the authority where the trial site is located",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Life-threatening SUSARs require 7-day initial reporting to all relevant regulatory authorities.",
              "points": [
                {
                  "label": "Day 0",
                  "detail": "Wednesday (today) - when sponsor received the SAE form",
                  "status": "met"
                },
                {
                  "label": "Classification",
                  "detail": "Life-threatening SUSAR",
                  "status": "met"
                },
                {
                  "label": "Deadline",
                  "detail": "Next Wednesday - initial report due within 7 calendar days",
                  "status": "info"
                },
                {
                  "label": "Follow-up",
                  "detail": "Complete information due within 8 additional days (15 total)",
                  "status": "info"
                }
              ],
              "inspectorTip": "For multinational trials, SUSARs must be reported to regulatory authorities in ALL countries where the trial is conducted, plus Ethics Committees/IRBs."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "15 days applies to serious unexpected reactions that are NOT fatal or life-threatening. This has been assessed as life-threatening."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "The standard ICH timeline for life-threatening SUSARs is 7 calendar days for the initial report."
            },
            "D": {
              "title": "Partially correct timeline, wrong scope",
              "explanation": "7 days is correct, but SUSARs must be reported to ALL countries where the trial is being conducted."
            }
          },
          "hints": [
            "What determines whether a SUSAR gets 7-day or 15-day reporting?",
            "Who needs to receive SUSAR reports in a multinational trial?"
          ],
          "relatedTerms": [
            "susar",
            "seven-day-report",
            "fifteen-day-report",
            "day-zero",
            "expedited-reporting"
          ]
        }
      ],
      "debrief": {
        "summary": "You've processed a clinical trial SAE through unblinding, SUSAR classification, and reporting timeline determination.",
        "keyTakeaways": [
          "Unblinding is the first critical step for SAEs in blinded trials",
          "SUSAR = Serious + Unexpected (vs IB) + Suspected relationship",
          "Never pressure investigators to change their causality assessment",
          "Expectedness in trials is assessed against the IB, not the SmPC",
          "'Mild rash' does not equal SJS",
          "Life-threatening SUSARs: 7-day initial report to ALL countries in the trial"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "reporting-002",
      "title": "The Follow-Up Dilemma",
      "category": "reporting",
      "categoryName": "Regulatory Reporting",
      "difficulty": "intermediate",
      "icon": "üìù",
      "estimatedTime": "6 min",
      "description": "Manage follow-up information and determine when new reports are needed",
      "learningObjectives": [
        "Determine when follow-up information triggers a new expedited report",
        "Understand what constitutes significant new information",
        "Handle reclassification scenarios (non-serious to serious)"
      ],
      "briefing": {
        "role": "Drug Safety Case Processor",
        "context": "Several cases in your queue have received follow-up information. You need to determine how this new information affects each case's reporting requirements.",
        "task": "Assess the impact of follow-up information on reporting obligations."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Case 1: The Escalation",
          "contentType": "case",
          "content": "Original report (received 10 days ago): 65-year-old male developed mild rash after starting Dermaclear. Non-serious case processed in periodic reporting.\n\nFollow-up received today: The patient was hospitalized yesterday. The rash progressed to erythema multiforme with mucosal involvement. Dermaclear was discontinued.",
          "highlight": "Original: non-serious rash ‚Üí Follow-up: hospitalization for erythema multiforme",
          "question": "What action is required?",
          "options": [
            {
              "id": "A",
              "text": "Update the existing case with new information - no change to reporting",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "New Day 0 today - this is now a serious unexpected case requiring expedited reporting",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Original Day 0 still applies - case is now 10 days old, submit within 5 days",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Wait for discharge summary before reclassifying",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "When follow-up changes a case from non-serious to serious AND unexpected, a new Day 0 starts from when you received that information.",
              "points": [
                {
                  "label": "Reclassification",
                  "detail": "Non-serious ‚Üí Serious (hospitalization)",
                  "status": "info"
                },
                {
                  "label": "New Day 0",
                  "detail": "Today - when the upgrade information was received",
                  "status": "met"
                },
                {
                  "label": "Timeline",
                  "detail": "15 calendar days from today (serious + unexpected, non-fatal)",
                  "status": "info"
                },
                {
                  "label": "Key Principle",
                  "detail": "Significant new info that changes reporting requirements resets the clock",
                  "status": "info"
                }
              ],
              "inspectorTip": "Reclassification from non-serious to serious is a common inspection focus. Inspectors check: Was the reclassification timely? Was a new Day 0 correctly established?"
            },
            "A": {
              "title": "Not quite right",
              "explanation": "Simply updating isn't sufficient when seriousness classification changes. This now triggers expedited reporting obligations."
            },
            "C": {
              "title": "Common mistake",
              "explanation": "The original Day 0 does NOT apply. When follow-up makes a previously non-expedited case into an expedited one, a NEW Day 0 is established."
            },
            "D": {
              "title": "Dangerous delay",
              "explanation": "You have enough information to reclassify now. Hospitalization for erythema multiforme is clearly serious."
            }
          },
          "hints": [
            "What happens to reporting requirements when seriousness changes?",
            "Does Day 0 reset when significant new information is received?"
          ],
          "relatedTerms": [
            "follow-up-report",
            "day-zero",
            "serious-ae",
            "expedited-reporting"
          ]
        },
        {
          "id": "step-2",
          "title": "Case 2: The Outcome Update",
          "contentType": "case",
          "content": "Original report (submitted 20 days ago as 15-day expedited): 71-year-old female hospitalized for pneumonia while on immunosuppressant Suppressix. Outcome: 'Not recovered.'\n\nFollow-up received today: Patient recovered and was discharged. No change in seriousness, expectedness, or causality.",
          "question": "What follow-up action is required?",
          "options": [
            {
              "id": "A",
              "text": "Submit an expedited follow-up report within 15 days with the new outcome",
              "isCorrect": true
            },
            {
              "id": "B",
              "text": "No action needed - the initial expedited report was submitted on time",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Reclassify as non-serious since patient recovered",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Submit a new initial expedited report with the updated information",
              "isCorrect": false
            }
          ],
          "correctAnswer": "A",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Significant new information on previously expedited cases should be submitted as follow-up reports.",
              "points": [
                {
                  "label": "New Information",
                  "detail": "Outcome changed from 'Not recovered' to 'Recovered' with discharge details",
                  "status": "info"
                },
                {
                  "label": "Action Required",
                  "detail": "Follow-up expedited report within 15 days of receiving new info",
                  "status": "met"
                },
                {
                  "label": "Why It Matters",
                  "detail": "Outcome data informs benefit-risk assessment",
                  "status": "info"
                }
              ],
              "inspectorTip": "Follow-up reports should be submitted for any significant new information: outcome changes, new diagnosis, causality updates, additional medical history."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Your obligation doesn't end after the initial report. When significant new information becomes available, follow-up reports must be submitted."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "Recovery does NOT change seriousness classification. Seriousness is determined at the time of the event, not by the outcome."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "This is follow-up for an existing case, not a new case. Submit as a follow-up report linked to the original."
            }
          },
          "hints": [
            "Does your reporting obligation end after the initial expedited report?",
            "Is outcome information considered significant new information?"
          ],
          "relatedTerms": [
            "follow-up-report",
            "expedited-reporting",
            "case-processing"
          ]
        },
        {
          "id": "step-3",
          "title": "Case 3: The Duplicate Question",
          "contentType": "case",
          "content": "Your database has Case A: reported by Dr. Smith on Jan 5 - 45-year-old male, hepatotoxicity with Viralex.\n\nToday you receive a literature report: A 45-year-old male with hepatotoxicity attributed to Viralex, published in Journal of Hepatology. Corresponding author: Dr. Smith from the same institution.",
          "question": "How should you handle this literature report?",
          "options": [
            {
              "id": "A",
              "text": "Enter as a new case - literature reports are a separate source",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Discard it - we already have this case",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Flag as suspected duplicate, attempt to confirm, and if confirmed, merge as follow-up to Case A",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Enter as new case now, then merge later if confirmed as duplicate",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Suspected duplicates should be investigated before data entry to maintain database integrity.",
              "points": [
                {
                  "label": "Duplicate Indicators",
                  "detail": "Same reporter, demographics, product, event, timing",
                  "status": "met"
                },
                {
                  "label": "Confirmation Steps",
                  "detail": "Contact Dr. Smith to verify, or compare clinical details",
                  "status": "info"
                },
                {
                  "label": "If Confirmed",
                  "detail": "Merge literature details into Case A as follow-up",
                  "status": "info"
                },
                {
                  "label": "If Different Patient",
                  "detail": "Enter as new case with cross-reference",
                  "status": "info"
                }
              ],
              "inspectorTip": "Duplicate detection is a critical quality metric. Undetected duplicates can distort signal detection."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "Entering suspected duplicates inflates your database and can distort signal detection."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Never simply discard a report. The literature may contain additional clinical details not in the original report."
            },
            "D": {
              "title": "Not ideal",
              "explanation": "Entering as new before confirming creates temporary duplicates that can trigger unnecessary signal alerts."
            }
          },
          "hints": [
            "What indicators suggest these might be the same case?",
            "How should suspected duplicates be handled before entry?"
          ],
          "relatedTerms": [
            "duplicate-case",
            "literature-report",
            "case-processing",
            "follow-up-report"
          ]
        }
      ],
      "debrief": {
        "summary": "You've practiced handling follow-up information scenarios including case upgrades, outcome updates, and duplicate detection.",
        "keyTakeaways": [
          "Non-serious to serious reclassification creates a new Day 0 for expedited reporting",
          "Recovery does NOT change seriousness - it's assessed at time of event",
          "Significant follow-up info on expedited cases requires follow-up reports within 15 days",
          "Suspected duplicates should be investigated BEFORE database entry",
          "Literature reports may be duplicates of spontaneous reports - check systematically"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "reporting-003",
      "title": "The Global Reporting Puzzle",
      "category": "reporting",
      "categoryName": "Regulatory Reporting",
      "difficulty": "advanced",
      "icon": "üåç",
      "estimatedTime": "7 min",
      "description": "Navigate different reporting requirements across regulatory regions",
      "learningObjectives": [
        "Understand key differences between FDA, EMA, and PMDA reporting requirements",
        "Determine when region-specific rules override ICH harmonized standards",
        "Apply correct reporting timelines for different authorities"
      ],
      "briefing": {
        "role": "Global Drug Safety Lead",
        "context": "Your product Cardizol is marketed in the US, EU, and Japan. You need to ensure compliance with each region's reporting requirements.",
        "task": "Determine the correct reporting actions for cases affecting multiple regions."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Case 1: The Non-Serious Report",
          "contentType": "case",
          "content": "You receive a non-serious adverse event report from a US physician: 55-year-old patient developed mild headache while taking Cardizol. Headache is listed in all regional labeling. Non-serious and expected.",
          "question": "Which regions require reporting of this individual case?",
          "options": [
            {
              "id": "A",
              "text": "No individual reporting to any region - periodic reports only",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "FDA requires individual reporting of all US cases; EMA and PMDA only periodic",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "All three regions require individual case reporting",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Only report to the US where the event occurred",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "FDA has unique requirements for non-serious case reporting.",
              "points": [
                {
                  "label": "FDA (US)",
                  "detail": "Requires ALL domestic AE reports, including non-serious, via FAERS",
                  "status": "info"
                },
                {
                  "label": "EMA (EU)",
                  "detail": "Non-serious and serious expected go in PSUR only",
                  "status": "info"
                },
                {
                  "label": "PMDA (Japan)",
                  "detail": "Similar to EMA - expedited for serious unexpected; periodic for others",
                  "status": "info"
                },
                {
                  "label": "Key Distinction",
                  "detail": "FDA requires non-serious reports within specific timeframes",
                  "status": "met"
                }
              ],
              "inspectorTip": "Many companies get citations for not submitting non-serious US cases to FDA. Know your regional requirements."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "FDA requires individual submission of all AE reports received from US sources, including non-serious expected events."
            },
            "C": {
              "title": "Not quite right",
              "explanation": "EMA and PMDA don't require individual expedited reporting of non-serious expected cases."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "In global safety reporting, region of marketing matters, not just region of occurrence."
            }
          },
          "hints": [
            "How does FDA reporting differ from EMA/PMDA for non-serious cases?",
            "Does the FDA have a unique requirement for domestic AE reports?"
          ],
          "relatedTerms": [
            "periodic-reporting",
            "psur",
            "expedited-reporting",
            "fda",
            "ema"
          ]
        },
        {
          "id": "step-2",
          "title": "Case 2: The Worldwide Serious Case",
          "contentType": "case",
          "content": "A German physician reports a 62-year-old hospitalized with severe hepatotoxicity (liver failure) while on Cardizol. Mild liver enzyme elevation IS listed; liver failure is NOT. Cardizol is marketed in all three regions.",
          "question": "Which regions require expedited reporting?",
          "options": [
            {
              "id": "A",
              "text": "EMA only - event occurred in EU",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "EMA and PMDA only",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "All three regions - serious unexpected cases must be reported worldwide",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "EMA expedited, FDA and PMDA periodic",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Serious unexpected reactions must be reported expedited to all regions where the product is marketed.",
              "points": [
                {
                  "label": "FDA",
                  "detail": "15-day Alert Report for serious unexpected worldwide cases",
                  "status": "met"
                },
                {
                  "label": "EMA",
                  "detail": "15-day ICSR submission via EudraVigilance",
                  "status": "met"
                },
                {
                  "label": "PMDA",
                  "detail": "15-day report for serious unexpected foreign cases",
                  "status": "met"
                },
                {
                  "label": "Key Principle",
                  "detail": "Serious + unexpected = expedited to ALL marketed regions",
                  "status": "info"
                }
              ],
              "inspectorTip": "A common finding is late or missing foreign case reports. Ensure your global distribution process captures all marketed regions."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "Where the event occurred doesn't limit reporting obligations to other marketed regions."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "FDA also requires expedited reporting of serious unexpected cases worldwide."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "All three major regions require expedited reporting of serious unexpected cases."
            }
          },
          "hints": [
            "Does event location limit your reporting obligations?",
            "What is the general rule for serious unexpected cases across ICH regions?"
          ],
          "relatedTerms": [
            "expedited-reporting",
            "fifteen-day-report",
            "serious-ae",
            "unexpected-ae"
          ]
        },
        {
          "id": "step-3",
          "title": "Case 3: The Labeling Difference",
          "contentType": "case",
          "content": "Important: Angioedema IS listed in the EU SmPC for Cardizol (added 6 months ago) but is NOT listed in the US PI or Japan PI (updates pending).\n\nNew case: 48-year-old in Brazil experienced angioedema requiring hospitalization while taking Cardizol.",
          "question": "How does the labeling difference affect reporting?",
          "options": [
            {
              "id": "A",
              "text": "Expected for all regions - EU SmPC is the global reference",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Unexpected for all regions - use the most conservative assessment",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Expected for EU (in SmPC), unexpected for US and Japan (not in PI) - different reporting per region",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Cannot determine until pending label updates are approved",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct!",
              "explanation": "Expectedness is assessed against EACH region's own reference safety information.",
              "points": [
                {
                  "label": "EU Reporting",
                  "detail": "Serious EXPECTED - periodic reporting (angioedema in SmPC)",
                  "status": "info"
                },
                {
                  "label": "US Reporting",
                  "detail": "Serious UNEXPECTED - 15-day Alert Report",
                  "status": "met"
                },
                {
                  "label": "Japan Reporting",
                  "detail": "Serious UNEXPECTED - 15-day expedited report",
                  "status": "met"
                },
                {
                  "label": "Key Principle",
                  "detail": "Expectedness is region-specific based on local approved labeling",
                  "status": "info"
                }
              ],
              "inspectorTip": "When labels differ across regions, your safety database must track expectedness per region. This is a common source of compliance errors."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "There is no single global reference document. Each region uses its own approved labeling."
            },
            "B": {
              "title": "Close but not standard",
              "explanation": "The regulatory requirement is to assess per each region's own labeling. Over-reporting could be seen as a quality issue."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Assess against CURRENT approved labeling, not pending updates."
            }
          },
          "hints": [
            "Which document determines expectedness in each region?",
            "Can the same event be expected in one region and unexpected in another?"
          ],
          "relatedTerms": [
            "expectedness",
            "smpc",
            "rsi",
            "expedited-reporting",
            "periodic-reporting"
          ]
        }
      ],
      "debrief": {
        "summary": "You've navigated the complexities of global regulatory reporting across FDA, EMA, and PMDA requirements.",
        "keyTakeaways": [
          "FDA uniquely requires individual reporting of ALL domestic AE cases, including non-serious",
          "Serious unexpected cases must be reported expedited to ALL marketed regions worldwide",
          "Event location doesn't limit reporting obligations",
          "Expectedness is assessed per region against each region's own approved labeling",
          "Labeling differences create different reporting obligations for the same case",
          "Track regional labeling differences in your safety database"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "inspection-002",
      "title": "The Document Request",
      "category": "inspection",
      "categoryName": "Inspection Readiness",
      "difficulty": "intermediate",
      "icon": "üìÇ",
      "estimatedTime": "6 min",
      "description": "Handle inspector document requests and navigate common inspection scenarios",
      "learningObjectives": [
        "Respond appropriately to various inspector document requests",
        "Understand what documents should be readily accessible",
        "Manage situations where requested documents have issues"
      ],
      "briefing": {
        "role": "Quality Assurance Lead (PV)",
        "context": "Day 2 of an FDA inspection. The inspector has reviewed your PADER submissions and now wants to examine your internal processes more closely.",
        "task": "Respond appropriately to each document request and situation."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "The SOP Request",
          "contentType": "interview",
          "content": "Inspector: 'I'd like to see your current SOP for adverse event intake and processing. I'd also like to see the previous two versions and the change history showing what was modified and why.'",
          "metadata": {
            "inspector": "Dr. Rachel Torres",
            "role": "FDA Investigator",
            "demeanor": "Thorough, methodical"
          },
          "question": "What's the best way to handle this request?",
          "options": [
            {
              "id": "A",
              "text": "Provide current SOP immediately but explain previous versions may take time to retrieve",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Provide all three versions with change control documentation, organized chronologically",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Provide current SOP and offer a verbal summary of what changed",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Ask the inspector why they need previous versions",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Excellent preparation!",
              "explanation": "Having current and historical SOPs with change documentation readily available demonstrates strong document control.",
              "points": [
                {
                  "label": "What This Shows",
                  "detail": "Robust document management system with version control",
                  "status": "met"
                },
                {
                  "label": "What This Shows",
                  "detail": "Traceability of process changes with documented rationale",
                  "status": "met"
                },
                {
                  "label": "Best Practice",
                  "detail": "Pre-inspection prep should include pulling SOPs + change history",
                  "status": "info"
                }
              ],
              "inspectorTip": "Inspectors compare SOP versions to see if changes correlate with findings or CAPAs. Quick retrieval demonstrates inspection readiness."
            },
            "A": {
              "title": "Reflects poor preparation",
              "explanation": "Previous versions should be readily accessible. Needing extra time suggests weak document management."
            },
            "C": {
              "title": "Insufficient",
              "explanation": "Inspectors want to SEE the documents, not hear about them."
            },
            "D": {
              "title": "Never question inspector requests",
              "explanation": "It appears defensive and can escalate the inspection."
            }
          },
          "hints": [
            "What level of document control demonstrates good quality systems?",
            "Should historical versions be readily available during inspections?"
          ],
          "relatedTerms": [
            "sop",
            "inspection-readiness",
            "pv-inspection",
            "quality-control"
          ]
        },
        {
          "id": "step-2",
          "title": "The Missing Training Record",
          "contentType": "interview",
          "content": "Inspector: 'I see Janet Williams joined 4 months ago as Case Processor. Can I see her training records and competency assessment?'\n\nYou find Janet's training was completed, but the competency assessment form was never signed by her supervisor. Janet HAS been processing cases independently for 3 months.",
          "question": "How do you handle this situation?",
          "options": [
            {
              "id": "A",
              "text": "Show training records and quickly get the supervisor to sign the assessment",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Tell the inspector Janet was trained, the signature is just an administrative oversight",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Acknowledge the documentation gap, show what training was completed, explain corrective actions",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Show only completed training records without mentioning the missing assessment",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct - honesty is always the right approach!",
              "explanation": "Acknowledging gaps openly builds more credibility than trying to hide or minimize them.",
              "points": [
                {
                  "label": "Why Transparency Works",
                  "detail": "Inspectors will likely discover the gap anyway - being proactive shows integrity",
                  "status": "met"
                },
                {
                  "label": "Recommended Response",
                  "detail": "1) Show completed training, 2) Acknowledge missing signature, 3) Explain corrective action",
                  "status": "info"
                },
                {
                  "label": "Potential Impact",
                  "detail": "May result in an observation, but covering it up could be much more serious",
                  "status": "warning"
                }
              ],
              "inspectorTip": "Fabricating or backdating documentation during an inspection is a serious regulatory offense. NEVER alter documents during an inspection."
            },
            "A": {
              "title": "This is document fabrication!",
              "explanation": "Getting a supervisor to sign NOW for something that should have been done 3 months ago is backdating. If discovered, this could result in criminal charges."
            },
            "B": {
              "title": "Minimizing won't work",
              "explanation": "A missing competency assessment means there's no evidence Janet was qualified before handling cases."
            },
            "D": {
              "title": "Risky and dishonest",
              "explanation": "Withholding information from inspectors is a serious offense."
            }
          },
          "hints": [
            "What's the worst outcome of trying to hide a documentation gap?",
            "How do inspectors respond to transparent vs. evasive behavior?"
          ],
          "relatedTerms": [
            "pv-inspection",
            "inspection-finding",
            "capa",
            "quality-control"
          ]
        },
        {
          "id": "step-3",
          "title": "The Case Selection",
          "contentType": "interview",
          "content": "Inspector: 'I'd like 15 cases for detailed review.'\n\nYou notice 3 of 15 are your most problematic cases - one late submission, one data entry error (corrected), one reclassified from non-serious to serious.\n\nYour manager whispers: 'Maybe offer to pull files tomorrow to review them first.'",
          "question": "How should you respond?",
          "options": [
            {
              "id": "A",
              "text": "Agree with manager - overnight review is standard practice",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Provide all 15 case files immediately",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Provide 12 now, say 3 are with another department",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Provide files but preemptively explain the issues with those 3 cases",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct - provide files immediately!",
              "explanation": "Prompt document provision is expected. Delays for internal review are transparent and counterproductive.",
              "points": [
                {
                  "label": "Why Immediate",
                  "detail": "Stalling is obvious and creates suspicion",
                  "status": "met"
                },
                {
                  "label": "The Problem Cases",
                  "detail": "If properly documented (deviations, CAPAs), they demonstrate a functioning quality system",
                  "status": "info"
                },
                {
                  "label": "Silver Lining",
                  "detail": "A late submission WITH a documented deviation/CAPA is better than one without",
                  "status": "info"
                }
              ],
              "inspectorTip": "Inspectors often deliberately select cases they suspect have issues. Attempting to delay confirms their suspicions."
            },
            "A": {
              "title": "Suspicious",
              "explanation": "Requesting overnight to 'prepare' files is a red flag suggesting you have something to hide."
            },
            "C": {
              "title": "Dishonest",
              "explanation": "Claiming files are unavailable when they're not is misrepresentation to a federal inspector."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Don't preemptively disclose issues not yet asked about. Provide files and answer questions as they come."
            }
          },
          "hints": [
            "What do delays communicate to an experienced inspector?",
            "If those 3 cases have proper documentation of issues and corrections, are they actually a problem?"
          ],
          "relatedTerms": [
            "pv-inspection",
            "inspection-readiness",
            "deviation",
            "capa"
          ]
        }
      ],
      "debrief": {
        "summary": "You've practiced handling document requests during regulatory inspections, learning that transparency and preparation always produce better outcomes.",
        "keyTakeaways": [
          "Keep current + historical SOPs with change documentation readily accessible",
          "NEVER fabricate, backdate, or alter documents during an inspection",
          "Acknowledge documentation gaps honestly - cover-ups are always worse",
          "Provide requested documents promptly - delays raise suspicion",
          "Problem cases with proper documentation demonstrate quality system effectiveness",
          "Don't preemptively explain issues - answer questions as asked"
        ],
        "passingScore": 2
      }
    },
    {
      "id": "assessment-004",
      "title": "Signal Detection Basics",
      "category": "case-assessment",
      "categoryName": "Case Assessment",
      "difficulty": "advanced",
      "icon": "üìä",
      "estimatedTime": "8 min",
      "description": "Recognize patterns that may indicate emerging safety signals",
      "learningObjectives": [
        "Understand what constitutes a safety signal",
        "Recognize patterns in case series that warrant investigation",
        "Distinguish between true signals and background noise"
      ],
      "briefing": {
        "role": "Signal Detection Lead",
        "context": "Your quarterly signal detection review is due. You're analyzing data from your safety database for Cardizol (antihypertensive, marketed 3 years, ~500,000 patient-years exposure).",
        "task": "Evaluate each data pattern and determine if signal investigation is warranted."
      },
      "steps": [
        {
          "id": "step-1",
          "title": "Pattern 1: The Frequency Shift",
          "contentType": "case",
          "content": "Disproportionality analysis for 'tendon rupture' with Cardizol:\n\nPRR (Proportional Reporting Ratio): 3.8 (threshold: >2.0)\nReporting Rate: Q1: 2 cases, Q2: 3 cases, Q3: 8 cases, Q4: 12 cases\nTotal cases: 25\nTendon rupture is NOT in Cardizol labeling.\nBackground incidence: ~3 per 100,000 per year.",
          "highlight": "PRR 3.8, accelerating case count, unlisted event",
          "question": "Does this pattern warrant signal investigation?",
          "options": [
            {
              "id": "A",
              "text": "No - 25 cases out of 500,000 patient-years is very low",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "No - tendon rupture occurs in the general population, could be coincidence",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Yes - PRR above threshold, accelerating trend, and unlisted event justify investigation",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Maybe - need at least 50 cases before investigating",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Correct - this warrants investigation!",
              "explanation": "Multiple indicators align to support signal investigation.",
              "points": [
                {
                  "label": "Statistical Signal",
                  "detail": "PRR 3.8 exceeds threshold of 2.0",
                  "status": "met"
                },
                {
                  "label": "Temporal Trend",
                  "detail": "Accelerating from 2‚Üí3‚Üí8‚Üí12 per quarter",
                  "status": "met"
                },
                {
                  "label": "Unlisted Event",
                  "detail": "Not in current labeling - potential new safety finding",
                  "status": "met"
                },
                {
                  "label": "Clinical Plausibility",
                  "detail": "Should investigate mechanism",
                  "status": "info"
                }
              ],
              "inspectorTip": "Signal detection should use multiple methods: disproportionality analysis, temporal trends, clinical review, and case-level assessment."
            },
            "A": {
              "title": "Not quite right",
              "explanation": "Absolute count alone doesn't determine signal existence. PRR of 3.8 means tendon rupture is reported 3.8x more frequently than expected."
            },
            "B": {
              "title": "Not quite right",
              "explanation": "Background incidence doesn't negate a signal. The question is whether Cardizol INCREASES the risk."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "No minimum case threshold for investigation. Signals can be detected from few cases if other indicators are strong."
            }
          },
          "hints": [
            "Consider all data points together - statistical, temporal, and clinical",
            "What does a PRR above threshold tell you?"
          ],
          "relatedTerms": [
            "safety-signal",
            "disproportionality-analysis",
            "prr"
          ]
        },
        {
          "id": "step-2",
          "title": "Pattern 2: The Cluster",
          "contentType": "case",
          "content": "In 2 weeks, 4 reports of rhabdomyolysis with Cardizol. All four patients:\n- Also taking a statin (simvastatin or atorvastatin)\n- Event within 2-4 weeks of starting Cardizol\n- Over 65 years old\n- Had mild renal impairment\n\nRhabdomyolysis is NOT listed for Cardizol but IS a known rare statin adverse event.",
          "question": "How should you evaluate this cluster?",
          "options": [
            {
              "id": "A",
              "text": "Not a Cardizol signal - caused by statins",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Definite Cardizol signal - 4 cases in 2 weeks is clearly drug-related",
              "isCorrect": false
            },
            {
              "id": "C",
              "text": "Potential interaction signal - investigate whether Cardizol increases rhabdomyolysis risk with statins",
              "isCorrect": true
            },
            {
              "id": "D",
              "text": "Insufficient data - need more cases",
              "isCorrect": false
            }
          ],
          "correctAnswer": "C",
          "feedback": {
            "correct": {
              "title": "Excellent clinical reasoning!",
              "explanation": "The pattern suggests a potential drug-drug interaction.",
              "points": [
                {
                  "label": "Common Factor",
                  "detail": "All on statins + Cardizol - interaction hypothesis",
                  "status": "met"
                },
                {
                  "label": "Mechanism to Investigate",
                  "detail": "Could Cardizol inhibit statin metabolism (CYP3A4)?",
                  "status": "info"
                },
                {
                  "label": "Risk Factors",
                  "detail": "Age >65 and renal impairment increase vulnerability",
                  "status": "info"
                },
                {
                  "label": "Action Required",
                  "detail": "Drug interaction study, PK analysis, label assessment",
                  "status": "info"
                }
              ],
              "inspectorTip": "Signal detection isn't just single drug-event pairs. Drug-drug interactions, specific populations, and risk factor combinations are equally important."
            },
            "A": {
              "title": "Too dismissive",
              "explanation": "The cluster occurring after adding Cardizol suggests a potential interaction."
            },
            "B": {
              "title": "Too definitive",
              "explanation": "Four cases don't prove causation, but the pattern warrants investigation."
            },
            "D": {
              "title": "Not quite right",
              "explanation": "Four cases with a consistent pattern is enough to investigate."
            }
          },
          "hints": [
            "What do all four cases have in common besides Cardizol?",
            "Could the pattern suggest something other than a direct drug effect?"
          ],
          "relatedTerms": [
            "safety-signal",
            "drug-interaction",
            "causality-assessment"
          ]
        },
        {
          "id": "step-3",
          "title": "Pattern 3: The Publication Alert",
          "contentType": "case",
          "content": "A Lancet meta-analysis (12 RCTs, N=45,000) concludes: patients receiving ACE inhibitors in Cardizol's class show increased pancreatic cancer risk (HR 1.34, 95% CI 1.12-1.61, p=0.002) with ‚â•5 years exposure.\n\nYour database: 8 pancreatic cancer cases with Cardizol, none previously flagged. Product marketed 3 years.",
          "question": "What should you do with this information?",
          "options": [
            {
              "id": "A",
              "text": "No action - your product has only 3 years of data, study describes ‚â•5 year risk",
              "isCorrect": false
            },
            {
              "id": "B",
              "text": "Initiate a formal signal assessment combining the publication with your post-market data",
              "isCorrect": true
            },
            {
              "id": "C",
              "text": "Wait for regulatory authority request - this is a class-level finding",
              "isCorrect": false
            },
            {
              "id": "D",
              "text": "Add pancreatic cancer to labeling immediately as precaution",
              "isCorrect": false
            }
          ],
          "correctAnswer": "B",
          "feedback": {
            "correct": {
              "title": "Correct approach!",
              "explanation": "Published evidence combined with your own data should trigger a comprehensive signal assessment.",
              "points": [
                {
                  "label": "Literature Evidence",
                  "detail": "Large meta-analysis with statistically significant class finding",
                  "status": "info"
                },
                {
                  "label": "Your Data",
                  "detail": "8 cases - need to assess in context of new hypothesis",
                  "status": "info"
                },
                {
                  "label": "Assessment Plan",
                  "detail": "Review cases, calculate expected vs observed, assess class relevance",
                  "status": "info"
                },
                {
                  "label": "Timeline",
                  "detail": "Begin promptly - don't wait for regulatory query",
                  "status": "met"
                }
              ],
              "inspectorTip": "Proactive signal management based on literature demonstrates scientific rigor. Regulators expect MAHs to monitor and act on published evidence."
            },
            "A": {
              "title": "Too passive",
              "explanation": "The 5-year latency is relevant even with 3 years of data. Your 8 cases may represent early signals."
            },
            "C": {
              "title": "Unacceptable passivity",
              "explanation": "MAHs are expected to proactively assess signals. Waiting for regulatory requests is unacceptable."
            },
            "D": {
              "title": "Premature",
              "explanation": "A class-level finding needs product-specific evaluation before label changes."
            }
          },
          "hints": [
            "Should MAHs wait for regulators to point out safety concerns?",
            "What combination of evidence sources informs signal assessment?"
          ],
          "relatedTerms": [
            "safety-signal",
            "literature-report",
            "benefit-risk"
          ]
        }
      ],
      "debrief": {
        "summary": "You've practiced evaluating potential safety signals using statistical data, clinical patterns, and published literature.",
        "keyTakeaways": [
          "Signal detection uses multiple methods: disproportionality, temporal trends, clinical patterns",
          "No single metric or minimum case count defines a signal - evaluate holistically",
          "Drug-drug interactions and specific populations are important signal types",
          "Published literature demands proactive assessment, not passive waiting",
          "MAHs must be proactive in signal detection",
          "Signal ‚â† confirmed risk - signals warrant investigation, not immediate labeling changes"
        ],
        "passingScore": 2
      }
    }
  ]
};
    </script>
    <script>
        /**
 * PV Glossary Application
 * Interactive Pharmacovigilance Terminology Reference
 */

const PVGlossary = {
    data: null,
    scenarios: null,
    state: {
        currentView: 'welcome',
        currentCategory: null,
        currentTerm: null,
        searchQuery: '',
        navigationHistory: [],
        quizState: null,
        scenarioState: null
    },
    storage: {
        bookmarks: [],
        learned: [],
        recentTerms: [],
        quizStats: { total: 0, correct: 0 },
        termStats: {},
        scenarioProgress: {}
    },

    init() {
        this.data = GLOSSARY_DATA;
        this.scenarios = SCENARIOS_DATA;
        this.loadStorage();
        this.initTheme();
        this.renderCategories();
        this.renderWelcome();
        this.bindEvents();
        this.updateProgress();
        this.updateFooter();
    },

    // Storage Management
    loadStorage() {
        try {
            const saved = localStorage.getItem('pvGlossaryData');
            if (saved) {
                const parsed = JSON.parse(saved);
                this.storage = { ...this.storage, ...parsed };
            }
        } catch (e) { console.log('Storage load error:', e); }
    },

    saveStorage() {
        try {
            localStorage.setItem('pvGlossaryData', JSON.stringify(this.storage));
        } catch (e) { console.log('Storage save error:', e); }
    },

    // Event Bindings
    bindEvents() {
        const searchInput = document.getElementById('searchInput');
        const clearBtn = document.getElementById('clearSearch');
        
        searchInput.addEventListener('input', (e) => this.handleSearch(e.target.value));
        searchInput.addEventListener('keydown', (e) => {
            if (e.key === 'Escape') this.clearSearch();
        });
        
        clearBtn.addEventListener('click', () => this.clearSearch());
        
        document.getElementById('scenarioModeBtn').addEventListener('click', () => this.showScenarioLibrary());
        document.getElementById('quizModeBtn').addEventListener('click', () => this.startQuiz());
        document.getElementById('bookmarksBtn').addEventListener('click', () => this.showBookmarks());
        document.getElementById('statsBtn').addEventListener('click', () => this.showStats());
        document.getElementById('toggleSidebar').addEventListener('click', () => this.toggleSidebar());
        
        document.getElementById('bookmarkBtn').addEventListener('click', () => this.toggleBookmark());
        document.getElementById('learnedBtn').addEventListener('click', () => this.toggleLearned());
        document.getElementById('shareBtn').addEventListener('click', () => this.shareTerm());
        document.getElementById('printTermBtn').addEventListener('click', () => this.printTerm());
        document.getElementById('themeToggleBtn').addEventListener('click', () => this.toggleTheme());
        
        // Mobile menu
        document.getElementById('mobileMenuBtn').addEventListener('click', () => this.toggleMobileMenu());
        document.addEventListener('click', (e) => {
            const menu = document.getElementById('mobileMenu');
            const btn = document.getElementById('mobileMenuBtn');
            if (menu.classList.contains('open') && !menu.contains(e.target) && e.target !== btn) {
                menu.classList.remove('open');
            }
        });

        // Handle browser back button
        window.addEventListener('popstate', (e) => {
            if (e.state) this.restoreState(e.state);
        });
        
        // Keyboard shortcuts
        document.addEventListener('keydown', (e) => {
            if (e.ctrlKey && e.key === 'k') {
                e.preventDefault();
                searchInput.focus();
            }
            // Escape closes mobile menu
            if (e.key === 'Escape') {
                const menu = document.getElementById('mobileMenu');
                if (menu.classList.contains('open')) {
                    menu.classList.remove('open');
                    document.getElementById('mobileMenuBtn').focus();
                }
            }
        });
    },

    // Navigation
    showView(viewId) {
        document.querySelectorAll('.view').forEach(v => v.classList.remove('active'));
        const view = document.getElementById(viewId);
        view.classList.add('active');
        this.state.currentView = viewId;

        // Focus management: move focus to the first heading in the new view
        requestAnimationFrame(() => {
            const heading = view.querySelector('h2, h1');
            if (heading) {
                heading.setAttribute('tabindex', '-1');
                heading.focus();
            }
        });
    },

    // Screen reader announcement
    announce(message) {
        const el = document.getElementById('srAnnounce');
        if (el) {
            el.textContent = '';
            requestAnimationFrame(() => { el.textContent = message; });
        }
    },

    showWelcome() {
        this.state.currentCategory = null;
        this.state.currentTerm = null;
        this.showView('welcomeView');
        this.updateCategoryHighlight(null);
        this.renderRecentTerms();
    },

    // Mobile Menu
    toggleMobileMenu() {
        document.getElementById('mobileMenu').classList.toggle('open');
    },

    mobileMenuAction(action) {
        document.getElementById('mobileMenu').classList.remove('open');
        switch (action) {
            case 'scenarios': this.showScenarioLibrary(); break;
            case 'quiz': this.startQuiz(); break;
            case 'bookmarks': this.showBookmarks(); break;
            case 'stats': this.showStats(); break;
            case 'random': this.showRandomTerm(); break;
            case 'theme': this.toggleTheme(); break;
        }
    },

    // Theme Management
    initTheme() {
        const saved = localStorage.getItem('pvGlossaryTheme');
        if (saved) {
            this._setTheme(saved);
        } else if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
            this._setTheme('dark');
        } else {
            this._setTheme('light');
        }

        // Listen for OS theme changes
        window.matchMedia('(prefers-color-scheme: dark)').addEventListener('change', (e) => {
            if (!localStorage.getItem('pvGlossaryTheme')) {
                this._setTheme(e.matches ? 'dark' : 'light');
            }
        });
    },

    toggleTheme() {
        const current = document.documentElement.getAttribute('data-theme');
        const next = current === 'dark' ? 'light' : 'dark';
        localStorage.setItem('pvGlossaryTheme', next);
        this._setTheme(next);
    },

    _setTheme(theme) {
        document.documentElement.setAttribute('data-theme', theme);
        const isDark = theme === 'dark';

        // Update header toggle button
        const toggleBtn = document.getElementById('themeToggleBtn');
        if (toggleBtn) toggleBtn.textContent = isDark ? '‚òÄÔ∏è' : 'üåô';

        // Update mobile menu button
        const mobileBtn = document.getElementById('mobileThemeBtn');
        if (mobileBtn) mobileBtn.textContent = isDark ? '‚òÄÔ∏è Light Mode' : 'üåô Dark Mode';
    },

    pushState(state) {
        history.pushState(state, '', '');
        this.state.navigationHistory.push(state);
    },

    restoreState(state) {
        if (state.view === 'term' && state.termId) {
            this.showTerm(state.termId, false);
        } else if (state.view === 'category' && state.categoryId) {
            this.showCategory(state.categoryId, false);
        } else {
            this.showWelcome();
        }
    },

    // Render Categories Sidebar
    renderCategories() {
        const nav = document.getElementById('categoryNav');
        nav.innerHTML = this.data.categories.map(cat => `
            <div class="category-item" data-category="${cat.id}" role="button" tabindex="0" 
                 aria-label="${cat.name}, ${cat.termCount} terms"
                 onclick="PVGlossary.showCategory('${cat.id}')"
                 onkeydown="PVGlossary._handleKeyActivate(event, () => PVGlossary.showCategory('${cat.id}'))">
                <span class="category-icon" aria-hidden="true">${cat.icon}</span>
                <span class="category-name">${cat.name}</span>
                <span class="category-count">${cat.termCount}</span>
            </div>
        `).join('');
    },

    updateCategoryHighlight(categoryId) {
        document.querySelectorAll('.category-item').forEach(item => {
            item.classList.toggle('active', item.dataset.category === categoryId);
        });
    },

    // Welcome View
    renderWelcome() {
        const stats = document.getElementById('quickStats');
        stats.innerHTML = `
            <div class="stat-card">
                <div class="stat-value">${this.data.metadata.totalTerms}</div>
                <div class="stat-label">Total Terms</div>
            </div>
            <div class="stat-card">
                <div class="stat-value">${this.data.categories.length}</div>
                <div class="stat-label">Categories</div>
            </div>
            <div class="stat-card">
                <div class="stat-value">${this.storage.learned.length}</div>
                <div class="stat-label">Learned</div>
            </div>
            <div class="stat-card">
                <div class="stat-value">${this.storage.bookmarks.length}</div>
                <div class="stat-label">Bookmarked</div>
            </div>
        `;
        this.renderRecentTerms();
    },

    renderRecentTerms() {
        const container = document.getElementById('recentTerms');
        if (this.storage.recentTerms.length === 0) {
            container.innerHTML = '<p class="empty-state">No recently viewed terms</p>';
            return;
        }
        container.innerHTML = this.storage.recentTerms.slice(0, 10).map(id => {
            const term = this.data.terms[id];
            return term ? `<span class="recent-term-chip" onclick="PVGlossary.showTerm('${id}')">${term.term}</span>` : '';
        }).join('');
    },

    // Category View
    showCategory(categoryId, pushHistory = true) {
        const category = this.data.categories.find(c => c.id === categoryId);
        if (!category) return;

        this.state.currentCategory = categoryId;
        this.updateCategoryHighlight(categoryId);
        
        document.getElementById('categoryTitle').textContent = category.name;
        document.getElementById('categoryDescription').textContent = category.description;
        
        const terms = Object.values(this.data.terms).filter(t => t.categoryId === categoryId);
        const termsList = document.getElementById('termsList');
        
        termsList.innerHTML = terms.map(term => this.renderTermCard(term)).join('');
        
        this.showView('categoryView');
        
        if (pushHistory) {
            this.pushState({ view: 'category', categoryId });
        }
    },

    renderTermCard(term) {
        const isLearned = this.storage.learned.includes(term.id);
        const tags = term.tags ? term.tags.slice(0, 3).map(t => `<span class="term-tag">${t}</span>`).join('') : '';
        
        return `
            <div class="term-card ${isLearned ? 'learned' : ''}" role="button" tabindex="0"
                 aria-label="${term.term}${term.acronym ? ', ' + term.acronym : ''}${isLearned ? ', learned' : ''}"
                 onclick="PVGlossary.showTerm('${term.id}')"
                 onkeydown="PVGlossary._handleKeyActivate(event, () => PVGlossary.showTerm('${term.id}'))">
                <div class="term-card-header">
                    <h3>${term.term}</h3>
                    ${term.acronym ? `<span class="term-acronym">${term.acronym}</span>` : ''}
                </div>
                <p>${term.definition}</p>
                ${tags ? `<div class="term-card-footer">${tags}</div>` : ''}
            </div>
        `;
    },

    // Term Detail View
    showTerm(termId, pushHistory = true) {
        const term = this.data.terms[termId];
        if (!term) return;

        this.state.currentTerm = termId;
        this.addToRecent(termId);
        
        // Update back button
        const backBtn = document.getElementById('termBackBtn');
        if (this.state.currentCategory) {
            backBtn.textContent = '‚Üê Back to Category';
            backBtn.onclick = () => this.showCategory(this.state.currentCategory);
        } else {
            backBtn.textContent = '‚Üê Back';
            backBtn.onclick = () => this.showWelcome();
        }
        
        // Update action buttons
        this.updateTermActions();
        
        // Render term detail
        const detail = document.getElementById('termDetail');
        detail.innerHTML = `
            <div class="term-detail-header">
                <h1>${term.term}${term.acronym ? `<span class="acronym-badge">${term.acronym}</span>` : ''}</h1>
                <div class="term-category-badge">${term.categoryName}</div>
            </div>
            
            <div class="term-section">
                <h2><span class="term-section-icon">üìñ</span> Definition</h2>
                <p>${term.definition}</p>
            </div>
            
            ${term.regulatorySource ? `
                <div class="term-section">
                    <h2><span class="term-section-icon">üìã</span> Regulatory Source</h2>
                    <p>${term.regulatorySource}</p>
                </div>
            ` : ''}
            
            ${term.example ? `
                <div class="term-section">
                    <h2><span class="term-section-icon">üí°</span> Real-World Example</h2>
                    <div class="example-box">${term.example}</div>
                </div>
            ` : ''}
            
            ${term.commonMistakes ? `
                <div class="term-section">
                    <h2><span class="term-section-icon">‚ö†Ô∏è</span> Common Mistakes</h2>
                    <div class="mistake-box">${term.commonMistakes}</div>
                </div>
            ` : ''}
            
            ${term.inspectorQuestion ? `
                <div class="term-section">
                    <h2><span class="term-section-icon">üîç</span> What an Inspector Might Ask</h2>
                    <div class="inspector-box">${term.inspectorQuestion}</div>
                </div>
            ` : ''}
            
            ${term.relatedTerms && term.relatedTerms.length > 0 ? `
                <div class="term-section">
                    <h2><span class="term-section-icon">üîó</span> Related Terms</h2>
                    <div class="related-terms">
                        ${term.relatedTerms.map(rt => {
                            const related = this.data.terms[rt];
                            return related ? `<span class="related-term" onclick="PVGlossary.showTerm('${rt}')">${related.term}</span>` : '';
                        }).join('')}
                    </div>
                </div>
            ` : ''}
        `;
        
        this.showView('termView');
        
        if (pushHistory) {
            this.pushState({ view: 'term', termId });
        }
    },

    updateTermActions() {
        const isBookmarked = this.storage.bookmarks.includes(this.state.currentTerm);
        const isLearned = this.storage.learned.includes(this.state.currentTerm);
        
        document.getElementById('bookmarkBtn').textContent = isBookmarked ? '‚òÖ' : '‚òÜ';
        document.getElementById('bookmarkBtn').classList.toggle('active', isBookmarked);
        document.getElementById('learnedBtn').classList.toggle('active', isLearned);
    },

    addToRecent(termId) {
        this.storage.recentTerms = this.storage.recentTerms.filter(id => id !== termId);
        this.storage.recentTerms.unshift(termId);
        this.storage.recentTerms = this.storage.recentTerms.slice(0, 20);
        this.saveStorage();
    },

    toggleBookmark() {
        const termId = this.state.currentTerm;
        if (!termId) return;
        
        const idx = this.storage.bookmarks.indexOf(termId);
        if (idx === -1) {
            this.storage.bookmarks.push(termId);
            this.announce('Term bookmarked');
        } else {
            this.storage.bookmarks.splice(idx, 1);
            this.announce('Bookmark removed');
        }
        this.saveStorage();
        this.updateTermActions();
        this.renderWelcome();
    },

    toggleLearned() {
        const termId = this.state.currentTerm;
        if (!termId) return;
        
        const idx = this.storage.learned.indexOf(termId);
        if (idx === -1) {
            this.storage.learned.push(termId);
            this.announce('Term marked as learned');
        } else {
            this.storage.learned.splice(idx, 1);
            this.announce('Learned mark removed');
        }
        this.saveStorage();
        this.updateTermActions();
        this.updateProgress();
        this.renderWelcome();
    },

    shareTerm() {
        const term = this.data.terms[this.state.currentTerm];
        if (!term) return;
        
        const text = `${term.term}: ${term.definition}`;
        navigator.clipboard.writeText(text).then(() => {
            alert('Term copied to clipboard!');
        });
    },

    // Print & Export
    printTerm() {
        window.print();
    },

    exportBookmarks(format) {
        if (this.storage.bookmarks.length === 0) {
            alert('No bookmarked terms to export.');
            return;
        }

        const terms = this.storage.bookmarks
            .map(id => this.data.terms[id])
            .filter(Boolean);

        const dateStr = new Date().toLocaleDateString('en-US', { 
            year: 'numeric', month: 'long', day: 'numeric' 
        });

        const html = `<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>PV Glossary - Study Sheet</title>
    <style>
        * { box-sizing: border-box; margin: 0; padding: 0; }
        body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif; color: #1f2937; line-height: 1.6; padding: 40px; max-width: 800px; margin: 0 auto; }
        h1 { font-size: 20pt; margin-bottom: 4px; }
        .subtitle { color: #6b7280; font-size: 10pt; margin-bottom: 24px; padding-bottom: 12px; border-bottom: 2px solid #1f2937; }
        .term { page-break-inside: avoid; margin-bottom: 24px; padding-bottom: 20px; border-bottom: 1px solid #e5e7eb; }
        .term:last-child { border-bottom: none; }
        .term h2 { font-size: 14pt; color: #1f2937; margin-bottom: 2px; }
        .term .acronym { display: inline-block; background: #2563eb; color: white; padding: 1px 8px; border-radius: 3px; font-size: 9pt; font-weight: 600; margin-left: 8px; vertical-align: middle; }
        .term .category { font-size: 9pt; color: #6b7280; margin-bottom: 8px; }
        .section { margin-bottom: 10px; }
        .section-label { font-size: 8pt; text-transform: uppercase; letter-spacing: 0.5px; color: #6b7280; font-weight: 600; margin-bottom: 2px; }
        .section p { font-size: 10pt; }
        .highlight-box { padding: 8px 12px; border-radius: 4px; font-size: 10pt; margin-top: 4px; }
        .example { background: #f0fdf4; border-left: 3px solid #059669; }
        .mistakes { background: #fef2f2; border-left: 3px solid #dc2626; }
        .inspector { background: #fffbeb; border-left: 3px solid #f59e0b; }
        .reg-source { font-size: 9pt; color: #4b5563; font-style: italic; }
        @media print { body { padding: 20px; } }
    </style>
</head>
<body>
    <h1>PV Glossary ‚Äî Study Sheet</h1>
    <div class="subtitle">${terms.length} bookmarked terms ‚Ä¢ Generated ${dateStr} ‚Ä¢</div>
    ${terms.map(term => `
    <div class="term">
        <h2>${term.term}${term.acronym ? `<span class="acronym">${term.acronym}</span>` : ''}</h2>
        <div class="category">${term.categoryName}</div>
        <div class="section">
            <div class="section-label">Definition</div>
            <p>${term.definition}</p>
        </div>
        ${term.regulatorySource ? `<div class="reg-source">Source: ${term.regulatorySource}</div>` : ''}
        ${term.example ? `
        <div class="section">
            <div class="section-label">Real-World Example</div>
            <div class="highlight-box example">${term.example}</div>
        </div>` : ''}
        ${term.commonMistakes ? `
        <div class="section">
            <div class="section-label">Common Mistakes</div>
            <div class="highlight-box mistakes">${term.commonMistakes}</div>
        </div>` : ''}
        ${term.inspectorQuestion ? `
        <div class="section">
            <div class="section-label">Inspector Question</div>
            <div class="highlight-box inspector">${term.inspectorQuestion}</div>
        </div>` : ''}
    </div>`).join('\n')}
</body>
</html>`;

        if (format === 'print') {
            const printWindow = window.open('', '_blank');
            printWindow.document.write(html);
            printWindow.document.close();
            printWindow.onload = () => {
                printWindow.print();
            };
        } else if (format === 'html') {
            const blob = new Blob([html], { type: 'text/html' });
            const url = URL.createObjectURL(blob);
            const a = document.createElement('a');
            a.href = url;
            a.download = `pv-glossary-study-sheet-${new Date().toISOString().slice(0, 10)}.html`;
            document.body.appendChild(a);
            a.click();
            document.body.removeChild(a);
            URL.revokeObjectURL(url);
        }
    },

    // Search
    handleSearch(query) {
        this.state.searchQuery = query.trim().toLowerCase();
        const clearBtn = document.getElementById('clearSearch');
        clearBtn.classList.toggle('visible', query.length > 0);
        
        if (query.length < 2) {
            if (this.state.currentView === 'searchView') {
                this.showWelcome();
            }
            return;
        }
        
        const results = this.searchTerms(query);
        this.renderSearchResults(results, query);
    },

    searchTerms(query) {
        const q = query.toLowerCase();
        return Object.values(this.data.terms).filter(term => {
            return term.term.toLowerCase().includes(q) ||
                   (term.acronym && term.acronym.toLowerCase().includes(q)) ||
                   term.definition.toLowerCase().includes(q) ||
                   (term.tags && term.tags.some(t => t.toLowerCase().includes(q)));
        }).sort((a, b) => {
            // Prioritize term name matches
            const aNameMatch = a.term.toLowerCase().includes(q);
            const bNameMatch = b.term.toLowerCase().includes(q);
            if (aNameMatch && !bNameMatch) return -1;
            if (!aNameMatch && bNameMatch) return 1;
            return a.term.localeCompare(b.term);
        });
    },

    renderSearchResults(results, query) {
        document.getElementById('searchResultsCount').textContent = `${results.length} result${results.length !== 1 ? 's' : ''}`;
        this.announce(`${results.length} search result${results.length !== 1 ? 's' : ''} found for ${query}`);
        
        const container = document.getElementById('searchResults');
        if (results.length === 0) {
            container.innerHTML = '<p class="empty-state">No terms found matching your search</p>';
        } else {
            container.innerHTML = results.map(term => {
                const highlighted = this.highlightMatch(term.definition, query);
                return `
                    <div class="search-result-item" role="button" tabindex="0"
                         onclick="PVGlossary.showTerm('${term.id}')"
                         onkeydown="PVGlossary._handleKeyActivate(event, () => PVGlossary.showTerm('${term.id}'))"
                         aria-label="${term.term}, ${term.categoryName}">
                        <h3>${this.highlightMatch(term.term, query)} ${term.acronym ? `(${term.acronym})` : ''}</h3>
                        <div class="category">${term.categoryName}</div>
                        <p>${highlighted}</p>
                    </div>
                `;
            }).join('');
        }
        
        this.showView('searchView');
    },

    highlightMatch(text, query) {
        if (!query) return text;
        const regex = new RegExp(`(${query.replace(/[.*+?^${}()|[\]\\]/g, '\\$&')})`, 'gi');
        return text.replace(regex, '<mark>$1</mark>');
    },

    clearSearch() {
        document.getElementById('searchInput').value = '';
        document.getElementById('clearSearch').classList.remove('visible');
        this.state.searchQuery = '';
        this.showWelcome();
    },

    // Quiz Mode
    startQuiz(categoryId = null) {
        this.showQuizSetup(categoryId);
    },

    showQuizSetup(preselectedCategory = null) {
        const weakTermIds = this.getWeakTerms();
        const container = document.getElementById('quizSetup');

        container.innerHTML = `
            <div class="quiz-setup-card">
                <div class="quiz-setup-section">
                    <h3>üìÅ Category</h3>
                    <div class="quiz-setup-options" id="quizCategoryOptions">
                        <div class="quiz-setup-option ${!preselectedCategory ? 'active' : ''}" data-value="all" onclick="PVGlossary.selectQuizSetup('category', 'all', this)">
                            All Categories
                        </div>
                        ${this.data.categories.map(cat => `
                            <div class="quiz-setup-option ${preselectedCategory === cat.id ? 'active' : ''}" data-value="${cat.id}" onclick="PVGlossary.selectQuizSetup('category', '${cat.id}', this)">
                                ${cat.icon} ${cat.name}
                            </div>
                        `).join('')}
                        ${weakTermIds.length >= 4 ? `
                            <div class="quiz-setup-option weak-terms" data-value="weak" onclick="PVGlossary.selectQuizSetup('category', 'weak', this)">
                                üîÑ Weak Terms
                            </div>
                            <div class="quiz-weak-count">${weakTermIds.length} terms you've previously answered incorrectly</div>
                        ` : ''}
                    </div>
                </div>

                <div class="quiz-setup-section">
                    <h3>üß© Quiz Type</h3>
                    <div class="quiz-setup-options" id="quizTypeOptions">
                        <div class="quiz-setup-option active" data-value="normal" onclick="PVGlossary.selectQuizSetup('type', 'normal', this)">
                            üìñ Term ‚Üí Definition
                        </div>
                        <div class="quiz-setup-option" data-value="reverse" onclick="PVGlossary.selectQuizSetup('type', 'reverse', this)">
                            üîÑ Definition ‚Üí Term
                        </div>
                        <div class="quiz-setup-option" data-value="mixed" onclick="PVGlossary.selectQuizSetup('type', 'mixed', this)">
                            üé≤ Mixed
                        </div>
                    </div>
                </div>

                <div class="quiz-setup-section">
                    <h3>üî¢ Questions</h3>
                    <div class="quiz-setup-options" id="quizCountOptions">
                        <div class="quiz-setup-option" data-value="5" onclick="PVGlossary.selectQuizSetup('count', 5, this)">5</div>
                        <div class="quiz-setup-option active" data-value="10" onclick="PVGlossary.selectQuizSetup('count', 10, this)">10</div>
                        <div class="quiz-setup-option" data-value="15" onclick="PVGlossary.selectQuizSetup('count', 15, this)">15</div>
                        <div class="quiz-setup-option" data-value="20" onclick="PVGlossary.selectQuizSetup('count', 20, this)">20</div>
                    </div>
                </div>

                <div class="quiz-setup-start">
                    <button onclick="PVGlossary.launchQuiz()">Start Quiz</button>
                </div>
            </div>
        `;

        // Store setup state
        this.state.quizSetup = {
            category: preselectedCategory || 'all',
            type: 'normal',
            count: 10
        };

        this.showView('quizSetupView');
    },

    selectQuizSetup(group, value, element) {
        // Update UI
        const parentId = group === 'category' ? 'quizCategoryOptions' : 
                         group === 'type' ? 'quizTypeOptions' : 'quizCountOptions';
        document.getElementById(parentId).querySelectorAll('.quiz-setup-option').forEach(opt => {
            opt.classList.remove('active');
        });
        element.classList.add('active');

        // Update state
        this.state.quizSetup[group] = value;
    },

    getWeakTerms() {
        return Object.entries(this.storage.termStats)
            .filter(([id, stats]) => stats.wrong > 0 && stats.wrong >= stats.right)
            .map(([id]) => id)
            .filter(id => this.data.terms[id]);
    },

    launchQuiz() {
        const { category, type, count } = this.state.quizSetup;
        let terms;

        if (category === 'weak') {
            const weakIds = this.getWeakTerms();
            terms = weakIds.map(id => this.data.terms[id]).filter(Boolean);
        } else if (category === 'all') {
            terms = Object.values(this.data.terms);
        } else {
            terms = Object.values(this.data.terms).filter(t => t.categoryId === category);
        }

        // Shuffle and limit
        terms = this.shuffle(terms).slice(0, count);

        if (terms.length === 0) {
            alert('No terms available for this selection. Try a different category.');
            return;
        }

        this.state.quizState = {
            terms,
            currentIndex: 0,
            score: 0,
            answered: false,
            quizType: type,
            results: []
        };

        this.renderQuizQuestion();
        this.showView('quizView');
    },

    renderQuizQuestion() {
        const quiz = this.state.quizState;
        if (!quiz || quiz.currentIndex >= quiz.terms.length) {
            this.showQuizResults();
            return;
        }

        const term = quiz.terms[quiz.currentIndex];
        const wrongAnswers = this.getWrongAnswers(term, 3);
        const isReverse = quiz.quizType === 'reverse' || 
                          (quiz.quizType === 'mixed' && Math.random() > 0.5);

        // Store the mode for this question
        quiz.currentReverse = isReverse;

        document.getElementById('quizProgress').textContent = `${quiz.currentIndex + 1} / ${quiz.terms.length}`;
        document.getElementById('quizScore').textContent = `Score: ${quiz.score}`;

        const container = document.getElementById('quizContent');

        if (isReverse) {
            // Reverse: show definition, pick the term
            const options = this.shuffle([term, ...wrongAnswers]);
            container.innerHTML = `
                <div class="quiz-card">
                    <div class="quiz-mode-badge">Definition ‚Üí Term</div>
                    <div class="quiz-question">
                        <strong>Which term matches this definition?</strong><br><br>
                        "${term.definition}"
                    </div>
                    <div class="quiz-options" role="listbox" aria-label="Choose the correct term">
                        ${options.map((opt, i) => `
                            <div class="quiz-option" role="option" tabindex="0" data-correct="${opt.id === term.id}" data-index="${i}" 
                                 onclick="PVGlossary.selectQuizOption(this, '${opt.id}', '${term.id}')"
                                 onkeydown="PVGlossary._handleKeyActivate(event, () => PVGlossary.selectQuizOption(this, '${opt.id}', '${term.id}'))">
                                <strong>${opt.term}</strong>${opt.acronym ? ` (${opt.acronym})` : ''}
                            </div>
                        `).join('')}
                    </div>
                    <div class="quiz-actions">
                        <button class="quiz-btn quiz-btn-primary" id="nextQuizBtn" onclick="PVGlossary.nextQuizQuestion()" disabled>Next Question</button>
                    </div>
                </div>
            `;
        } else {
            // Normal: show term, pick the definition
            const options = this.shuffle([term, ...wrongAnswers]);
            container.innerHTML = `
                <div class="quiz-card">
                    <div class="quiz-mode-badge">Term ‚Üí Definition</div>
                    <div class="quiz-question">
                        <strong>What is the definition of:</strong><br><br>
                        "${term.term}"${term.acronym ? ` (${term.acronym})` : ''}
                    </div>
                    <div class="quiz-options" role="listbox" aria-label="Choose the correct definition">
                        ${options.map((opt, i) => `
                            <div class="quiz-option" role="option" tabindex="0" data-correct="${opt.id === term.id}" data-index="${i}" 
                                 onclick="PVGlossary.selectQuizOption(this, '${opt.id}', '${term.id}')"
                                 onkeydown="PVGlossary._handleKeyActivate(event, () => PVGlossary.selectQuizOption(this, '${opt.id}', '${term.id}'))">
                                ${opt.definition}
                            </div>
                        `).join('')}
                    </div>
                    <div class="quiz-actions">
                        <button class="quiz-btn quiz-btn-primary" id="nextQuizBtn" onclick="PVGlossary.nextQuizQuestion()" disabled>Next Question</button>
                    </div>
                </div>
            `;
        }
    },

    getWrongAnswers(correctTerm, count) {
        // Prefer wrong answers from the same category for harder quiz
        const sameCategory = Object.values(this.data.terms).filter(
            t => t.id !== correctTerm.id && t.categoryId === correctTerm.categoryId
        );
        const others = Object.values(this.data.terms).filter(
            t => t.id !== correctTerm.id && t.categoryId !== correctTerm.categoryId
        );

        const pool = this.shuffle(sameCategory);
        // Take up to 2 from same category, rest from others
        const result = pool.slice(0, Math.min(2, count));
        if (result.length < count) {
            result.push(...this.shuffle(others).slice(0, count - result.length));
        }
        return this.shuffle(result).slice(0, count);
    },

    selectQuizOption(element, selectedId, correctId) {
        if (this.state.quizState.answered) return;
        this.state.quizState.answered = true;

        const isCorrect = selectedId === correctId;
        const term = this.state.quizState.terms[this.state.quizState.currentIndex];

        const options = document.querySelectorAll('.quiz-option');
        options.forEach(opt => {
            if (opt.dataset.correct === 'true') {
                opt.classList.add('correct');
            } else if (opt === element && !isCorrect) {
                opt.classList.add('incorrect');
            }
        });

        if (isCorrect) {
            this.state.quizState.score++;
            document.getElementById('quizScore').textContent = `Score: ${this.state.quizState.score}`;
        }

        // Track per-term performance
        if (!this.storage.termStats[term.id]) {
            this.storage.termStats[term.id] = { right: 0, wrong: 0 };
        }
        if (isCorrect) {
            this.storage.termStats[term.id].right++;
        } else {
            this.storage.termStats[term.id].wrong++;
        }
        this.saveStorage();

        // Store result for review
        this.state.quizState.results.push({
            termId: term.id,
            termName: term.term,
            correct: isCorrect,
            reverse: this.state.quizState.currentReverse
        });

        document.getElementById('nextQuizBtn').disabled = false;
        document.getElementById('nextQuizBtn').focus();

        // Announce result
        this.announce(isCorrect ? 'Correct!' : `Incorrect. The correct answer was ${term.term}.`);
    },

    nextQuizQuestion() {
        this.state.quizState.currentIndex++;
        this.state.quizState.answered = false;
        this.renderQuizQuestion();
    },

    showQuizResults() {
        const quiz = this.state.quizState;
        const percent = Math.round((quiz.score / quiz.terms.length) * 100);

        // Update global stats
        this.storage.quizStats.total += quiz.terms.length;
        this.storage.quizStats.correct += quiz.score;
        this.saveStorage();

        const wrongResults = quiz.results.filter(r => !r.correct);
        const correctResults = quiz.results.filter(r => r.correct);

        const container = document.getElementById('quizContent');
        container.innerHTML = `
            <div class="quiz-card">
                <div class="quiz-question">
                    <div style="font-size: 3rem; margin-bottom: 16px;">${percent >= 70 ? 'üéâ' : 'üìö'}</div>
                    <strong>Quiz Complete!</strong><br><br>
                    You scored <strong>${quiz.score} out of ${quiz.terms.length}</strong> (${percent}%)
                </div>

                ${quiz.results.length > 0 ? `
                    <div class="quiz-results-details">
                        ${wrongResults.length > 0 ? `
                            <h3>‚úó Review These Terms (${wrongResults.length})</h3>
                            ${wrongResults.map(r => `
                                <div class="quiz-result-item incorrect" role="button" tabindex="0"
                                     onclick="PVGlossary.showTerm('${r.termId}')"
                                     onkeydown="PVGlossary._handleKeyActivate(event, () => PVGlossary.showTerm('${r.termId}'))">
                                    <span class="quiz-result-icon" aria-hidden="true">‚úó</span>
                                    <span class="quiz-result-term">${r.termName}</span>
                                </div>
                            `).join('')}
                        ` : ''}
                        ${correctResults.length > 0 ? `
                            <h3 style="margin-top: 16px;">‚úì Got Right (${correctResults.length})</h3>
                            ${correctResults.map(r => `
                                <div class="quiz-result-item correct" role="button" tabindex="0"
                                     onclick="PVGlossary.showTerm('${r.termId}')"
                                     onkeydown="PVGlossary._handleKeyActivate(event, () => PVGlossary.showTerm('${r.termId}'))">
                                    <span class="quiz-result-icon" aria-hidden="true">‚úì</span>
                                    <span class="quiz-result-term">${r.termName}</span>
                                </div>
                            `).join('')}
                        ` : ''}
                    </div>
                ` : ''}

                <div class="quiz-actions">
                    <button class="quiz-btn quiz-btn-primary" onclick="PVGlossary.launchQuiz()">Retry Same Settings</button>
                    <button class="quiz-btn quiz-btn-secondary" onclick="PVGlossary.showQuizSetup()">Change Settings</button>
                    <button class="quiz-btn quiz-btn-secondary" onclick="PVGlossary.showWelcome()">Home</button>
                </div>
            </div>
        `;
    },

    exitQuiz() {
        if (this.state.quizState && this.state.quizState.currentIndex > 0) {
            if (!confirm('Exit quiz? Your progress will be lost.')) return;
        }
        this.state.quizState = null;
        this.showWelcome();
    },

    // Bookmarks View
    showBookmarks() {
        const container = document.getElementById('bookmarksList');
        const hasBookmarks = this.storage.bookmarks.length > 0;
        document.getElementById('bookmarksCount').textContent = `${this.storage.bookmarks.length} saved term${this.storage.bookmarks.length !== 1 ? 's' : ''}`;
        document.getElementById('bookmarksExportActions').style.display = hasBookmarks ? 'flex' : 'none';
        
        if (!hasBookmarks) {
            container.innerHTML = '<p class="empty-state">No bookmarked terms yet. Click the ‚òÜ icon on any term to save it.</p>';
        } else {
            container.innerHTML = this.storage.bookmarks.map(id => {
                const term = this.data.terms[id];
                return term ? this.renderTermCard(term) : '';
            }).join('');
        }
        
        this.showView('bookmarksView');
    },

    // Stats View
    showStats() {
        const container = document.getElementById('statsContent');
        const totalTerms = this.data.metadata.totalTerms;
        const learnedCount = this.storage.learned.length;
        const learnedPercent = Math.round((learnedCount / totalTerms) * 100);
        
        // Scenario stats
        const totalScenarios = this.scenarios.scenarios.length;
        const completedScenarios = Object.keys(this.storage.scenarioProgress).filter(
            id => this.storage.scenarioProgress[id]?.completed
        ).length;
        const scenarioPercent = totalScenarios > 0 ? Math.round((completedScenarios / totalScenarios) * 100) : 0;

        const categoryProgress = this.data.categories.map(cat => {
            const catTerms = Object.values(this.data.terms).filter(t => t.categoryId === cat.id);
            const catLearned = catTerms.filter(t => this.storage.learned.includes(t.id)).length;
            return {
                name: cat.name,
                total: catTerms.length,
                learned: catLearned,
                percent: Math.round((catLearned / catTerms.length) * 100)
            };
        });
        
        container.innerHTML = `
            <div class="stats-card">
                <h3>üìñ Terms Progress</h3>
                <div class="stat-value" style="font-size: 2.5rem; margin-bottom: 8px;">${learnedPercent}%</div>
                <p>${learnedCount} of ${totalTerms} terms learned</p>
            </div>
            <div class="stats-card">
                <h3>üé¨ Scenarios Progress</h3>
                <div class="stat-value" style="font-size: 2.5rem; margin-bottom: 8px;">${scenarioPercent}%</div>
                <p>${completedScenarios} of ${totalScenarios} scenarios completed</p>
            </div>
            <div class="stats-card">
                <h3>üéØ Quiz Performance</h3>
                ${this.storage.quizStats.total > 0 ? `
                    <div class="stat-value" style="font-size: 2.5rem; margin-bottom: 8px;">
                        ${Math.round((this.storage.quizStats.correct / this.storage.quizStats.total) * 100)}%
                    </div>
                    <p>${this.storage.quizStats.correct} correct out of ${this.storage.quizStats.total} questions</p>
                ` : '<p class="empty-state">Take a quiz to see your stats!</p>'}
            </div>
            <div class="stats-card">
                <h3>üîÑ Weak Terms</h3>
                ${(() => {
                    const weakTerms = this.getWeakTerms();
                    if (weakTerms.length === 0) {
                        return '<p class="empty-state">No weak terms yet ‚Äî keep quizzing!</p>';
                    }
                    return `
                        <p style="margin-bottom: 12px;">${weakTerms.length} term${weakTerms.length !== 1 ? 's' : ''} to review</p>
                        ${weakTerms.slice(0, 5).map(id => {
                            const term = this.data.terms[id];
                            const stats = this.storage.termStats[id];
                            return `<div class="category-progress-item" style="cursor:pointer" onclick="PVGlossary.showTerm('${id}')">
                                <span class="name">${term.term}</span>
                                <span class="percent" style="color: var(--danger); width: auto;">${stats.wrong}‚úó / ${stats.right}‚úì</span>
                            </div>`;
                        }).join('')}
                        ${weakTerms.length > 5 ? `<p style="font-size:0.85rem; color: var(--gray-500); margin-top: 8px;">+ ${weakTerms.length - 5} more</p>` : ''}
                        <button class="quiz-btn quiz-btn-primary" style="margin-top: 12px; width: 100%; padding: 10px;" onclick="PVGlossary.state.quizSetup = {category:'weak',type:'mixed',count:10}; PVGlossary.launchQuiz();">
                            Practice Weak Terms
                        </button>
                    `;
                })()}
            </div>
            <div class="stats-card full-width">
                <h3>Progress by Category</h3>
                ${categoryProgress.map(cp => `
                    <div class="category-progress-item">
                        <span class="name">${cp.name}</span>
                        <div class="bar"><div class="bar-fill" style="width: ${cp.percent}%"></div></div>
                        <span class="percent">${cp.learned}/${cp.total}</span>
                    </div>
                `).join('')}
            </div>
        `;
        
        this.showView('statsView');
    },

    // Utility Functions
    showRandomTerm() {
        const termIds = Object.keys(this.data.terms);
        const randomId = termIds[Math.floor(Math.random() * termIds.length)];
        this.showTerm(randomId);
    },

    toggleSidebar() {
        const sidebar = document.getElementById('sidebar');
        sidebar.classList.toggle('collapsed');
        const isCollapsed = sidebar.classList.contains('collapsed');
        const btn = document.getElementById('toggleSidebar');
        btn.textContent = isCollapsed ? '‚ñ∂' : '‚óÄ';
        btn.setAttribute('aria-label', isCollapsed ? 'Expand sidebar' : 'Collapse sidebar');
        sidebar.setAttribute('aria-hidden', isCollapsed);
    },

    updateProgress() {
        const total = this.data.metadata.totalTerms;
        const learned = this.storage.learned.length;
        const percent = Math.round((learned / total) * 100);
        
        document.getElementById('progressPercent').textContent = `${percent}%`;
        document.getElementById('progressFill').style.width = `${percent}%`;
        
        const progressBar = document.getElementById('progressBar');
        if (progressBar) {
            progressBar.setAttribute('aria-valuenow', percent);
        }
    },

    // Keyboard activation handler: Enter or Space triggers action
    _handleKeyActivate(event, callback) {
        if (event.key === 'Enter' || event.key === ' ') {
            event.preventDefault();
            callback();
        }
    },

    updateFooter() {
        document.getElementById('versionNum').textContent = this.data.metadata.version;
        document.getElementById('totalTermsFooter').textContent = this.data.metadata.totalTerms;
        document.getElementById('buildDate').textContent = new Date(this.data.metadata.buildDate).toLocaleDateString();
    },

    shuffle(array) {
        const arr = [...array];
        for (let i = arr.length - 1; i > 0; i--) {
            const j = Math.floor(Math.random() * (i + 1));
            [arr[i], arr[j]] = [arr[j], arr[i]];
        }
        return arr;
    },

    // ==========================================
    // SCENARIO ENGINE
    // ==========================================

    showScenarioLibrary() {
        const categories = [...new Set(this.scenarios.scenarios.map(s => s.category))];
        
        // Render category filters
        const catContainer = document.getElementById('scenarioCategories');
        catContainer.innerHTML = `
            <button class="scenario-category-btn active" data-category="all">All Scenarios</button>
            ${categories.map(cat => {
                const catName = this.scenarios.scenarios.find(s => s.category === cat)?.categoryName || cat;
                const count = this.scenarios.scenarios.filter(s => s.category === cat).length;
                return `<button class="scenario-category-btn" data-category="${cat}">${catName} (${count})</button>`;
            }).join('')}
        `;

        // Add click handlers to category buttons
        catContainer.querySelectorAll('.scenario-category-btn').forEach(btn => {
            btn.addEventListener('click', () => {
                catContainer.querySelectorAll('.scenario-category-btn').forEach(b => b.classList.remove('active'));
                btn.classList.add('active');
                this.filterScenarios(btn.dataset.category);
            });
        });

        this.filterScenarios('all');
        this.showView('scenarioLibraryView');
    },

    filterScenarios(category) {
        const scenarios = category === 'all' 
            ? this.scenarios.scenarios 
            : this.scenarios.scenarios.filter(s => s.category === category);
        
        const container = document.getElementById('scenarioList');
        container.innerHTML = scenarios.map(scenario => {
            const progress = this.storage.scenarioProgress[scenario.id];
            const isCompleted = progress?.completed;
            const score = progress?.score || 0;
            const total = scenario.steps.length;

            return `
                <div class="scenario-card" onclick="PVGlossary.showScenarioBriefing('${scenario.id}')">
                    <div class="scenario-card-content">
                        <div class="scenario-icon">${scenario.icon}</div>
                        <div class="scenario-info">
                            <h3>
                                ${scenario.title}
                                <span class="scenario-difficulty ${scenario.difficulty}">${scenario.difficulty}</span>
                            </h3>
                            <p>${scenario.description}</p>
                            <div class="scenario-meta">
                                <span>‚è±Ô∏è ${scenario.estimatedTime}</span>
                                <span>üìã ${scenario.steps.length} decisions</span>
                                <span>üè∑Ô∏è ${scenario.categoryName}</span>
                            </div>
                        </div>
                        <div class="scenario-card-action">
                            ${isCompleted 
                                ? `<div class="scenario-completed">‚úì ${score}/${total}</div>`
                                : `<button class="scenario-start-btn">Start ‚Üí</button>`
                            }
                        </div>
                    </div>
                </div>
            `;
        }).join('');
    },

    showScenarioBriefing(scenarioId) {
        const scenario = this.scenarios.scenarios.find(s => s.id === scenarioId);
        if (!scenario) return;

        const allTerms = scenario.steps.flatMap(s => s.relatedTerms || []);
        const uniqueTerms = [...new Set(allTerms)].slice(0, 6);

        const container = document.getElementById('scenarioBriefing');
        container.innerHTML = `
            <div class="briefing-header">
                <div class="scenario-icon">${scenario.icon}</div>
                <h1>${scenario.title}</h1>
                <div class="meta">
                    <span class="scenario-difficulty ${scenario.difficulty}">${scenario.difficulty}</span>
                    <span>‚è±Ô∏è ${scenario.estimatedTime}</span>
                    <span>üìã ${scenario.steps.length} decisions</span>
                </div>
            </div>
            <div class="briefing-body">
                <div class="briefing-section">
                    <h2>üë§ Your Role</h2>
                    <p>${scenario.briefing.role}</p>
                </div>
                <div class="briefing-section">
                    <h2>üìç Situation</h2>
                    <p>${scenario.briefing.context}</p>
                </div>
                <div class="briefing-section">
                    <h2>üéØ Your Task</h2>
                    <p>${scenario.briefing.task}</p>
                </div>
                <div class="briefing-section">
                    <h2>üìö Learning Objectives</h2>
                    <div class="briefing-objectives">
                        <ul>
                            ${scenario.learningObjectives.map(obj => `<li>${obj}</li>`).join('')}
                        </ul>
                    </div>
                </div>
                <div class="briefing-section">
                    <h2>üîó Terms You'll Learn</h2>
                    <div class="briefing-terms">
                        ${uniqueTerms.map(termId => {
                            const term = this.data.terms[termId];
                            return term ? `<span class="briefing-term">${term.term}</span>` : '';
                        }).join('')}
                    </div>
                </div>
                <button class="briefing-start-btn" onclick="PVGlossary.startScenario('${scenario.id}')">
                    Begin Scenario ‚Üí
                </button>
            </div>
        `;

        this.showView('scenarioBriefingView');
    },

    startScenario(scenarioId) {
        const scenario = this.scenarios.scenarios.find(s => s.id === scenarioId);
        if (!scenario) return;

        this.state.scenarioState = {
            scenario,
            currentStep: 0,
            score: 0,
            answers: [],
            selectedAnswer: null,
            showFeedback: false,
            showHint: false
        };

        this.renderScenarioStep();
        this.showView('scenarioActiveView');
    },

    renderScenarioStep() {
        const { scenario, currentStep, score, answers, selectedAnswer, showFeedback, showHint } = this.state.scenarioState;
        const step = scenario.steps[currentStep];

        // Render header
        const header = document.getElementById('scenarioHeader');
        header.innerHTML = `
            <div class="scenario-header-left">
                <button class="scenario-exit-btn" onclick="PVGlossary.exitScenario()" title="Exit">‚úï</button>
                <span class="scenario-title-small">${scenario.title}</span>
            </div>
            <div class="scenario-header-right">
                <div class="scenario-progress-bar">
                    ${scenario.steps.map((_, i) => `
                        <div class="scenario-progress-dot ${i < currentStep ? 'completed' : ''} ${i === currentStep ? 'current' : ''}"></div>
                    `).join('')}
                </div>
                <span class="scenario-score">Score: ${score}/${currentStep + (showFeedback ? 1 : 0)}</span>
            </div>
        `;

        // Determine content type styling
        const contentType = step.contentType || 'info';
        const contentClass = contentType === 'voicemail' ? 'voicemail' 
            : contentType === 'email' ? 'email'
            : contentType === 'case' ? 'case'
            : contentType === 'interview' ? 'interview'
            : '';

        // Render content
        const content = document.getElementById('scenarioContent');
        content.innerHTML = `
            <div class="scenario-step-card">
                <div class="scenario-step-header">
                    <h2>Step ${currentStep + 1}: ${step.title}</h2>
                </div>
                <div class="scenario-step-body">
                    <div class="scenario-content-box ${contentClass}">
                        ${step.metadata ? `
                            <div class="scenario-content-meta">
                                ${contentType === 'voicemail' ? 'üìû Voicemail' : ''}
                                ${contentType === 'email' ? 'üìß Email' : ''}
                                ${contentType === 'interview' ? 'üé§ Inspector' : ''}
                                ${step.metadata.received ? ` ‚Ä¢ ${step.metadata.received}` : ''}
                                ${step.metadata.duration ? ` ‚Ä¢ ${step.metadata.duration}` : ''}
                            </div>
                        ` : ''}
                        <div class="scenario-content-text ${contentType === 'voicemail' || contentType === 'interview' ? 'quote' : ''}">
                            ${contentType === 'voicemail' ? `"${step.content}"` : step.content}
                        </div>
                        ${step.highlight ? `<div style="margin-top: 12px;"><strong>Key details:</strong> <span class="scenario-highlight">${step.highlight}</span></div>` : ''}
                    </div>

                    <div class="scenario-question">
                        <h3>‚ùì ${step.question}</h3>
                    </div>

                    <div class="scenario-options">
                        ${step.options.map(opt => {
                            let optClass = '';
                            if (showFeedback) {
                                if (opt.isCorrect) optClass = 'correct';
                                else if (selectedAnswer === opt.id) optClass = 'incorrect';
                                optClass += ' disabled';
                            } else if (selectedAnswer === opt.id) {
                                optClass = 'selected';
                            }
                            return `
                                <div class="scenario-option ${optClass}" onclick="PVGlossary.selectScenarioOption('${opt.id}')">
                                    <input type="radio" name="scenario-answer" value="${opt.id}" 
                                        ${selectedAnswer === opt.id ? 'checked' : ''} 
                                        ${showFeedback ? 'disabled' : ''}>
                                    <span class="scenario-option-text"><strong>${opt.id})</strong> ${opt.text}</span>
                                    ${showFeedback && opt.isCorrect ? '<span class="scenario-option-icon">‚úì</span>' : ''}
                                    ${showFeedback && !opt.isCorrect && selectedAnswer === opt.id ? '<span class="scenario-option-icon">‚úó</span>' : ''}
                                </div>
                            `;
                        }).join('')}
                    </div>

                    ${!showFeedback ? `
                        ${showHint && step.hints ? `
                            <div class="scenario-hint-box">
                                üí° ${step.hints[0]}
                            </div>
                        ` : step.hints ? `
                            <button class="scenario-hint-btn" onclick="PVGlossary.showScenarioHint()">üí° Need a hint?</button>
                        ` : ''}
                    ` : ''}

                    ${showFeedback ? this.renderScenarioFeedback(step, selectedAnswer) : ''}

                    <div class="scenario-actions">
                        ${!showFeedback ? `
                            <button class="scenario-submit-btn" onclick="PVGlossary.submitScenarioAnswer()" ${!selectedAnswer ? 'disabled' : ''}>
                                Submit Answer
                            </button>
                        ` : `
                            <button class="scenario-next-btn" onclick="PVGlossary.nextScenarioStep()">
                                ${currentStep < scenario.steps.length - 1 ? 'Next Question ‚Üí' : 'View Results ‚Üí'}
                            </button>
                        `}
                    </div>
                </div>
            </div>
        `;
    },

    renderScenarioFeedback(step, selectedAnswer) {
        const isCorrect = step.options.find(o => o.id === selectedAnswer)?.isCorrect;
        const feedback = isCorrect ? step.feedback.correct : step.feedback[selectedAnswer];

        return `
            <div class="scenario-feedback ${isCorrect ? 'correct' : 'incorrect'}">
                <h4>${isCorrect ? '‚úì' : '‚úó'} ${feedback.title}</h4>
                <p>${feedback.explanation}</p>
                
                ${feedback.points ? `
                    <div class="scenario-feedback-points">
                        ${feedback.points.map(p => `
                            <div class="scenario-feedback-point">
                                <span class="scenario-feedback-point-icon ${p.status}">${
                                    p.status === 'met' ? '‚úì' : 
                                    p.status === 'notmet' ? '‚úó' : 
                                    p.status === 'warning' ? '!' : 'i'
                                }</span>
                                <span><strong>${p.label}:</strong> ${p.detail}</span>
                            </div>
                        `).join('')}
                    </div>
                ` : ''}

                ${feedback.inspectorTip ? `
                    <div class="scenario-inspector-tip">
                        <strong>üîç Inspector Tip:</strong> ${feedback.inspectorTip}
                    </div>
                ` : ''}
            </div>

            ${step.relatedTerms ? `
                <div class="scenario-related-terms">
                    <p>üìö Related Terms:</p>
                    <div class="terms">
                        ${step.relatedTerms.map(termId => {
                            const term = this.data.terms[termId];
                            return term ? `<span class="term" onclick="PVGlossary.showTerm('${termId}')">${term.term}</span>` : '';
                        }).join('')}
                    </div>
                </div>
            ` : ''}
        `;
    },

    selectScenarioOption(optionId) {
        if (this.state.scenarioState.showFeedback) return;
        this.state.scenarioState.selectedAnswer = optionId;
        this.renderScenarioStep();
    },

    showScenarioHint() {
        this.state.scenarioState.showHint = true;
        this.renderScenarioStep();
    },

    submitScenarioAnswer() {
        const { scenario, currentStep, selectedAnswer } = this.state.scenarioState;
        const step = scenario.steps[currentStep];
        const isCorrect = step.options.find(o => o.id === selectedAnswer)?.isCorrect;

        if (isCorrect) {
            this.state.scenarioState.score++;
        }

        this.state.scenarioState.answers.push({
            step: currentStep,
            stepTitle: step.title,
            answer: selectedAnswer,
            correct: isCorrect
        });

        this.state.scenarioState.showFeedback = true;
        this.renderScenarioStep();
    },

    nextScenarioStep() {
        const { scenario, currentStep } = this.state.scenarioState;

        if (currentStep < scenario.steps.length - 1) {
            this.state.scenarioState.currentStep++;
            this.state.scenarioState.selectedAnswer = null;
            this.state.scenarioState.showFeedback = false;
            this.state.scenarioState.showHint = false;
            this.renderScenarioStep();
        } else {
            this.showScenarioDebrief();
        }
    },

    showScenarioDebrief() {
        const { scenario, score, answers } = this.state.scenarioState;
        const total = scenario.steps.length;
        const percentage = Math.round((score / total) * 100);
        const passed = score >= (scenario.debrief.passingScore || Math.ceil(total / 2));

        // Save progress
        this.storage.scenarioProgress[scenario.id] = {
            completed: true,
            score,
            total,
            percentage,
            passed,
            completedAt: new Date().toISOString()
        };
        this.saveStorage();

        // Collect all related terms
        const allTerms = scenario.steps.flatMap(s => s.relatedTerms || []);
        const uniqueTerms = [...new Set(allTerms)];

        const container = document.getElementById('scenarioDebrief');
        container.innerHTML = `
            <div class="debrief-header ${passed ? 'passed' : 'failed'}">
                <div class="icon">${passed ? 'üéâ' : 'üìö'}</div>
                <h1>${passed ? 'Scenario Complete!' : 'Keep Learning!'}</h1>
                <p>You scored ${score} out of ${total} (${percentage}%)</p>
            </div>
            <div class="debrief-body">
                <div class="debrief-section">
                    <h2>üìã Your Decisions</h2>
                    <div class="debrief-answers">
                        ${answers.map(a => `
                            <div class="debrief-answer ${a.correct ? 'correct' : 'incorrect'}">
                                <span class="debrief-answer-icon">${a.correct ? '‚úì' : '‚úó'}</span>
                                <span>${a.stepTitle}</span>
                            </div>
                        `).join('')}
                    </div>
                </div>

                <div class="debrief-section">
                    <h2>üí° Key Takeaways</h2>
                    <div class="debrief-takeaways">
                        <ul>
                            ${scenario.debrief.keyTakeaways.map(t => `<li>${t}</li>`).join('')}
                        </ul>
                    </div>
                </div>

                <div class="debrief-section">
                    <h2>üìö Terms Learned</h2>
                    <div class="debrief-terms">
                        ${uniqueTerms.map(termId => {
                            const term = this.data.terms[termId];
                            return term ? `<span class="debrief-term" onclick="PVGlossary.showTerm('${termId}')">${term.term}</span>` : '';
                        }).join('')}
                    </div>
                </div>

                <div class="debrief-actions">
                    <button class="debrief-btn debrief-btn-secondary" onclick="PVGlossary.showScenarioLibrary()">
                        ‚Üê Back to Library
                    </button>
                    <button class="debrief-btn debrief-btn-primary" onclick="PVGlossary.restartScenario()">
                        Try Again
                    </button>
                </div>
            </div>
        `;

        this.showView('scenarioDebriefView');
    },

    restartScenario() {
        const scenarioId = this.state.scenarioState.scenario.id;
        this.startScenario(scenarioId);
    },

    exitScenario() {
        if (confirm('Are you sure you want to exit? Your progress will be lost.')) {
            this.state.scenarioState = null;
            this.showScenarioLibrary();
        }
    }
};

// Initialize on DOM ready
document.addEventListener('DOMContentLoaded', () => PVGlossary.init());

    </script>
</body>
</html>
